<SEC-DOCUMENT>0001493152-21-029140.txt : 20211117
<SEC-HEADER>0001493152-21-029140.hdr.sgml : 20211117
<ACCEPTANCE-DATETIME>20211117171627
ACCESSION NUMBER:		0001493152-21-029140
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20211117
DATE AS OF CHANGE:		20211117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celcuity Inc.
		CENTRAL INDEX KEY:			0001603454
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-261155
		FILM NUMBER:		211421512

	BUSINESS ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446
		BUSINESS PHONE:		763-392-0767

	MAIL ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celcuity LLC
		DATE OF NAME CHANGE:	20140324
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>forms-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
filed with the Securities and Exchange Commission on November 17, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Form
S-3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Exact
name of registrant as specified in its charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>82-2863566</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State
    or other jurisdiction</I></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.
    Employer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>of
    incorporation or organization)</I></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Identification
    Number)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>16305
36th Avenue N., Suite 100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minneapolis,
MN 55446<FONT STYLE="background-color: white"><BR>
</FONT>(763) 392-0123</B><BR>
<I>(Address, including zip code, and telephone number, including area code, of principal executive offices)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Brian
F. Sullivan<BR>
Chief Executive Officer<BR>
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16305 36th Avenue N., Suite 100</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minneapolis,
MN 55446<FONT STYLE="background-color: white"><BR>
</FONT>(763) 392-0123</B><BR>
<I>(Name, address, including zip code, and telephone number, including area code, of agent for service)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Please
send copies of all communications to:</I></B><BR>
<FONT STYLE="background-color: white"><B>Eric O. Madson<BR>
Joseph J. Schauer<BR>
Fredrikson &amp; Byron, P.A.<BR>
200 South Sixth Street, Suite 4000</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Minneapolis,
Minnesota 55402<BR>
(612) 492-7000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Approximate
date of commencement of proposed sale to the public: </B>From time to time after the effectiveness of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check
the following box: <FONT STYLE="background-color: white">&#9744;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following
box: <FONT STYLE="background-color: white">&#9746;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. <FONT STYLE="background-color: white">&#9744;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="background-color: white">&#9744;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. <FONT STYLE="background-color: white">&#9744;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. <FONT STYLE="background-color: white">&#9744;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
<FONT STYLE="background-color: white">by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated
filer,&rdquo; &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="background-color: white"></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="background-color: white"></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Large accelerated filer &#9744;</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Accelerated filer &#9744;</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Non-accelerated filer &#9746;</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Smaller reporting company &#9746;</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Emerging growth company &#9746;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. <FONT STYLE="background-color: white">&#9746;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CALCULATION
OF REGISTRATION FEE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed Maximum</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed Maximum</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; width: 40%; font-weight: bold">Title of Each Class of</TD><TD STYLE="text-align: center; width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="width: 11%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount to be</B></FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="width: 11%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering Price</B></FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="width: 11%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate <B>Offering</B></FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="width: 11%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
                                                                            of Registration </B></FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Securities to be Registered</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> Fee</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Common Stock, $0.001 par value per share (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Preferred Stock, $0.001 par value per share (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Warrants (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Debt Securities (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Units (7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A </FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A </FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 150,000,000 </FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">(1)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 13,905 </FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">(2)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    no event will the aggregate offering price of all securities issued from time to time by the registrant under this registration statement
    (&ldquo;Securities&rdquo;) exceed $150,000,000.00 or its equivalent in any other currency, currency units, or composite currency
    or currencies. The Securities covered by this registration statement may be sold separately, together, or as units with other Securities
    registered under this registration statement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    proposed maximum aggregate price of the Securities has been estimated solely for the purpose of calculating the registration fee
    pursuant to Rule 457(o) under the Securities Act. Pursuant to Rule 457(p) under the Securities Act, $4,773.00 remaining of the filing
    fee previously paid with respect to $43,750,000 of unsold securities that were registered pursuant to a Registration Statement on
    Form S-3 (No. 333-254625) filed by the registrant on March 23, 2021 is being carried forward in connection with this Registration
    Statement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to note (1), the Securities being registered in this registration statement consist of such an indeterminate amount of common stock
    (with accompanying purchase rights, if any), as may be sold, from time to time, at indeterminate prices, by the registrant.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to note (1), the Securities being registered in this registration statement consist of such an indeterminate number of shares of
    preferred stock (with accompanying purchase rights, if any) as may be sold from time to time at indeterminate prices by the registrant.
    In addition, the Securities being registered in this registration statement also consist of such an indeterminate amount of common
    stock (with accompanying purchase rights, if any) (i) as may be issuable or deliverable upon conversion of shares of preferred stock,
    and (ii) as may be required for delivery upon conversion of shares of preferred stock as a result of anti-dilution provisions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to note (1), the Securities being registered in this registration statement consist of such an indeterminate amount and number of
    warrants, representing rights to purchase common stock, preferred stock and debt securities registered under this registration statement
    as may be sold from time to time at indeterminate prices by the registrant. In addition, the Securities being registered in this
    registration statement also consist of such an indeterminate amount of common stock and preferred stock (in each case, with accompanying
    purchase rights, if any) and debt securities (i) as may be issuable or deliverable upon exercise of warrants and (ii) as may be required
    for delivery upon exercise of any warrants as a result of anti-dilution provisions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to note (1), the Securities being registered in this registration statement consist of such an indeterminate amount of debt securities
    as may be sold from time to time at indeterminate prices by the registrant. If any debt securities are issued at an original issue
    discount, then the offering price shall be in such greater principal amount as shall result in an aggregate initial offering price
    not to exceed $150,000,000.00. In addition, the Securities being registered in this registration statement also consist of such an
    indeterminate amount of common stock and preferred stock (in each case, with accompanying purchase rights, if any) (i) as may be
    issuable or deliverable upon the exercise or conversion of debt securities and (ii) as may be required for delivery upon exercise
    or conversion of debt securities as a result of anti-dilution.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to note (1), the Securities being registered in this registration statement consist of such an indeterminate amount of units, consisting
    of one or more shares of common stock, shares of preferred stock, warrants, debt securities, or any combination of such securities,
    as may be sold from time to time at indeterminate prices by the registrant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>Information
contained in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed
with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBJECT
TO COMPLETION DATED NOVEMBER 17, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expanding
Treatment Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$150,000,000</B><BR>
Common Stock<BR>
Preferred Stock<BR>
Warrants<BR>
Debt Securities<BR>
Units</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities covered by this prospectus may include shares of our common stock; shares of preferred stock; warrants to purchase shares
of our common stock, preferred stock and/or debt securities; debt securities consisting of debentures, notes or other evidences of indebtedness;
or units consisting of any combination of such securities. We may offer the securities from time to time in one or more series or issuances
directly to our stockholders or purchasers, or through agents, underwriters or dealers as designated from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus provides a general description of the securities we may offer. Each time we sell securities, we will provide specific terms
of the securities offered in a supplement to this prospectus. Such a prospectus supplement may also add, update or change information
contained in this prospectus. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable
prospectus supplement. We will sell these securities directly to our stockholders or to purchasers or through agents on our behalf or
through underwriters or dealers as designated from time to time. If any agents or underwriters are involved in the sale of any of these
securities, the applicable prospectus supplement will provide the names of the agents or underwriters and any applicable fees, commissions
or discounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on The Nasdaq Capital Market under the symbol &ldquo;CELC.&rdquo; On November 16, 2021, the closing price
of our common stock was $18.34.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves risks. See &ldquo;Risk Factors&rdquo; on page 14. </B>You should carefully read this prospectus, the
documents incorporated herein, and the applicable prospectus supplement before making any investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Page </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">About this Prospectus</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Our Company</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Risk Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Use of Proceeds</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Plan of Distribution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Description of Capital Stock</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Description of Warrants</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Description of Debt Securities</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Description of Units</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Where You Can Find More Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Incorporation of Certain Documents by Reference</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Legal Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Experts</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities described in this prospectus are part of a registration statement that we filed with the Securities and Exchange Commission,
or the SEC, using a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may offer to sell any combination
of the securities described in this prospectus in one or more offerings up to a total dollar amount of $150,000,000.00. This prospectus
provides you with a general description of the securities we may offer. Each time we sell securities under this shelf registration, we
will provide a prospectus supplement that will contain specific information about the terms of such offering. The prospectus supplement
may also add, update or change information contained in this prospectus. You should read both this prospectus and any applicable prospectus
supplement, including all documents incorporated herein by reference, together with additional information described under &ldquo;Where
You Can Find More Information&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained
or incorporated by reference in this prospectus and any accompanying prospectus supplement. You must not rely upon any information or
representation not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement. This prospectus
and the accompanying prospectus supplement, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities
other than the registered securities to which they relate, nor do this prospectus and any accompanying prospectus supplement constitute
an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such
offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and any accompanying
prospectus supplement, if any, is accurate on any date subsequent to the date set forth on the front of the document or that any information
we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though
this prospectus and any accompanying prospectus supplement is delivered or securities are sold on a later date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, &ldquo;CELC,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo;
and similar names refer to Celcuity Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_002"></A><B>OUR
COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursing an integrated therapeutic (Rx) and
companion diagnostic (CDx) strategy. Our therapeutic strategy aims to utilize CELsignia&rsquo;s unique insights into tumor cell biology
to identify, in-license, and develop potential first-in-class or best-in-class targeted therapies that treat the same cancer driver a
CELsignia CDx can identify. CELsignia is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients
likely to benefit from targeted therapies. This enables a CELsignia CDx to support advancement of new indications for already approved
targeted therapies. We believe this integrated Rx and CDx strategy will maximize the impact our CELsignia platform has on the treatment
landscape for cancer patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first drug candidate we are developing internally is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered
intravenously, that selectively targets all Class 1 isoforms of PI3K and mammalian target of rapamycin (mTOR). In April 2021, we obtained
exclusive global development and commercialization rights to gedatolisib under a license agreement with Pfizer, Inc. Our interest in
gedatolisib was prompted after we conducted a study of various PI3K targeted therapeutics while developing our CELsignia PI3K Activity
test. Our CELsignia platform allows us to obtain proprietary insights about the relative effectiveness of PI3K targeted therapies. This
study found that gedatolisib inhibited higher levels of PI3K-involved signaling activity than the other PI3K targeted therapeutics we
evaluated and demonstrated superior drug synergy when combined with other targeted therapies. Gedatolisib&rsquo;s initial clinical development
program will focus on the treatment of patients with estrogen receptor positive (ER+), HER2-negative, advanced or metastatic breast cancer.
Additional clinical development programs are expected to focus on other tumor types that involve a hormonal signaling pathway, such as
endometrial, ovarian, or prostate cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supporting
the development of a potential first-in-class targeted therapy for breast cancer, like gedatolisib, with our CELsignia platform is a
natural extension of our strategy to use our CELsignia CDx to enable new indications for other companies&rsquo; targeted therapies. By
combining companion diagnostics designed to enable proprietary new drug indications with targeted therapies that treat signaling dysregulation
our CDx identifies, we believe we are uniquely positioned to improve the standard-of-care for many early and late-stage breast cancer
patients. Our goal is to play a key role in the multiple treatment approaches required to treat breast cancer patients at various stages
of their disease. With each program, we are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
    the proprietary insights CELsignia provides into live patient tumor cell function</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using
    a CELsignia CDx to identify new patients likely to respond to the paired targeted therapy</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
    a new targeted therapeutic option for breast cancer patients</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximizing
    the probability of getting regulatory approval to market the targeted therapy indication</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutic
(Rx) Product Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Gedatolisib
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
(PF-05212384) is a potent, reversible dual inhibitor that selectively targets PI3K and mTOR. Gedatolisib was originally developed by
Wyeth and clinical development was continued by Pfizer after it acquired Wyeth. We exclusively licensed global rights to gedatolisib
from Pfizer in April 2021. An on-going Phase 1b trial evaluating patients with ER+/HER2- metastatic breast cancer was initiated in 2016
and subsequently enrolled 138 patients. Patient enrollment for the four expansion arms of the trial is complete. Based on the favorable
preliminary results reported to date from the Phase 1b trial, we intend to initiate, subject to feedback from the FDA, a Phase 2/3 clinical
trial evaluating gedatolisib in combination with palbociclib and an endocrine therapy in patients with ER+/HER2- advanced or metastatic
breast cancer in the first half of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Background
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast
cancer is the most prevalent cancer in women, accounting for 30% of all female cancers and 13% of cancer-related deaths in the United
States. The National Cancer Institute estimated that approximately 270,000 new cases of breast cancer would be diagnosed in the United
States in 2019, and approximately 42,000 breast cancer patients would die of the disease. Approximately 190,000, or 70%, of these new
cases are for ER+/HER2- breast cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
different breast cancer subtypes are currently identified using molecular tests that determine the level of ER and HER2 expression. About
70% of breast cancers are ER+/HER2-, which is indicative of hormone dependency. Despite progress in treatment strategies, metastatic
ER+/HER2- breast cancer (mBC) remains an incurable disease, with a median overall survival (OS) of three years and a five-year survival
rate of 25%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
different classes of targeted therapies are currently used to treat ER+/HER2- tumors: endocrine-based therapies, CDK4/6 inhibitors, PI3K
inhibitors and mTOR inhibitors. Each of the CDK4/6 inhibitors, PI3K inhibitors and mTOR inhibitors are generally used to respond to the
related mechanisms of resistance to endocrine therapy, namely, activation of the CDK4/6, PI3K and mTOR pathways. These drugs generated
revenues of over $8 billion globally in 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
specifically relates to gedatolisib, activation of the PI3K/mTOR pathway has been implicated in a wide variety of human cancers, involving
either activating mutations, or other unknown drivers of pathway amplification. These include cancers of the breast, prostate, endometrial,
colon, rectum, and lung, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI3K
constitutes a lipid kinase family involved in the regulation of diverse cellular processes, including cell proliferation, survival, cytoskeletal
organization, and glucose transport. Class I PI3Ks are of particular therapeutic interest. They are heterodimers, comprising a catalytic
(p110&alpha;, p110&beta;, p110&delta;, or p110&gamma;) and a regulatory (p85&alpha;, p55&alpha;, p50&alpha;, p85&beta;, p55&gamma;, or
p101) subunit. Oncogenic PI3K signaling is activated by cell-surface receptors such as receptor tyrosine kinases, G-protein-coupled receptors,
and also by well-known oncogenic proteins such as RAS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activities
associated with PI3K involve complex essential cell regulatory mechanisms including feedforward and feedback signaling loops. Overactivation
of the pathway is frequently present in human malignancies and plays a key role in cancer progression. Each of the four catalytic isoforms
of class I PI3K preferentially mediate signal transduction and tumor cell survival based on the type of malignancy and the genetic or
epigenetic alterations an individual patient harbors. For example, studies have demonstrated the p110&alpha; catalytic isoform is necessary
for the growth of tumors driven by PIK3CA mutations and/or oncogenic RAS and receptor tyrosine kinases; the p110&beta; catalytic isoform
mediates tumorigenesis arising from the loss of the dephosphorylase activity of PTEN; and the p110&delta; catalytic isoform is highly
expressed in leukocytes, making it a desirable target for inhibition in the treatment of hematologic malignancies. Due to the multiple
subcellular locations, activities, and importance of the different PI3K complexes in regulating many types of cancer cell proliferation,
control of PI3K activity is an important target in cancer therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mTOR
is as a critical effector in cell-signaling pathways commonly dysregulated in human cancers. The mTOR signaling pathway integrates both
intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation, and survival. mTOR
is a serine/threonine protein kinase, a downstream effector of PI3K, and regulated by hormones, growth factors, and nutrients, that is
contained in two functionally distinct protein assemblies: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 belongs to a complex
network of regulatory feedback loops, and once certain levels of activation are reached, is normally responsible for limiting the proliferative
signals transmitted by upstream effectors such as PI3K/AKT activity. Equally complex mTORC2 regulates AKT phosphorylation, GSK3&beta;,
and control over glycolysis, and participates in organizing the cellular actin cytoskeleton. In addition, mTORC1 activation leads to
the direct reduction of mTORC2 activity and mTOR can activate the functional domain of the ER, leading to ligand-independent hormone
receptor activation. In cancer, dysfunctional signaling leads to various constitutive activities of mTOR complexes, making mTOR a good
therapeutic target.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PI3K/mTOR
as Resistance Mechanism to Endocrine and CDK4/6 Inhibitors </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
upregulation of the PI3K/AKT/mTOR pathway promotes hormone dependent and independent ER transcriptional activity, which contributes to
endocrine resistance, leading to tumor cell growth, survival, motility, and metabolism. It has also been demonstrated in vivo that PI3K
and mTOR inhibition can restore sensitivity to endocrine therapy, providing a strong rationale for the combination of the two therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the PI3K/AKT/mTOR pathway, like other mitogenic pathways, can also promote the activities of cyclin D and CDK4/6 to drive proliferative
cell cycling. Internal preclinical studies conducted by Pfizer provided evidence in cell-line xenograft models that the combination of
PI3K and CDK4/6 inhibitors may overcome both intrinsic and adaptive resistance to endocrine therapy, leading to tumor regressions. In
an MCF7 xenograft model (ER+/HER2-/PIK3CA mutant) the combination of gedatolisib with palbociclib and Faslodex (fulvestrant) led to durable
tumor regressions. Importantly, tumors regressed to minimal volumes within 20 days of triplet therapy, and continued to remain dormant,
without further therapy, for up to 90 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<IMG SRC="image_002.jpg" ALT="" STYLE="height: 224px; width: 554px"><BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advantages
of Gedatolisib over other PI3K and mTOR inhibitors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
important role the PI3K/AKT/mTOR pathway plays in cancer has led to significant investment in the development of many different PI3K
and mTOR inhibitors for solid tumors. However, developing efficacious and well-tolerated therapies that target this pathway has been
challenging. This reflects the inherent adaptability and complexity of the PI3K pathway, where numerous feedforward and feedback loops,
crosstalk with other pathways, and compensatory pathways enable resistance to PI3K inhibition. Another major hurdle for the development
of PI3K pathway inhibitors has been the inability to achieve optimal drug-target blockade in tumors while avoiding undue toxicities in
patients. These challenges may explain why PI3K and mTOR inhibitors have not yielded the outstanding clinical activity many researchers
expected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there is significant potential for gedatolisib to address previously treated breast cancer tumors and has the potential to be
used in other tumor types where the PI3K/AKT/mTOR pathway is either: i) driving tumorigenesis directly; ii) cooperating with other dysregulated
signaling pathways; or iii) a mechanism of resistance to other drug therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we believe gedatolisib&rsquo;s unique mechanism of action and intravenous formulation offer distinct advantages over currently
approved and investigational therapies that target PI3K or mTOR alone or together.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overcomes
    drug resistance that can occur with isoform-specific PI3K inhibitors. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
    is a pan-class I isoform PI3K inhibitor with low nanomolar potency for the p110&alpha;, p110&beta;, p110&gamma;, and p110&delta;
    isoforms. Each isoform is known to preferentially affect different signal transduction events that involve tumor cell survival, depending
    upon the aberrations associated with the linked pathway. A pan-PI3K inhibitor can thus treat tumors harboring abnormalities that
    signal through different PI3K isoforms, which would potentially induce anti-tumor activity in a broader population of patients than
    an isoform-specific PI3K inhibitor. In addition, it has been reported that inhibition of one PI3K isoform may be offset by the increased
    activity of the other isoforms through different adaptive mechanisms. Inhibiting all four PI3K isoforms, as gedatolisib does, can
    thus prevent the confounding effect of isoform interaction that may occur with isoform-specific PI3K inhibitors.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overcomes
    paradoxical activation of PI3K induced by mTOR inhibition.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a potent inhibitor of mTOR, in addition to PI3K, gedatolisib, inhibits the PI3K/AKT/mTOR pathway both upstream and downstream of
    AKT. Furthermore, it has been demonstrated that the PI3K pathway is activated following selective mTOR inhibition by relief of normal
    feedback regulatory mechanisms, thus providing a compelling rationale for simultaneous inhibition of PI3K and mTOR.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Better
    tolerated by patients than oral PI3K and mTOR drugs.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
    is administered intravenously (IV) once weekly or on a four-week cycle of three weeks-on, one week-off, in contrast to the orally
    administered pan-PI3K or dual PI3K/mTOR inhibitors that are no longer being clinically developed. Oral pan-PI3K or PI3K/mTOR inhibitors
    have repeatably been found to induce significant side effects that were not well tolerated by patients. This typically leads to a
    high proportion of patients requiring dose reductions or treatment discontinuation. The challenging toxicity profile of these drug
    candidates ultimately played a significant role in the decisions to halt their development, despite showing promising efficacy. By
    contrast, gedatolisib stabilizes at lower concentration levels in plasma compared to orally administered PI3K inhibitors, resulting
    in less toxicity, while maintaining concentrations sufficient to inhibit PI3K/AKT/mTOR signaling.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isoform-specific
    PI3K inhibitors administered orally were developed to reduce toxicities in patients. While the range of toxicities associated with
    isoform-specific inhibitors is narrower than oral pan-PI3K or PI3K/mTOR inhibitors, administering them orally on a continuous basis
    still leads to challenging toxicities. The experience with an FDA approved oral p110-&alpha; specific inhibitor, Piqray, illustrates
    the challenge. In its Phase 3 pivotal trial Piqray was found to induce a Grade 3 or 4 adverse event (AE) related to hyperglycemia
    in 39% of patients evaluated. In addition, 26% of patients discontinued treatment. By contrast, in the 103-patient dose expansion
    portion of the Phase 1b clinical trial with gedatolisib, only 7% of patients experienced Grade 3 or 4 hyperglycemia and less than
    10% discontinued treatment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Experience with Gedatolisib</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2021, 492 patients with solid tumors have received gedatolisib in eight clinical trials sponsored by Pfizer. Of the
492 patients, 129 were treated with gedatolisib as a single agent in three clinical trials. The remaining 363 patients received gedatolisib
in combination with other anti-cancer agents in five clinical trials. Additional patients received gedatolisib in combination with other
anti-cancer agents in nine investigator sponsored clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Phase
1 First-in-Human Study </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pfizer
conducted a Phase 1, open-label, dose-escalation first-in human study of single-agent gedatolisib in patients with advanced solid tumors.
The primary objective of Part 1 of the study was to determine the safety, tolerability, and maximum tolerated dose (MTD) of single-agent
gedatolisib administered once weekly as an intravenous (IV) infusion. Seventy-seven patients with advanced solid tumors received doses
of gedatolisib and the MTD was determined to be 154 mg IV once weekly (n = 42). Subsequent analysis determined that the recommended Phase
2 dose could be increased to 180 mg IV once weekly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the MTD, the majority of patients enrolled in the MTD group experienced only grade 1 treatment-related adverse events (AEs). Grade 3
treatment-related adverse events were noted in 23.8% of patients, and the most frequently reported included mucosal inflammation and
stomatitis (7.1%), increased alternative lengthening of telomeres (ALT) (7.1%), and increased aspartate aminotransferase (AST) (4.8%).
No treatment-related AEs of grade 4 or 5 severity were reported at any dose level.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Phase
1b ER+/HER2- mBC Clinical Trial Results (preliminary)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, Pfizer initiated a Phase 1b trial dose-finding trial with an expansion portion for safety and efficacy to evaluate gedatolisib
when added to either the standard doses of palbociclib plus letrozole or palbociclib plus fulvestrant in patients with ER+/HER2- metastatic
breast cancer. PI3K mutation status was not used as an eligibility criterion. Patient enrollment for the trial is complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
illustration below depicts how the combination of gedatolisib, palbociclib, and fulvestrant is intended to simultaneously block interdependent
ER, PI3K, mTOR &amp; CDK signaling pathways in ER+ breast cancer to address ER and CDKi resistance mechanisms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 138 patients with ER+/HER2- metastatic breast cancer were dosed in the clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35
    patients were enrolled in two dose escalation arms to evaluate the safety and tolerability and determine the MTD of gedatolisib when
    used in combination with the standard doses of palbociclib and endocrine therapies. The MTD was determined to be 180 mg administered
    intravenously once weekly.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">103
    patients were enrolled in one of four expansion arms (A, B, C, D) to determine if the triplet combination of gedatolisib plus palbociclib
    and letrozole or gedatolisib plus palbociclib and fulvestrant produced a superior objective response (OR), compared to historical
    control data of the doublet combination (palbociclib plus endocrine therapy). All patients received gedatolisib in combination with
    standard doses of palbociclib and endocrine therapy (either letrozole or fulvestrant). In Arms A, B, and C, patients received an
    intravenous dose of 180 mg of gedatolisib once weekly. In Arm D, patients received an intravenous dose of 180 mg of gedatolisib on
    a four-week cycle of three weeks-on, one week-off. Objective response was determined using Response Evaluation Criteria in Solid
    Tumors v1.0, or RECIST v1.0.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Arm
    A</B>: mBC with progression and no prior endocrine-based systemic therapy or a CDK4/6 inhibitor in the metastatic setting. First-line
    endocrine-based therapy for metastatic disease (CDK4/6 treatment naive).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Arm
    B</B>: mBC with progression during one or two prior endocrine-based systemic therapy in the metastatic setting, with no prior therapy
    with any CDK inhibitor. Second- or third-line endocrine-based therapy for metastatic disease.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Arm
    C</B>: mBC with progression during one or two prior endocrine-based systemic therapies in the metastatic setting and following prior
    therapy with a CDK inhibitor. Second- or third-line endocrine-based therapy for metastatic disease.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Arm
    D</B>: mBC having progressed on a CDK inhibitor in combination with endocrine therapy as the most recent regimen for metastatic disease.
    Second- or third-line endocrine-based therapy for metastatic disease.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
preliminary analysis for the 103 patients enrolled in the expansion portion of the Phase 1b clinical trial, as of the database cutoff
date of January 11, 2021, showed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efficacy
    analysis for all arms in aggregate:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>  <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9675;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60%
    objective response rate (ORR): 53 of the 88 evaluable patients had either a confirmed or unconfirmed partial response, or PR (48
    confirmed, 5 unconfirmed).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &#9675;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75%
    clinical benefit rate (CBR): 66 of the 88 evaluable patients had either a confirmed PR or had stable disease for 24 weeks.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Best
    responses, as measured by RECIST v1.0, are shown in the following chart. The dotted line represents the cutoff for PR (defined as
    a 30% reduction from baseline).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>&nbsp;<IMG SRC="image_004.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
    safety analysis:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>  &#9675;
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    all arms in aggregate, all patients experienced at least one Grade 1 or Grade 2 treatment-emergent adverse event. The most commonly
    reported adverse events regardless of grade and occurring in at least 30% of patients included stomatitis (81%), neutropenia (80%),
    nausea (75%), fatigue (68%), dysgeusia (46%), vomiting (45%), anemia (40%), diarrhea (34%), decreased appetite (32%), leukopenia
    (32%).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &#9675;
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    all arms in aggregate, the Grade 3 and 4 treatment-emergent adverse events occurring in at least 20% of patients were neutropenia
    (67%), stomatitis (27%) and rash (20%). Neutropenia is a known class effect of CDK4/6 inhibitors. Stomatitis was reversible in most
    patients with a steroidal mouth rinse. All grades of treatment-related adverse events related to hyperglycemia was reported in 22%
    of patients; Grade 3 or 4 hyperglycemia was reported in 7% of patients. Gedatolisib was discontinued in 10% of patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9675;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the patients in Arm D, who received the recommended phase two dose, Grade 3 and 4 treatment-emergent adverse events occurring in
    at least 20% of patients were neutropenia (67%) stomatitis and (22%). All grades of treatment-related adverse events related to hyperglycemia
    was reported in 22% of patients; Grade 3 or 4 hyperglycemia was reported in 7% of patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9675;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
    was discontinued in 7% of patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9675;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of the cutoff date, 22 patients were continuing to receive gedatolisib in combination with the other study drugs, 17 of whom have
    been on study treatment for more than two years.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
    best overall response data for each arm is presented in the table below:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Arm</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(evaluable patients)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A (N=24)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">B (N=12)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">C (N=27)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">D (N=25)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Patients</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">1L: <BR>CDKi-na&iuml;ve</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2L+: <BR>CDKi-na&iuml;ve</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2L/3L: <BR>CDKi-pretreated</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">2L/3L: <BR>Immediately <BR>prior CDKi</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; width: 32%; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overall Response Rate </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(evaluable patients) </B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">83</TD><TD STYLE="padding-bottom: 1.5pt; width: 3%; text-align: left">%<SUP>1</SUP></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">75</TD><TD STYLE="padding-bottom: 1.5pt; width: 3%; text-align: left">%<SUP>2</SUP></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">33</TD><TD STYLE="padding-bottom: 1.5pt; width: 3%; text-align: left">%<SUP>3</SUP></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">60</TD><TD STYLE="padding-bottom: 1.5pt; width: 3%; text-align: left">%<SUP>4</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical Benefit Rate </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(evaluable patients)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">92</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">92</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">76</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Arm A: 20 of the 24 evaluable patients had a confirmed PR.</FONT></P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Arm B: 9 of the 12 evaluable patients had either a confirmed PR or unconfirmed PR (7 confirmed PR, 2 unconfirmed PR).</FONT></P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Arm C: 9 of the 27 evaluable patients had either a confirmed PR or unconfirmed PR (7 confirmed PR, 2 unconfirmed PR).</FONT></P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Arm D: 15 of the 25 evaluable patients had either a confirmed PR or unconfirmed PR (14 confirmed PR, 1 unconfirmed PR).</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
    progression free survival (PFS) data for each arm is presented in the table below:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; width: 40%; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Arm</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(enrolled patients)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; width: 3%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A (N=31)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 3%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B (N=13)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 3%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C (N=32)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 3%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D (N=27)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Median PFS </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(months) (95% CI)</B></FONT></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&gt;29</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Not Yet Reached)</FONT></P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.7, NR)</FONT></P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.4, 7.5)</FONT></P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9.0, 16.7)</FONT></P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In light of the preliminary results
reported to date from the Phase 1b trial, we intend to initiate, subject to feedback from the FDA, a Phase 2/3 clinical trial evaluating
gedatolisib in combination with palbociclib and an endocrine therapy in patients with ER+/HER2- advanced or metastatic breast cancer in
the first half of 2022.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to use the CELsignia PI3K Activity Test to help support development of gedatolisib for breast cancer indications. Our internal
studies demonstrate how measurement of PI3K-involved signaling may provide a sensitive and specific method of identifying patients most
likely to benefit from PI3K inhibitors. We believe CELsignia tests uniquely enable us to pursue indications simultaneously for unselected
patient populations and CELsignia selected patient sub-groups. This approach can greatly reduce the risk of pursing an indication for
a large, but unselected patient population, as we plan to do for the initial gedatolisib indication. By combining the capabilities of
CELsignia PI3K Activity Test with a potent pan-PI3K/mTOR inhibitor like gedatolisib, we believe we are uniquely suited to maximize the
probability of obtaining regulatory approval to market gedatolisib.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Phase
2 Pilot Clinical Trial for HER2+/PIK3CA+ Patients</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Korean Cancer Study Group sponsored a Phase 2 pilot clinical trial to evaluate gedatolisib combined with a trastuzumab biosimilar (Herzuma&reg;),
in patients with HER2+/PIK3CA+ metastatic breast cancers whose disease had progressed after treatment with three or more prior HER2 targeted
therapy regimens. The clinical trial commenced in December 2019 and interim efficacy data from the first 16 patients enrolled was presented
at the San Antonio Breast Cancer Symposium in December 2020. Patients received a trastuzumab biosimilar (8 mg/kg IV for 1st cycle loading
dose, and then 6 mg/kg IV every 3 weeks) plus gedatolisib (180 mg, weekly IV). The primary endpoint was objective response, a reduction
of at least 30% in tumor volume by RECIST v1.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of a data cutoff date of October 30, 2020, nine of 16 patients achieved a partial response, an ORR of 56%, and four patients had stable
disease. Thirteen of 16 patients thus received either a partial response or stable disease, resulting in a clinical benefit rate of 81%.
Best responses are shown in the following chart. The dotted lines represent the cutoff for progressive disease (&gt;20% tumor growth)
and for partial response (&gt;30% tumor regression).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Best
Response</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_005.jpg" ALT=""><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Patient whose target lesion decreased by 63% but a new leptomeningeal seeding occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duration of treatment for the 16 patients evaluated is shown in the chart below. As of the October 30, 2020 data cutoff, 16 patients
(80%) remained on therapy. Four patients discontinued treatment, one due to disease progression, one due to an adverse event of Grade
1 diarrhea, one participant decision, and one patient being unable to undergo the required MRI imaging due to a titanium rod implant
from non-treatment related worsening of scoliosis. At the time of data cut-off, the median time on treatment for these 20 patients was
10.1 cycles (approximately 10 months) and all 10 patients who had achieved an objective response remained on therapy assessment. At the
time of the analysis, nine patients had a continuing response. The dashed lines show the response at 3 months and 6 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duration
of Treatment </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_006.jpg" ALT=""><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELsignia
Development and CDx Programs </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary CELsignia diagnostic platform is the only commercially ready technology we are aware of that uses a patient&rsquo;s living
tumor cells to identify the specific abnormal cellular process driving a patient&rsquo;s cancer and the targeted therapy that best treats
it. This enables us to identify patients whose tumors may respond to a targeted therapy, even though they lack a previously associated
molecular mutation. By identifying cancer patients whose tumors lack an associated genetic mutation but have abnormal cellular activity
a matching targeted therapeutic is designed to inhibit, CELsignia CDx can expand the markets for a number of already approved targeted
therapies. Our current CDx identifies breast and ovarian cancer patients whose tumors have cancer drivers potentially responsive to treatment
with human epidermal growth factor receptor 2-negative (HER2), mesenchymal-epithelial transition factor (c-MET), or phosphatidylinositol
3-kinases (PI3K) targeted therapeutics. While U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) approval or clearance is not currently
required for CELsignia tests offered as a stand-alone laboratory developed test, if we are partnered with a drug company to launch a
CELsignia test as a companion diagnostic for a new drug indication, we would be required to obtain premarket approval, or PMA, in conjunction
with the pharmaceutical company seeking a new drug approval for the matching therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CELsignia platform provides an important advantage over traditional molecular diagnostics. Current molecular diagnostics analyze fragmented
cells to obtain a snapshot of the genetic mutations present in a patient&rsquo;s tumor. Using cell fragments prevents molecular diagnostics
from analyzing the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival. Cancer can develop
when critical cell signaling, regulating physiologic activity such as cell proliferation, becomes abnormal or dysregulated. Since genetic
mutations are often only weakly correlated to the dysregulated cell signaling activity driving a patient&rsquo;s cancer, a molecular
diagnostic is prone to providing an incomplete diagnosis. CELsignia tests overcome this limitation by measuring dynamic cell signaling
activity in a cancer patient&rsquo;s living tumor cells. When a CELsignia test detects abnormal signaling activity, a more accurate diagnosis
of the patient&rsquo;s cancer driver is obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are supporting the advancement of new potential indications for seven different targeted therapies, controlled by other pharmaceutical
companies, that would rely on a CELsignia CDx to select patients. Six Phase 2 trials are underway to evaluate the efficacy and safety
of these therapies in CELsignia selected patients. These patients are not currently eligible to receive these drugs and are not identifiable
with a molecular test.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first analytically validated and commercially ready test using our CELsignia platform, the CELsignia HER2 Pathway Activity Test for breast
cancer, diagnoses two new sub-types of HER2-negative breast cancer that traditional molecular diagnostics cannot detect. Our internal
studies show that approximately 15-20% of HER2-negative breast cancer patients have abnormal HER2 signaling activity similar to levels
found in HER2-positive breast cancer cells. As a result, these HER2-negative patients have undiagnosed HER2-driven breast cancer and
would be likely to respond to the same anti-HER2 targeted therapies only HER2-positive patients receive today. We have four interventional
clinical trials underway to evaluate the efficacy of HER2 targeted therapies in breast cancer patients selected with our CELsignia HER2
Pathway Activity Test.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second CELsignia test for breast cancer evaluates independent c-Met signaling activity and its involvement with HER family signaling
in HER2-negative breast cancer tumor cells. Our internal studies show that approximately 20%-25% of HER2-negative breast cancer patients
have abnormal c-Met signaling activity that is co-activated with abnormal HER family signaling. These studies suggest that this sub-group
of HER2-negative breast cancer patients may best respond to treatment with a combination of HER family and c-Met inhibitors. We have
two interventional clinical trials underway to evaluate the efficacy of HER2 and c-Met targeted therapies, in previously treated metastatic
HER2-negative breast cancer patients selected with our CELsignia Multi-Pathway Activity Test, or CELsignia MP Test.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
third CELsignia test for breast cancer evaluates PI3K signaling in HER2-negative breast cancer tumor cells. Our internal studies demonstrate
how measurement of PI3K-involved signaling may provide a more sensitive and specific method of identifying patients most likely to benefit
from PI3K inhibitors than current genetic tests that measure PI3K mutations. We intend to combine these three tests to expand the CELsignia
MP Test. With this next generation CELsignia test, we plan to provide an analysis of EGFR/HER1, HER2, HER3, c-MET, and PI3K-node involved
signaling activity for each patient tumor specimen received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed development of our first CELsignia test for ovarian cancer in 2020. This test identifies a new sub-group of ovarian cancer
patients with tumors that have abnormal c-Met and HER2 signaling activity. These findings suggest that a significant sub-group of ovarian
cancer patients may respond to treatment with a combination of ErbB and c-Met inhibitors. Nearly 14,000 women a year die from ovarian
cancer, a disease that has less than a 50% five-year survival rate and a limited range of targeted therapy options. There is thus a significant
unmet need for additional therapeutic options for ovarian cancer patients. As a companion diagnostic, our CELsignia test for ovarian
cancer will be intended to help pharmaceutical companies obtain new drug indications and expand treatment options for this challenging
tumor type. We are currently in discussions with pharmaceutical companies about collaborating on future clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our CELsignia tests for HER2-negative breast cancer and ovarian cancer, we expect to develop CELsignia tests to diagnose
eight new potential cancer sub-types we have discovered in lung, ovarian, kidney, and bladder cancers. Approved or investigational drugs
are currently available to treat these new potential cancer sub-types. We expect to launch these additional tests on a staggered basis
over the next few years while continuing our research to identify additional new cancer sub-types.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
overall commercialization strategy is to develop diagnostics that expand the patient population eligible for targeted therapies. In furtherance
of this strategy, we will seek collaborations with pharmaceutical companies to field clinical trials to advance the clinical development
of their targeted therapies with the eventual goal of obtaining FDA approval of a new drug indication. Collaborations are expected to
involve initially Phase I or Phase II interventional clinical trials to evaluate the efficacy of our collaboration partners&rsquo; targeted
therapies on patients selected with one of our CELsignia tests. These trials would not be intended to separately evaluate the CELsignia
tests, whether as standalone tests or companion diagnostics. While FDA approval or clearance is not currently required for CELsignia
tests offered as a stand-alone laboratory developed test, if we are partnered with a drug company to launch a CELsignia test as a companion
diagnostic for a new drug indication, we would be required to obtain premarket approval, or PMA, in conjunction with the pharmaceutical
company seeking a new drug approval for the matching therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently collaborating on six Phase II clinical trials to evaluate the efficacy of our collaboration partners&rsquo; targeted therapies
in patients selected with one of our CELsignia tests. The goal of these trials is to support the development of six potential new drug
indications to treat patient groups found responsive by our CELsignia test to their approved targeted therapies. These clinical trials
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FACT-1
    Clinical Trial to Evaluate Efficacy of Genentech&rsquo;s HER2 Targeted Therapies. We are collaborating with NSABP Foundation, Inc.
    (&ldquo;NSABP&rdquo;) and Genentech, Inc. (&ldquo;Genentech&rdquo;) to evaluate the efficacy and safety of Genentech&rsquo;s drugs,
    Herceptin (trastuzumab) and Perjeta (pertuzumab), and chemotherapy in breast cancer patients selected with our CELsignia test. Based
    on NSABP&rsquo;s updated estimates of patient enrollment rates to reflect the impact of COVID-19 and the impact in the third quarter
    of hospitalizations associated with the SARS-CoV-2 Delta variant, interim results are expected to be available in the second half
    of 2022 and final results approximately nine months later. The goal is to demonstrate that patients who have an abnormal HER2 signaling
    pathway, as identified by our CELsignia test, respond to treatment with a matching targeted therapy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FACT-2
    Clinical Trial to Evaluate Efficacy of Puma&rsquo;s HER2 Targeted Therapy. We are collaborating with Puma Biotechnology, Inc. (&ldquo;Puma&rdquo;)
    and West Cancer Center to conduct a Phase II single-arm interventional trial to evaluate the efficacy and safety of Puma&rsquo;s
    drug, Nerlynx (neratinib), and chemotherapy in breast cancer patients selected with our CELsignia test. Based on West Cancer Center&rsquo;s
    updated estimates of patient enrollment rates to reflect the impact of COVID-19 and the impact in the third quarter of hospitalizations
    associated with the SARS-CoV-2 Delta variant, interim results are expected to be available in the second half of 2022 and final results
    approximately nine months later. The goal of the trial is to demonstrate that triple-negative breast cancer patients who have a hyperactive
    HER2 signaling tumor, as identified by the CELsignia test, respond to treatment with Nerlynx, a matching HER2 therapy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FACT-3
    Clinical Trial to Evaluate Efficacy of Pfizer&rsquo;s pan-HER and c-Met Targeted Therapies. In January 2021, we announced a clinical
    trial collaboration with Sarah Cannon Research Institute and Pfizer to conduct a Phase II clinical trial. This open-label Phase II
    trial will evaluate the efficacy and safety of two Pfizer targeted therapies, Vizimpro (dacomitinib), a pan-HER inhibitor, and Xalkori
    (crizotinib), a c-Met inhibitor, in previously treated metastatic HER2-negative breast cancer patients selected with our CELsignia
    MP Test. Based on the Sarah Cannon Research Institute&rsquo;s estimates of patient enrollment rates, interim results are expected
    12-15 months after the protocol is activated and final results 12-15 months later.. The goal of the trial is to demonstrate that
    previously treated HER2-negative metastatic breast cancer patients who have hyperactive HER2 and c-Met signaling tumors, as identified
    by the CELsignia test, respond to treatment with Vizimpro in combination with Xalkori.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FACT-4
    Clinical Trial to Evaluate Efficacy of Puma&rsquo;s HER2 Targeted Therapy. In December 2020, we announced a clinical trial collaboration
    with Massachusetts General Hospital and Puma, a biopharmaceutical company, to conduct a Phase II clinical trial. This open-label
    Phase II trial will evaluate the efficacy and safety of Puma&rsquo;s drug, Nerlynx (neratinib), and fulvestrant, an AstraZeneca drug,
    in previously treated metastatic HR-positive (HR+), HER2-negative breast cancer patients selected with our CELsignia HER2 Pathway
    Activity Test. Based on Massachusetts General Hospital&rsquo;s estimates of patient enrollment rates, we expect to obtain interim
    results 12-15 months after the protocol is activated and final results 12 to 15 months later. The goal of the trial is to demonstrate
    that previously treated HR+, HER2-negative metastatic breast cancer patients who have hyperactive HER2 signaling tumors, as identified
    by the CELsignia test, respond to treatment with Nerlynx in combination with Faslodex, a hormonal therapy that targets the estrogen
    receptor.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;FACT-5
    Clinical Trial to Evaluate Efficacy of Puma&rsquo;s pan-HER Inhibitor and chemotherapy. In October 2021, we announced a clinical
    trial collaboration with University of Rochester Wilmot Cancer Center and Puma, to conduct a Phase II clinical trial. This open-label
    Phase II trial will evaluate the efficacy and safety of Puma&rsquo;s drug, Nerlynx (neratinib), and the chemotherapy capecitabine,
    in previously treated metastatic HER2-negative breast cancer patients with brain metastases selected with our CELsignia HER2 Pathway
    Activity Test. Based on University of Rochester Wilmot Cancer Center estimates of patient enrollment rates, we expect to obtain interim
    results 12-15 months after the protocol is activated and the final results 12 to 15 months later. We expect enrollment to begin in
    the second quarter of 2022. The goal of the trial is to demonstrate that previously treated HER2-negative metastatic breast cancer
    patients with brain metastases who have hyperactive HER2 signaling tumors, as identified by the CELsignia test, respond to treatment
    with Nerlynx in combination with capecitabine.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FACT-6
    Clinical Trial to Evaluate Efficacy of Novartis&rsquo;s c-Met Inhibitor and Puma&rsquo;s pan-HER Inhibitor. In March 2021, we announced
    a clinical trial collaboration with MD Anderson, Novartis AG, and Puma, to conduct a Phase I/II clinical trial. This open-label Phase
    I/II trial will evaluate the efficacy and safety of Novartis&rsquo; c-Met inhibitor, Tabrecta (capmatinib), and Puma&rsquo;s pan-HER
    inhibitor, Nerlynx (neratinib), in previously treated metastatic HER2-negative breast cancer patients selected with our CELsignia
    MP Test. Based on MD Anderson&rsquo;s estimates of patient enrollment rates, we expect to obtain interim results 12-15 months after
    the protocol is activated and final results 12-15 months later. The goal of the trial is to demonstrate that previously treated HER2-negative
    metastatic breast cancer patients who have hyperactive HER2 and c-Met signaling tumors, as identified by the CELsignia test, respond
    to treatment with Tabrecta in combination with Nerlynx.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
of COVID-19 on our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Health
and Safety </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
help protect the health and safety of our employees, suppliers and collaborators, we took proactive, aggressive action from the earliest
signs of the outbreak. We enacted rigorous safety measures in our laboratory and administrative offices, including implementing social
distancing protocols, allowing working from home for those employees that do not need to be physically present in a lab to perform their
work, suspending travel, implementing temperature checks at the entrances to our facilities, extensively and frequently disinfecting
our workspaces and providing masks to those employees who must be physically present. We expect to continue with these measures until
the COVID-19 pandemic is better contained and we may take further actions as government authorities require or recommend or as we determine
to be in the best interests of our employees, suppliers, and collaborators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Trials and Collaborations </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the COVID-19 pandemic, governmental authorities implemented numerous and constantly evolving measures to try to contain the
virus, such as travel bans and restrictions, limits on gatherings, quarantines, shelter-in-place orders, and business shutdowns. While
many of these measures have been relaxed in recent months, new variants of the coronavirus, such as the Delta variant, appear likely
to cause new or former protective measures to be reconsidered. As we continue to advance our clinical trial collaborations, we are in
close contact with our current clinical sponsors, and principal investigators, as well as prospective pharmaceutical company and clinical
collaborators, to assess the impact of COVID-19 on our trial enrollment timelines and collaboration discussions. Based on delays in the
enrollment of patients in our ongoing clinical trials due to the increased hospitalizations associated with the SARS-CoV-2 Delta variant,
we now expect interim results from the FACT-1 and FACT-2 trials to be delayed until the second half of 2022 and final results approximately
nine months later. As the impact of COVID-19 on our industry becomes clearer, we may need to reassess the timing of our anticipated clinical
milestones. Prospective clinical trial collaborations with pharmaceutical companies and sponsors may also be delayed but the impact on
the timing of finalizing agreements is not yet known.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our facility currently remains operational, the evolving measures to try to contain the virus have impacted and may further impact our
workforce and operations, as well as those of our vendors and suppliers. Our laboratory remains operational as of this date, but, in
response to the COVID-19 pandemic, we have implemented protective policies that reduce the number of research and development staff operating
in our laboratory at any one time. However, in light of the focus of healthcare providers and hospitals on fighting the virus, several
of the clinical sites that provide us tumor tissue for research have halted this service, reducing the number of new tumor tissue specimens
we would typically expect to receive. These various constraints may slow or diminish our research and development activities, particularly
if the pandemic continues to experience rising infections from the Delta variant of the coronavirus or otherwise. In addition, cancer
research-related industry meetings, such as the American Association for Cancer Research (AACR), were previously delayed for several
months and could be again in the future as a result of the virus. So far, our submissions to present research results at these meetings
have been accepted, but the release of the results have been postponed in conjunction with the delayed meeting schedules. We cannot be
certain as to whether these types of delays will continue and what the impact will be on our ability to present research results in the
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office is located at 16305 36th Avenue North, Suite 100, Minneapolis, Minnesota. Our telephone number is (763) 392-0767,
and our website is www.celcuity.com. The information contained on or accessible through our website is not incorporated by reference
into, and should not be considered part of, this prospectus supplement, the accompanying prospectus or the information incorporated herein
by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, for
as long as we continue to be an &ldquo;emerging growth company,&rdquo; we may choose to take advantage of exemptions from various reporting
requirements applicable to other public companies but not to &ldquo;emerging growth companies,&rdquo; including, but not limited to,
not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure
obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding
a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
We could be an &ldquo;emerging growth company&rdquo; for up to five years, or until the earliest of (i) the last day of the first fiscal
year in which our annual gross revenues exceed $1.07 billion, (ii) the date that we become a &ldquo;large accelerated filer&rdquo; as
defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which would occur if the market value of our common shares
that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter,
or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_003"></A><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves risk. You should consider the risks, uncertainties and assumptions discussed under the heading &ldquo;Risk
Factors&rdquo; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed on February 16, 2021 with the Securities
and Exchange Commission (&ldquo;SEC&rdquo;), and in Exhibit 99.4 (&ldquo;Supplemental Risk Factors&rdquo;) to our Current Report on Form
8-K, filed on April 8, 2021 with the SEC, which are incorporated herein by reference, and may be amended, supplemented or superseded
from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have described are not the only
ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations.
If any of these risks were to occur, our business, financial condition, and results of operations could be severely harmed. This could
cause the trading price of our common stock to decline, and you could lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any prospectus supplement applicable to each offering of our securities will contain a discussion of the risks applicable to
such an investment in us. Prior to making a decision about investing in our securities, you should carefully consider the specific factors
discussed under the heading &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement, together with all of the other information
contained or incorporated by reference in such prospectus supplement or appearing or incorporated by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, any prospectus supplement and the documents incorporated herein by reference contain forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as amended, or the &ldquo;Securities Act&rdquo;, and Section 21E of
the Securities Exchange Act of 1934, as amended, or the &ldquo;Exchange Act&rdquo;, which are subject to the safe harbor created by those
sections. These forward-looking statements and information regarding us, our business prospects and our results of operations are subject
to certain risks and uncertainties that could cause our actual business, prospects and results of operations to differ materially from
those that may be anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include,
but are not limited to, those described under &ldquo;Risk Factors&rdquo; herein and in our other filings with the SEC. You should not
place undue reliance on these forward-looking statements. You should assume that the information contained in or incorporated by reference
in this prospectus, and any prospectus supplement, is accurate only as of the date on the front cover of this prospectus, and any prospectus
supplement, or as of the date of the documents incorporated by reference herein or therein, as applicable. We expressly disclaim any
intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
You are urged to carefully review and consider the various disclosures made by us in this prospectus, any prospectus supplement and the
documents incorporated herein by reference and in our other reports filed with the SEC that advise interested parties of the risks and
uncertainties that may affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
statements, other than statements of historical facts, contained in this prospectus, any prospectus supplement and the documents incorporated
herein by reference, including statements regarding our plans, objectives and expectations for our business, operations and financial
performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by the following
words: &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;target,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; or the negative of these
terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause our results, performance or achievements to be materially different
from the information expressed or implied by the forward-looking statements in this prospectus, any prospectus supplement and the documents
incorporated herein by reference. Additionally, our forward-looking statements do not reflect the potential impact of any future acquisitions,
mergers, dispositions, joint ventures or investments that we may make. Forward-looking statements may include, among other things, statements
relating to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    clinical trial plans and the estimated costs for such trials, including the timing of launching a Phase 2/3 clinical trial for gedatolisib;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations with respect to costs and timelines to develop, validate and launch CELsignia tests and to continue to develop gedatolisib;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    beliefs related to the perceived advantages of our CELsignia tests compared to traditional molecular or other diagnostic tests;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expected benefits of gedatolisib;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding the timeline of patient enrollment and results from clinical trials, including the existing clinical trial
    for gedatolisib;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    future payments that may be owed to Pfizer under the License Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding partnering with pharmaceutical companies and other third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding revenue from sales of CELsignia tests and revenue from milestone or other payment sources;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    plans with respect to research and development and related expenses for the foreseeable future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding business development activities, including companion diagnostic related activities with pharmaceutical companies,
    expanding our sales and marketing functions and the costs associated with such activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations with respect to the CELsignia tests and the analytical capabilities of such tests;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    beliefs regarding the adequacy of our cash on hand to fund our research and development expenses, clinical trial expenditures, capital
    expenditures, working capital, sales and marketing expenses, and general corporate expenses, as well as the increased costs associated
    with being a public company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding the impact that the COVID-19 pandemic and related economic effects will have on our business and results of
    operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_005"></A><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities covered
by this prospectus for general corporate purposes. General corporate purposes may include working capital, capital expenditures, research
and development expenditures, clinical trial expenditures, expansion of sales, marketing and reimbursement functions and other general
corporate purposes. We may also use a portion of our net proceeds to acquire or invest in complementary products, technologies or businesses.
Additional information on the use of net proceeds from the sale of securities covered by this prospectus may be set forth in any prospectus
supplement relating to the specific offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts and timing of our expenditures will depend on numerous factors, including the status, results and timing of the current and expected
clinical trials involving gedatolisib and our CELsignia tests and our current and expected nonclinical studies. Accordingly, our management
will have broad discretion over the use of the net proceeds from the sale of any securities offered by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities offered through this prospectus (1) to or through underwriters or dealers, (2) directly to purchasers, including
our affiliates, (3) through agents, or (4) through a combination of any of these methods. The securities may be distributed at a fixed
price or prices, which may be changed, market prices prevailing at the time of sale, prices related to the prevailing market prices,
or negotiated prices. The prospectus supplement will include the following information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms of the offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    names of any underwriters or agents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    name or names of any managing underwriter or underwriters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purchase price of the securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    net proceeds from the sale of the securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delayed delivery arrangements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    underwriting discounts, commissions and other items constituting underwriters&rsquo; compensation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    initial public offering price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    discounts or concessions allowed or reallowed or paid to dealers; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    commissions paid to agents.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sale
through underwriters or dealers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
underwriters are used in the sale, the underwriters will acquire the securities for their own account, including through underwriting,
purchase, security lending or repurchase agreements with us. The underwriters may resell the securities from time to time in one or more
transactions, including negotiated transactions. Underwriters may sell the securities in order to facilitate transactions in any of our
other securities (described in this prospectus or otherwise), including other public or private transactions and short sales. Underwriters
may offer securities to the public either through underwriting syndicates represented by one or more managing underwriters or directly
by one or more firms acting as underwriters. Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters
to purchase the securities will be subject to certain conditions, and the underwriters will be obligated to purchase all the offered
securities if they purchase any of them. The underwriters may change from time to time any initial public offering price and any discounts
or concessions allowed or reallowed or paid to dealers. The prospectus supplement will include the names of the principal underwriters,
the respective amount of securities underwritten, the nature of the obligation of the underwriters to take the securities and the nature
of any material relationship between an underwriter and us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
dealers are used in the sale of securities offered through this prospectus, we will sell the securities to them as principals. They may
then resell those securities to the public at varying prices determined by the dealers at the time of resale. The prospectus supplement
will include the names of the dealers and the terms of the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Direct
sales and sales through agents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities offered through this prospectus directly. In this case, no underwriters or agents would be involved. Such securities
may also be sold through agents designated from time to time. The prospectus supplement will name any agent involved in the offer or
sale of the offered securities and will describe any commissions payable to the agent by us. Unless otherwise indicated in the prospectus
supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning of the
Securities Act with respect to any sale of those securities. The terms of any such sales will be described in the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delayed
delivery contracts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the prospectus supplement indicates, we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions
to purchase securities at the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery
on a specified date in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The
applicable prospectus supplement will describe the commission payable for solicitation of those contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
making, stabilization and other transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the applicable prospectus supplement states otherwise, each series of securities offered by us will be a new issue and will have no established
trading market, other than our common stock, which is listed on The Nasdaq Capital Market. We may elect to list any series of offered
securities on an exchange. Any underwriters that we use in the sale of offered securities may make a market in such securities, but may
discontinue such market making at any time without notice. Therefore, we cannot assure you that the securities will have a liquid trading
market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
underwriter may also engage in stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Rule 104
under the Securities Exchange Act of 1934, as amended. Stabilizing transactions involve bids to purchase the underlying security in the
open market for the purpose of pegging, fixing or maintaining the price of the securities. Syndicate covering transactions involve purchases
of the securities in the open market after the distribution has been completed in order to cover syndicate short positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate
member are purchased in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering
transactions and penalty bids may cause the price of the securities to be higher than it would be in the absence of the transactions.
The underwriters may, if they commence these transactions, discontinue them at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Derivative
transactions and hedging</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
the underwriters or other agents may engage in derivative transactions involving the securities. These derivatives may consist of short
sale transactions and other hedging activities. The underwriters or agents may acquire a long or short position in the securities, hold
or resell securities acquired and purchase options or futures on the securities and other derivative instruments with returns linked
to or related to changes in the price of the securities. In order to facilitate these derivative transactions, we may enter into security
lending or repurchase agreements with the underwriters or agents. The underwriters or agents may effect the derivative transactions through
sales of the securities to the public, including short sales, or by lending the securities in order to facilitate short sale transactions
by others. The underwriters or agents may also use the securities purchased or borrowed from us or others (or, in the case of derivatives,
securities received from us in settlement of those derivatives) to directly or indirectly settle sales of the securities or close out
any related open borrowings of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
auctions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also make sales through the Internet or through other electronic means. Since we may from time to time elect to offer securities
directly to the public, with or without the involvement of agents, underwriters or dealers, utilizing the Internet or other forms of
electronic bidding or ordering systems for the pricing and allocation of such securities, you should pay particular attention to the
description of that system we will provide in a prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
electronic system may allow bidders to directly participate, through electronic access to an auction site, by submitting conditional
offers to buy that are subject to acceptance by us, and which may directly affect the price or other terms and conditions at which such
securities are sold. These bidding or ordering systems may present to each bidder, on a so-called &ldquo;real-time&rdquo; basis, relevant
information to assist in making a bid, such as the clearing spread at which the offering would be sold, based on the bids submitted,
and whether a bidder&rsquo;s individual bids would be accepted, prorated or rejected. For example, in the case of a debt security, the
clearing spread could be indicated as a number of &ldquo;basis points&rdquo; above an index treasury note. Of course, many pricing methods
can and may also be used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of such an electronic auction process, securities will be allocated based on prices bid, terms of bid or other factors. The
final offering price at which securities would be sold and the allocation of securities among bidders would be based in whole or in part
on the results of the Internet or other electronic bidding process or auction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents,
underwriters, and dealers may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities,
including liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_007"></A><B>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of the terms of our capital stock is subject to and qualified in its entirety by reference to our certificate of incorporation,
as amended, and bylaws, copies of which are on file with the SEC as exhibits to previous SEC filings. Please refer to &ldquo;Where You
Can Find More Information&rdquo; below for directions on obtaining these documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of November 16, 2021, we were authorized to issue 25,000,000 shares of common stock, $0.001 par value per share, and 2,500,000 shares
of preferred stock, $0.001 par value per share. As of November 16, 2021, we had 14,918,887 shares of common stock outstanding and no
shares of preferred stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available
for that purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Rights
and Preferences</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions
applicable to our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Right
to Liquidation Distributions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable
ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction
of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding
shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
Agent and Registrar</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Continental Stock Transfer &amp; Trust Company. The transfer agent and registrar&rsquo;s
address is One State Street Plaza, 30th Floor, New York, NY 10004.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Nasdaq Capital Market</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed for quotation on The Nasdaq Capital Market under the symbol &ldquo;CELC.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board or directors is authorized, without action by the stockholders, to designate and issue up to an aggregate of 2,500,000 shares of
preferred stock in one or more series. Our board of directors is authorized to designate the rights, preferences and privileges of the
shares of each series and any of its qualifications, limitations or restrictions. Our board of directors is able to authorize the issuance
of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common
stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and
other corporate purposes could, under certain circumstances, have the effect of restricting dividends on our common stock, diluting the
voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change
in control of the Company, which might harm the market price of our common stock. See also &ldquo;Anti-Takeover Effect of Delaware Law
and Certain Charter and Bylaw Provisions&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we offer a specific class or series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the
prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the
SEC. To the extent required and applicable, this description will include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title and stated value;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares offered, the liquidation preference per share and the purchase price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    procedures for any auction and remarketing, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions for a sinking fund, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions for redemption, if applicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    listing of the preferred stock on any securities exchange or market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be calculated)
    and conversion period;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated)
    and exchange period;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting
    rights, if any, of the preferred stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion of any material U.S. federal income tax considerations applicable to the preferred stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding
    up of the affairs of our Company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred
    stock as to dividend rights and rights upon liquidation, dissolution or winding up of our Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preferred stock offered by this prospectus, when issued, will not have, or be subject to, any preemptive or similar rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
Agent and Registrar</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for any series or class of preferred stock will be set forth in each applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effect of Delaware Law and Certain Charter and Bylaw Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, as amended, and bylaws contain provisions that could have the effect of discouraging potential acquisition
proposals or tender offers or delaying or preventing a change of control of our Company. A summary of these provisions is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
    of directors vacancies. </I></B>Our bylaws authorize only our board of directors to fill vacant directorships, including newly created
    seats. In addition, the number of directors constituting our board of directors will be permitted to be set only by a resolution
    adopted by our board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors
    and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult
    to change the composition of our board of directors but promotes continuity of management.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
    notice requirements for stockholder proposals and director nominations.</I></B> Our bylaws provide advance notice procedures for
    stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors
    at our annual meeting of stockholders. Our bylaws also specify certain requirements regarding the form and content of a stockholder&rsquo;s
    notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from
    making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. These provisions
    may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate
    of directors or otherwise attempting to obtain control of the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
    cumulative voting. </I></B>The Delaware General Corporation Law, or DGCL, provides that stockholders are not entitled to the right
    to cumulate votes in the election of directors unless a corporation&rsquo;s certificate of incorporation provides otherwise. Our
    certificate of incorporation, as amended, does not provide for cumulative voting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stockholder
    action; special meetings of stockholders.</I></B> Our certificate of incorporation, as amended, provides that our stockholders may
    not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder
    controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a meeting of
    our stockholders called in accordance with our bylaws. Further, our bylaws provide that special meetings of our stockholders may
    be called only by a majority of our board of directors, the chairperson of our board of directors, or our Chief Executive Officer,
    thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
    consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal
    of directors.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Issuance
    of undesignated preferred stock.</I></B> We have 2,500,000 shares of undesignated preferred stock. Our board of directors has the
    authority, without further action by the stockholders, to issue this preferred stock with rights and preferences, including voting
    rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock
    would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger,
    tender offer, proxy contest or other means.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment
    of charter and bylaw provisions.</I></B> The affirmative vote of stockholders representing at least two-thirds of the voting power
    of all then-outstanding capital stock is required to amend, alter or repeal certain provisions of our certificate of incorporation,
    as amended, including the provision noted above regarding stockholders not being able to act by written consent. A majority of our
    board of directors has authority to adopt, amend or repeal provisions of our bylaws. Stockholders also have the authority to adopt,
    amend or repeal provisions of our bylaws, but only with the affirmative vote of stockholders representing at least two-thirds of
    the voting power of all then-outstanding capital stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the provisions of Section 203 of the DGCL, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware
corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three
years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved
in a prescribed manner. For purposes of Section 203, a &ldquo;business combination&rdquo; includes a merger, asset sale or other transaction
resulting in a financial benefit to the interested stockholder, and an &ldquo;interested stockholder&rdquo; is a person who owns 15%
or more of the voting stock of a corporation, or any affiliate or associate of a corporation who, within three years prior, did own 15%
or more of the voting stock of that corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
of Directors and Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102(b)(7) of the DGCL provides that a Delaware corporation, in its certificate of incorporation, may limit the personal liability of
a director to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability
for any:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transaction
    from which the director derived an improper personal benefit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">act
    or omission not in good faith or that involved intentional misconduct or a knowing violation of law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful
    payment of dividends or redemption of shares; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach
    of the director&rsquo;s duty of loyalty to the corporation or its stockholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(a) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who was or is a party, or is threatened
to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the corporation) because that person is or was a director, officer, employee or agent of
the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation
or other enterprise. The indemnity may include expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by the person in connection with such action, so long as the person acted in good faith and in a manner
he or she reasonably believed was in or not opposed to the corporation&rsquo;s best interests, and, with respect to any criminal action
or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(b) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who was or is a party, or is threatened
to be made a party, to any threatened, pending or completed action or suit by or in the right of the corporation to obtain a judgment
in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses
(including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such
action, so long as the person acted in good faith and in a manner the person reasonably believed was in or not opposed to the corporation&rsquo;s
best interests, except that no indemnification shall be permitted without judicial approval if a court has determined that the person
is to be liable to the corporation with respect to such claim. Section 145(c) of the DGCL provides that, if a present or former director
or officer has been successful in defense of any action referred to in Sections 145(a) and (b) of the DGCL, the corporation must indemnify
such officer or director against the expenses (including attorneys&rsquo; fees) he or she actually and reasonably incurred in connection
with such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was
a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation or other enterprise against any liability asserted against and incurred by such person, in any
such capacity, or arising out of his or her status as such, whether or not the corporation could indemnify the person against such liability
under Section 145 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, as amended, and our bylaws provide for the limitation of liability and indemnification of our directors
and officers to the fullest extent permitted under the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also entered into separate indemnification agreements with our directors and officers in addition to the indemnification provided
for in our certificate of incorporation, as amended, and our bylaws. These indemnification agreements provide, among other things, that
we will indemnify our directors and officers for certain expenses, including damages, judgments, fines, penalties, settlements and costs
and attorneys&rsquo; fees and disbursements, incurred by a director or officer in any claim, action or proceeding arising in his or her
capacity as a director or officer of the Company or in connection with service at our request for another corporation or entity. The
indemnification agreements also provide for procedures that will apply in the event that a director or officer makes a claim for indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain a directors&rsquo; and officers&rsquo; insurance policy pursuant to which our directors and officers are insured against
liability for actions taken in their capacities as directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SEC
Position on Indemnification for Securities Act Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted for directors, officers or persons controlling our
Company, we understand that it is the SEC&rsquo;s opinion that such indemnification is against public policy as expressed in the Securities
Act and therefore is unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>DESCRIPTION
OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of November 16, 2021, we had warrants outstanding to purchase 377,652 shares of our common stock. We may issue warrants to purchase shares
of our common stock, preferred stock and/or debt securities in one or more series together with other securities or separately, as described
in each applicable prospectus supplement. Below is a description of certain general terms and provisions of the warrants that we may
offer. Particular terms of the warrants will be described in the applicable warrant agreements and the applicable prospectus supplement
for the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    specific designation and aggregate number of, and the price at which we will issue, the warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    currency or currency units in which the offering price, if any, and the exercise price are payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    designation, amount and terms of the securities purchasable upon exercise of the warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the exercise price for shares of our common stock and the number of shares of common stock to be received upon exercise
    of the warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the exercise price for shares of our preferred stock, the number of shares of preferred stock to be received upon exercise,
    and a description of that class or series of our preferred stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the exercise price for our debt securities, the amount of our debt securities to be received upon exercise, and a description
    of that series of debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the right to exercise the warrants will begin and the date on which that right will expire or, if the warrants may
    not be continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these
    forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security
    included in that unit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    applicable material U.S. federal income tax consequences;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars
    or other agents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the date from and after which the warrants and the common stock, preferred stock and/or debt securities will be separately
    transferable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
    with respect to book-entry procedures, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    anti-dilution provisions of the warrants, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    redemption or call provisions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the warrants are to be sold separately or with other securities as parts of units; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will issue the debt securities offered by this prospectus and any accompanying prospectus supplement under an indenture to be entered
into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will include those
stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as in effect on the date
of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement in which this prospectus
is included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of 1939.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer under this prospectus up to an aggregate principal amount of $150,000,000 in debt securities, or if debt securities are issued
at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may be sold for an initial
public offering price of up to $150,000,000. Unless otherwise specified in the applicable prospectus supplement, the debt securities
will represent our direct, unsecured obligations and will rank equally with all of our other unsecured indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following statements relating to the debt securities and the indenture are summaries, qualified in their entirety by reference to the
detailed provisions of the debt securities we issue and the indenture we enter into with the trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will
describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which we will file
with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus supplement will set forth, to the extent required and applicable, the following terms of the debt securities in respect of
which the prospectus supplement is delivered:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title of the series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    aggregate principal amount, and, if a series, the total amount authorized and the total amount outstanding;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    limit on the aggregate principal amount;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date or dates on which principal is payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such rate or rates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date or dates from which interest, if any, will be payable and any regular record date for the interest payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    place or places where principal and, if applicable, premium and interest, is payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    denominations in which such debt securities may be issuable, if other than denominations of $1,000 or any integral multiple of that
    number;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the debt securities are to be issuable in the form of certificated securities (as described below) or global securities (as described
    below);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    portion of principal amount that will be payable upon declaration of acceleration of the maturity date if other than the principal
    amount of the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    currency of denomination;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    designation of the currency, currencies or currency units in which payment of principal and, if applicable, premium and interest,
    will be made;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or more currencies or
    currency units other than the currency of denomination, the manner in which the exchange rate with respect to such payments will
    be determined;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    amounts of principal and, if applicable, premium and interest may be determined by reference to an index based on a currency or currencies
    or by reference to a commodity, commodity index, stock exchange index or financial index, then the manner in which such amounts will
    be determined;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions, if any, relating to any collateral provided for such debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    addition to or change in the covenants and/or the acceleration provisions described in this prospectus or in the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    events of default, if not otherwise described below under &ldquo;Events of Default&rdquo;;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions, if any, for conversion into or exchange for shares of our common stock or preferred stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    depositaries, interest rate calculation agents, exchange rate calculation agents or other agents; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to our other indebtedness,
    if any.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue discount debt securities that provide for an amount less than the stated principal amount to be due and payable upon acceleration
of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form,
with or without coupons. If we issue discount debt securities or debt securities in bearer form, we will describe material U.S. federal
income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do,
we will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency
or currencies or foreign currency unit or units in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange
and/or Conversion Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities that can be exchanged for or converted into shares of our common stock or preferred stock. If we do, we will
describe the terms of exchange or conversion in the prospectus supplement relating to these debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
and Exchange</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities that will be represented by either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;book-entry
    securities,&rdquo; which means that there will be one or more global securities registered in the name of a depositary or a nominee
    of a depositary; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;certificated
    securities,&rdquo; which means that they will be represented by a certificate issued in definitive registered form.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will specify in the prospectus supplement applicable to a particular offering whether the debt securities offered will be book-entry
or certificated securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certificated
Debt Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you hold certificated debt securities, you may transfer or exchange such debt securities at the trustee&rsquo;s office or at the paying
agent&rsquo;s office or agency in accordance with the terms of the indenture. You will not be charged a service charge for any transfer
or exchange of certificated debt securities but may be required to pay an amount sufficient to cover any tax or other governmental charge
payable in connection with such transfer or exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may effect the transfer of certificated debt securities and of the right to receive the principal of, premium, and/or interest, if any,
on the certificated debt securities only by surrendering the certificate representing the certificated debt securities and having us
or the trustee issue a new certificate to the new holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Global
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we decide to issue debt securities in the form of one or more global securities, then we will register the global securities in the name
of the depositary for the global securities or the nominee of the depositary, and the global securities will be delivered by the trustee
to the depositary for credit to the accounts of the holders of beneficial interests in the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus supplement will describe the specific terms of the depositary arrangement for debt securities of a series that are issued
in global form. None of us, the trustee, any payment agent or the security registrar will have any responsibility or liability for any
aspect of the records relating to or payments made on account of beneficial ownership interests in a global debt security or for maintaining,
supervising or reviewing any records relating to these beneficial ownership interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Protection in the Event of Change of Control</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture does not have any covenants or other provisions providing for a put or increased interest or otherwise that would afford holders
of our debt securities additional protection in the event of a recapitalization transaction, a change of control, or a highly leveraged
transaction. If we offer any covenants or provisions of this type with respect to any debt securities covered by this prospectus, we
will describe them in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Covenants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities will not have the benefit of any
covenants that limit or restrict our business or operations, the pledging of our assets or the incurrence by us of indebtedness. We will
describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidation,
Merger and Sale of Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
form of indenture provides that we will not consolidate with or merge into any other person or convey, transfer, sell or lease our properties
and assets substantially as an entirety to any person, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    person formed by the consolidation or into or with which we are merged or the person to which our properties and assets are conveyed,
    transferred, sold or leased, is a corporation organized and existing under the laws of the U.S., any state or the District of Columbia
    or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and, if we are not the surviving person,
    the surviving person has expressly assumed all of our obligations, including the payment of the principal of and, premium, if any,
    and interest on the debt securities and the performance of the other covenants under the indenture; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately
    before and immediately after giving effect to the transaction, no event of default, and no event which, after notice or lapse of
    time or both, would become an event of default, has occurred and is continuing under the indenture.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Events
of Default</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise specified in the applicable prospectus supplement, the following events will be events of default under the indenture with
respect to debt securities of any series:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    fail to pay any principal or premium, if any, when it becomes due;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    fail to pay any interest within 30 days after it becomes due;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    fail to observe or perform any other covenant in the debt securities or the indenture for 60 days after written notice specifying
    the failure from the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities
    of that series; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    events involving bankruptcy, insolvency or reorganization of us or any of our significant subsidiaries.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trustee may withhold notice to the holders of the debt securities of any series of any default, except in payment of principal of or
premium, if any, or interest on the debt securities of a series, if the trustee considers it to be in the best interest of the holders
of the debt securities of that series to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default (other than an event of default resulting from certain events of bankruptcy, insolvency or reorganization) occurs,
and is continuing, then the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities
of any series may accelerate the maturity of the debt securities. If this happens, the entire principal amount, plus the premium, if
any, of all the outstanding debt securities of the affected series plus accrued interest to the date of acceleration will be immediately
due and payable. At any time after the acceleration, but before a judgment or decree based on such acceleration is obtained by the trustee,
the holders of a majority in aggregate principal amount of outstanding debt securities of such series may rescind and annul such acceleration
if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    events of default (other than nonpayment of accelerated principal, premium or interest) have been cured or waived;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    lawful interest on overdue interest and overdue principal has been paid; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rescission would not conflict with any judgment or decree.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the acceleration occurs at any time when we have outstanding indebtedness that is senior to the debt securities, the payment
of the principal amount of outstanding debt securities may be subordinated in right of payment to the prior payment of any amounts due
under the senior indebtedness, in which case the holders of debt securities will be entitled to payment under the terms prescribed in
the instruments evidencing the senior indebtedness and the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default resulting from certain events of bankruptcy, insolvency or reorganization occurs, the principal, premium and interest
amount with respect to all of the debt securities of any series will be due and payable immediately without any declaration or other
act on the part of the trustee or the holders of the debt securities of that series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of a majority in principal amount of the outstanding debt securities of a series will have the right to waive any existing default
or compliance with any provision of the indenture or the debt securities of that series and to direct the time, method and place of conducting
any proceeding for any remedy available to the trustee, subject to certain limitations specified in the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
holder of any debt security of a series will have any right to institute any proceeding with respect to the indenture or for any remedy
under the indenture, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder gives to the trustee written notice of a continuing event of default;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holders of at least 25% in aggregate principal amount of the outstanding debt securities of the affected series make a written request
    and offer reasonable indemnity to the trustee to institute a proceeding as trustee;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    trustee fails to institute a proceeding within 60 days after such request; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holders of a majority in aggregate principal amount of the outstanding debt securities of the affected series do not give the trustee
    a direction inconsistent with such request during such 60-day period.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
limitations do not, however, apply to a suit instituted for payment on debt securities of any series on or after the due dates expressed
in the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will periodically deliver certificates to the trustee regarding our compliance with our obligations under the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modification
and Waiver</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we and the trustee may, without the consent of holders of the debt securities of one or more series, amend the indenture
or the debt securities of one or more series, or supplement the indenture, for certain specified purposes, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide that the surviving entity following a change of control permitted under the indenture will assume all of our obligations
    under the indenture and debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide for certificated debt securities in addition to uncertificated debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    comply with any requirements of the SEC under the Trust Indenture Act of 1939;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted by the
    indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    cure any ambiguity, defect or inconsistency, or make any other change that does not materially and adversely affect the rights of
    any holder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    appoint a successor trustee under the indenture with respect to one or more series.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time we and the trustee may, with the consent of holders of at least a majority in principal amount of an outstanding series
of debt securities, amend or supplement the indenture or the debt securities series, or waive compliance in a particular instance by
us with any provision of the indenture or the debt securities. We may not, however, without the consent of each holder affected by such
action, modify or supplement the indenture or the debt securities or waive compliance with any provision of the indenture or the debt
securities in order to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the amount of debt securities whose holders must consent to an amendment, supplement, or waiver to the indenture or such debt security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the rate of or change the time for payment of interest or reduce the amount of or postpone the date for payment of sinking fund or
    analogous obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the principal of or change the stated maturity of the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any debt security payable in money other than that stated in the debt security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">change
    the amount or time of any payment required or reduce the premium payable upon any redemption, or change the time before which no
    such redemption may be made;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">waive
    a default in the payment of the principal of, premium, if any, or interest on the debt securities or a redemption payment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">waive
    a redemption payment with respect to any debt securities or change any provision with respect to redemption of debt securities; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">take
    any other action otherwise prohibited by the indenture to be taken without the consent of each holder affected by the action.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Defeasance
of Debt Securities and Certain Covenants in Certain Circumstances</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture permits us, at any time, to elect to discharge our obligations with respect to one or more series of debt securities by following
certain procedures described in the indenture. These procedures will allow us either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    defease and be discharged from any and all of our obligations with respect to any debt securities, except for the following obligations
    (which discharge is referred to as &ldquo;legal defeasance&rdquo;):</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    register the transfer or exchange of such debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    replace temporary or mutilated, destroyed, lost or stolen debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    compensate and indemnify the trustee; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    maintain an office or agency in respect of the debt securities and to hold monies for payment in trust; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    be released from our obligations with respect to the debt securities under certain covenants contained in the indenture, as well
    as any additional covenants which may be contained in the applicable supplemental indenture (which release is referred to as &ldquo;covenant
    defeasance&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to exercise either defeasance option, we must deposit with the trustee or other qualifying trustee, in trust for that purpose:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">money;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    Government Obligations (as described below) or Foreign Government Obligations (as described below) that through the scheduled payment
    of principal and interest in accordance with their terms will provide money; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of money and/or U.S. Government Obligations and/or Foreign Government Obligations sufficient in the written opinion of
    a nationally-recognized firm of independent accountants to provide money;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that,
in each case specified above, provides a sufficient amount to pay the principal of, premium, if any, and interest, if any, on the debt
securities of the series, on the scheduled due dates or on a selected date of redemption in accordance with the terms of the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, defeasance may be effected only if, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of either legal or covenant defeasance, we deliver to the trustee an opinion of counsel, as specified in the indenture,
    stating that as a result of the defeasance neither the trust nor the trustee will be required to register as an investment company
    under the Investment Company Act of 1940;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of legal defeasance, we deliver to the trustee an opinion of counsel stating that we have received from, or there has been
    published by, the Internal Revenue Service a ruling to the effect that, or there has been a change in any applicable federal income
    tax law with the effect that (and the opinion shall confirm that), the holders of outstanding debt securities will not recognize
    income, gain or loss for U.S. federal income tax purposes solely as a result of such legal defeasance and will be subject to U.S.
    federal income tax on the same amounts, in the same manner, including as a result of prepayment, and at the same times as would have
    been the case if legal defeasance had not occurred;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of covenant defeasance, we deliver to the trustee an opinion of counsel to the effect that the holders of the outstanding
    debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of covenant defeasance and
    will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case
    if covenant defeasance had not occurred; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    other conditions described in the indenture are satisfied.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with our remaining obligations under the indenture and applicable supplemental indenture after a covenant defeasance
of the indenture and applicable supplemental indenture, and the debt securities are declared due and payable because of the occurrence
of any undefeased event of default, the amount of money and/or U.S. Government Obligations and/or Foreign Government Obligations on deposit
with the trustee could be insufficient to pay amounts due under the debt securities of the affected series at the time of acceleration.
We will, however, remain liable in respect of these payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;U.S. Government Obligations&rdquo; as used in the above discussion means securities that are direct obligations of or non-callable
obligations guaranteed by the United States of America for the payment of which obligation or guarantee the full faith and credit of
the United States of America is pledged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;Foreign Government Obligations&rdquo; as used in the above discussion means, with respect to debt securities of any series
that are denominated in a currency other than U.S. dollars, (1) direct obligations of the government that issued or caused to be issued
such currency for the payment of which obligations its full faith and credit is pledged or (2) obligations of a person controlled or
supervised by or acting as an agent or instrumentality of such government the timely payment of which is unconditionally guaranteed as
a full faith and credit obligation by that government, which in either case under clauses (1) or (2), are not callable or redeemable
at the option of the issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regarding
the Trustee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will identify the trustee with respect to any series of debt securities in the prospectus supplement relating to the applicable debt
securities. You should note that if the trustee becomes a creditor of ours, the indenture and the Trust Indenture Act of 1939 limit the
rights of the trustee to obtain payment of claims in certain cases, or to realize on certain property received in respect of any such
claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other
transactions with us and our affiliates. If, however, the trustee acquires any &ldquo;conflicting interest&rdquo; within the meaning
of the Trust Indenture Act of 1939, it must eliminate such conflict or resign.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of a majority in principal amount of the then outstanding debt securities of any series may direct the time, method and place
of conducting any proceeding for exercising any remedy available to the trustee. If an event of default occurs and is continuing, the
trustee, in the exercise of its rights and powers, must use the degree of care and skill of a prudent person in the conduct of his or
her own affairs. Subject to that provision, the trustee will be under no obligation to exercise any of its rights or powers under the
indenture at the request of any of the holders of the debt securities, unless they have offered to the trustee reasonable indemnity or
security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_010"></A>DESCRIPTION
OF UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We
may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements
with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit
agent in the applicable prospectus supplement relating to a particular series of units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description, together with the additional information included in any applicable prospectus supplement, summarizes the general
features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus
that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that
contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file as an
exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we
file with the SEC, the form of each unit agreement relating to units offered under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without
limitation, the following, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title of the series of units;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    and description of the separate constituent securities comprising the units;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices at which the units will be issued;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date, if any, on and after which the constituent securities comprising the units will be separately transferable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion of certain United States federal income tax considerations applicable to the units; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the units and their constituent securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed a registration statement on Form S-3 with the SEC for the securities we are offering by this prospectus. This prospectus does
not include all of the information contained in the registration statement. You should refer to the registration statement and its exhibits
for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to file annual and quarterly reports, special reports, proxy statements, and other information with the SEC. We make these
documents publicly available, free of charge, on our website at www.celcuity.com as soon as reasonably practicable after filing such
documents with the SEC. <FONT STYLE="background-color: white">Please note, however, that information on our website is not, and should
not be deemed to be, a part of this prospectus.</FONT> You can read our SEC filings, including the registration statement, on the SEC&rsquo;s
website at http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_012"></A><B>INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; into this prospectus the information we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to
be part of this prospectus, and information in documents that we file later with the SEC will automatically update and supersede information
in this prospectus. We incorporate by reference into this prospectus the documents listed below and any future filings made by us with
the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until we close this offering, including all filings made after the
date of the initial registration statement and prior to the effectiveness of the registration statement. We hereby incorporate by reference
the following documents:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on Form 10-K for the year ended December 31, 2020, filed on <A HREF="https://www.sec.gov/Archives/edgar/data/1603454/000165495421001743/0001654954-21-001743-index.htm" STYLE="-sec-extract: exhibit">February 16, 2021</A>;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1603454/000165495421005361/celc_10q.htm" STYLE="-sec-extract: exhibit">May 10, 2021</A>, our Quarterly Report on Form 10-Q for
    the quarter ended June 30, 2021, filed on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001603454/000165495421008769/celc_10q.htm" STYLE="-sec-extract: exhibit">August 11, 2021</A>, and our Quarterly Report on Form 10-Q for the quarter ended September
    30, 2021, filed on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001603454/000149315221027618/form10-q.htm" STYLE="-sec-extract: exhibit">November 9, 2021</A>;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form 8-K or Form 8-K/A (excluding any reports or portions thereof that are deemed to be furnished and not filed)
    filed on <A HREF="https://www.sec.gov/Archives/edgar/data/1603454/000165495421002061/0001654954-21-002061-index.htm" STYLE="-sec-extract: exhibit">February 24, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1603454/000165495421003990/celc-20211231.htm" STYLE="-sec-extract: exhibit">April 8, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1603454/000165495421005626/celc-20211231.htm" STYLE="-sec-extract: exhibit">May 13, 2021</A>, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001603454/000165495421007417/celc_8k.htm" STYLE="-sec-extract: exhibit">June 30, 2021</A>;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    definitive Proxy Statement filed on <A HREF="https://www.sec.gov/Archives/edgar/data/0001603454/000165495421003623/celc_def14a.htm" STYLE="-sec-extract: exhibit">March 31, 2021</A>; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    description of our common stock contained in our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007886/0001571049-17-007886-index.htm" STYLE="-sec-extract: exhibit">Form 8-A</A> filed September 15, 2017, under the Securities
    Act, including any amendment or report filed for the purpose of updating such description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may request a copy of these filings, at no cost, by writing or telephoning us at the following address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc.<BR>
16305 36th Avenue N., Suite 100</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
MN 55446<BR>
Attention: Investor Relations<BR>
Phone: (763) 392-0123</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of these filings are also available, without charge, through the &ldquo;Investors&rdquo; section of our website (www.celcuity.com) as
soon as reasonably practicable after they are filed electronically with the SEC. <FONT STYLE="background-color: white">Please note, however,
that information on our website is not, and should not be deemed to be, a part of this prospectus.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_013"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the issuance of the securities offered hereby will be passed upon for us by Fredrikson &amp; Byron, P.A., Minneapolis, Minnesota.
The validity of any securities will be passed upon for any underwriters or agents by counsel that we will name in the applicable prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_014"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited financial statements incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated
by reference in reliance upon the report of Boulay PLLP, our independent registered public accountants, upon the authority of said firm
as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="" STYLE="width: 224px; height: 61px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Expanding
Treatment Options</B></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$150,000,000</B><BR>
Common Stock<BR>
Preferred Stock<BR>
Warrants<BR>
Debt Securities<BR>
Units</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized any dealer, salesperson or other person to give any information or represent anything not contained in this prospectus.
You must not rely on any unauthorized information. If anyone provides you with different or inconsistent information, you should not
rely on it. This prospectus does not offer to sell any shares in any jurisdiction where it is unlawful. Neither the delivery of this
prospectus, nor any sale made hereunder, shall create any implication that the information in this prospectus is correct after the date
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. <I>Other Expenses of Issuance and Distribution</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the various expenses in connection with the sale and distribution of the securities being registered. All
amounts shown are estimates, except the SEC registration fee. The registrant has agreed to pay these costs and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">Securities and Exchange Commission registration fee</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">13,905</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA corporate filing fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Printing and engraving expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer Agent and Registrar fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Miscellaneous</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> *</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    expenses not presently known.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. <I>Indemnification of Directors and Officers</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102(b)(7) of the Delaware General Corporation Law, or DGCL, provides that a Delaware corporation, in its certificate of incorporation,
may limit the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duties
as a director, except for liability for any:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transaction
                                            from which the director derived an improper personal benefit;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">act
                                            or omission not in good faith or that involved intentional misconduct or a knowing violation
                                            of law;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful
                                            payment of dividends or redemption of shares; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach
                                            of the director&rsquo;s duty of loyalty to the corporation or its stockholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(a) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who was or is a party, or is threatened
to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the corporation) because that person is or was a director, officer, employee or agent of
the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation
or other enterprise. The indemnity may include expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by the person in connection with such action, so long as the person acted in good faith and in a manner
he or she reasonably believed was in or not opposed to the corporation&rsquo;s best interests, and, with respect to any criminal action
or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(b) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who was or is a party, or is threatened
to be made a party, to any threatened, pending or completed action or suit by or in the right of the corporation to obtain a judgment
in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses
(including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such
action, so long as the person acted in good faith and in a manner the person reasonably believed was in or not opposed to the corporation&rsquo;s
best interests, except that no indemnification shall be permitted without judicial approval if a court has determined that the person
is to be liable to the corporation with respect to such claim. Section 145(c) of the DGCL provides that, if a present or former director
or officer has been successful in defense of any action referred to in Sections 145(a) and (b) of the DGCL, the corporation must indemnify
such officer or director against the expenses (including attorneys&rsquo; fees) he or she actually and reasonably incurred in connection
with such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was
a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation or other enterprise against any liability asserted against and incurred by such person, in any
such capacity, or arising out of his or her status as such, whether or not the corporation could indemnify the person against such liability
under Section 145 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, as amended, and our bylaws provide for the limitation of liability and indemnification of our directors
and officers to the fullest extent permitted under the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also entered into separate indemnification agreements with our directors and officers in addition to the indemnification provided
for in our certificate of incorporation, as amended, and our bylaws. These indemnification agreements provide, among other things, that
we will indemnify our directors and officers for certain expenses, including damages, judgments, fines, penalties, settlements and costs
and attorneys&rsquo; fees and disbursements, incurred by a director or officer in any claim, action or proceeding arising in his or her
capacity as a director or officer of the Company or in connection with service at our request for another corporation or entity. The
indemnification agreements also provide for procedures that will apply in the event that a director or officer makes a claim for indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain a directors&rsquo; and officers&rsquo; insurance policy pursuant to which our directors and officers are insured against
liability for actions taken in their capacities as directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. <I>Exhibits</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a list of exhibits filed as part of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
    **</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001603454/000114420418043344/tv499834_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation of the Company as amended (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2018).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001603454/000114420417058480/tv478251_ex3-2.htm" STYLE="-sec-extract: exhibit">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2017).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex4-1.htm" STYLE="-sec-extract: exhibit">Specimen Certificate representing shares of common stock of Celcuity Inc. (incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1603454/000165495420002595/celc_ex42.htm" STYLE="-sec-extract: exhibit">Description of Registered Securities (incorporated by reference to Exhibit 4.2 to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on March 13, 2020).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
    **</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Preferred Stock Certificate</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
    **</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Common Stock Warrant Agreement and Warrant Certificate</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
    **</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Preferred Stock Warrant Agreement and Warrant Certificate</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
    **</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Debt Securities Warrant Agreement and Warrant Certificate</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
    **</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Unit Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
    *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex4-10.htm">Form of Indenture</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
    *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5-1.htm">Opinion of Fredrikson &amp; Byron, P.A. relating to the Securities</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1
    *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Fredrikson &amp; Byron, P.A. (included in Exhibit 5.1)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2
    *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-2.htm">Consent of Boulay PLLP</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1
    *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="#poa_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of attorney (included on the signature page)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement
    of Eligibility of Trustee Under Debt Indenture (to be filed separately pursuant to Section 305(b)(2) of the Trust Indenture Act of
    1939)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
    be filed by amendment or incorporated by reference in connection with the offering of the securities. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. <I>Undertakings</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The undersigned registrant hereby undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Provided</I>,
<I>however</I>, that the undertakings set forth in paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the
information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished
to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated
by reference in the registration statements or is contained in a form of prospectus filed pursuant to Rule 424(b) that is a part of the
registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial <I>bona fide </I>offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
date the filed prospectus was deemed part of and included in the registration statement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required
by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier
of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the
offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date
an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the
registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial
<I>bona fide </I>offering thereof. <I>Provided, however</I>, that no statement made in a registration statement or prospectus that is
part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective
date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such effective date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser: (i) any preliminary prospectus or prospectus
of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; (ii) any free writing prospectus relating
to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; (iii) the
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and (iv) any other communication that is an offer in the offering
made by the undersigned registrant to the purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing
of the registrant&rsquo;s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable,
each filing of an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that
is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is therefore
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, and will be governed
by the final adjudication of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The undersigned registrant hereby undertakes that: (i) for purposes of determining any liability under the Securities Act of 1933, the
information omitted from the form of prospectus filed as part of the registration statement in reliance upon Rule 430A and contained
in the form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed
to be part of the registration statement as of the time it was declared effective; and (ii) for the purpose of determining any liability
under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona
fide </I>offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
If and when applicable, the undersigned registrant, hereby undertakes to file an application for the purpose of determining the eligibility
of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed
by the Commission under Section 305(b)(2) of the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this registration statement on Form S-3 to be signed on its behalf by
the undersigned, thereunto duly authorized, in Minneapolis, Minnesota, on November 17, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
    INC. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian F. Sullivan</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="poa_001"></A>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below constitutes and appoints Brian F. Sullivan and Vicky Hahne, and each of them singly, his or her
true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name,
place, and stead, in any and all capacities, to sign any and all amendments and supplements (including post-effective amendments) to
this Registration Statement on Form S-3, and any related Rule 462(b) registration statement or amendment thereto, to be filed by Celcuity
Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to
all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
and on the dates indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian F. Sullivan</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
and Chief Executive Officer</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    17, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vicky Hahne</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Financial Officer</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    17, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky
    Hahne</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Lance G. Laing</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Science Officer, Vice President and Secretary, and Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    17, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    G. Laing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Richard E. Buller</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    17, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    E. Buller</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David F. Dalvey</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    17, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    F. Dalvey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Leo T. Furcht</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    17, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leo
    T. Furcht</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Richard J. Nigon</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    17, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    J. Nigon</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>2
<FILENAME>ex4-10.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.10</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________,
as Trustee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDENTURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated
as of ___________, _______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAGE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    1 DEFINITIONS AND INCORPORATION BY REFERENCE</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
    DEFINITIONS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
    OTHER DEFINITIONS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.
    INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4.
    RULES OF CONSTRUCTION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    2 THE SECURITIES</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.
    ISSUABLE IN SERIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.
    ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.
    EXECUTION AND AUTHENTICATION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.
    REGISTRAR AND PAYING AGENT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.
    PAYING AGENT TO HOLD ASSETS IN TRUST.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.
    SECURITYHOLDER LISTS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7.
    TRANSFER AND EXCHANGE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8.
    REPLACEMENT SECURITIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9.
    OUTSTANDING SECURITIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10.
    WHEN TREASURY SECURITIES DISREGARDED; DETERMINATION OF HOLDERS&rsquo; ACTION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11.
    TEMPORARY SECURITIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12.
    CANCELLATION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13.
    PAYMENT OF INTEREST; DEFAULTED INTEREST; COMPUTATION OF INTEREST.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14.
    CUSIP NUMBER.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15.
    PROVISIONS FOR GLOBAL SECURITIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16.
    PERSONS DEEMED OWNERS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    3 REDEMPTION</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.
    NOTICES TO TRUSTEE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.
    SELECTION BY TRUSTEE OF SECURITIES TO BE REDEEMED.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.
    NOTICE OF REDEMPTION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.
    EFFECT OF NOTICE OF REDEMPTION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.
    DEPOSIT OF REDEMPTION PRICE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6.
    SECURITIES REDEEMED IN PART.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    4 COVENANTS</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.
    PAYMENT OF SECURITIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.
    SEC REPORTS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.
    WAIVER OF STAY, EXTENSION OR USURY LAWS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.
    COMPLIANCE CERTIFICATE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.
    CORPORATE EXISTENCE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    5 SUCCESSOR CORPORATION</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.
    LIMITATION ON CONSOLIDATION, MERGER AND SALE OF ASSETS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.
    SUCCESSOR PERSON SUBSTITUTED.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">TABLE OF CONTENTS</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">(continued)</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">PAGE</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    6 DEFAULTS AND REMEDIES</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.
    EVENTS OF DEFAULT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.
    ACCELERATION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.
    REMEDIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.
    WAIVER OF PAST DEFAULTS AND EVENTS OF DEFAULT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.
    CONTROL BY MAJORITY.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6.
    LIMITATION ON SUITS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7.
    RIGHTS OF HOLDERS TO RECEIVE PAYMENT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8.
    COLLECTION SUIT BY TRUSTEE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9.
    TRUSTEE MAY FILE PROOFS OF CLAIM.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10.
    PRIORITIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11.
    UNDERTAKING FOR COSTS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    7 TRUSTEE</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.
    DUTIES OF TRUSTEE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.
    RIGHTS OF TRUSTEE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3.
    INDIVIDUAL RIGHTS OF TRUSTEE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.
    TRUSTEE&rsquo;S DISCLAIMER.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5.
    NOTICE OF DEFAULT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.
    REPORTS BY TRUSTEE TO HOLDERS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.
    COMPENSATION AND INDEMNITY.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8.
    REPLACEMENT OF TRUSTEE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9.
    SUCCESSOR TRUSTEE BY CONSOLIDATION, MERGER OR CONVERSION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10.
    ELIGIBILITY; DISQUALIFICATION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11.
    PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12.
    PAYING AGENTS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    8 AMENDMENTS, SUPPLEMENTS AND WAIVERS</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.
    WITHOUT CONSENT OF HOLDERS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.
    WITH CONSENT OF HOLDERS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.
    COMPLIANCE WITH TRUST INDENTURE ACT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.
    REVOCATION AND EFFECT OF CONSENTS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5.
    NOTATION ON OR EXCHANGE OF SECURITIES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6.
    TRUSTEE TO SIGN AMENDMENTS, ETC.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    9 DISCHARGE OF INDENTURE; DEFEASANCE</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.
    DISCHARGE OF INDENTURE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.
    LEGAL DEFEASANCE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.
    COVENANT DEFEASANCE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.
    CONDITIONS TO LEGAL DEFEASANCE OR COVENANT DEFEASANCE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5.
    DEPOSITED MONEY AND U.S. AND FOREIGN GOVERNMENT OBLIGATIONS TO BE HELD IN TRUST; OTHER MISCELLANEOUS PROVISIONS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6.
    REINSTATEMENT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7.
    MONEYS HELD BY PAYING AGENT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8.
    MONEYS HELD BY TRUSTEE.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    10 MISCELLANEOUS</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.
    TRUST INDENTURE ACT CONTROLS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.
    NOTICES.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.
    COMMUNICATIONS BY HOLDERS WITH OTHER HOLDERS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4.
    CERTIFICATE AND OPINION AS TO CONDITIONS PRECEDENT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5.
    STATEMENT REQUIRED IN CERTIFICATE AND OPINION.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6.
    RULES BY TRUSTEE AND AGENTS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.
    BUSINESS DAYS; LEGAL HOLIDAYS; PLACE OF PAYMENT.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8.
    GOVERNING LAW.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9.
    NO ADVERSE INTERPRETATION OF OTHER AGREEMENTS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10.
    NO RECOURSE AGAINST OTHERS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11.
    SUCCESSORS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.
    MULTIPLE COUNTERPARTS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13.
    TABLE OF CONTENTS, HEADINGS, ETC.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14.
    SEVERABILITY.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15.
    SECURITIES IN A FOREIGN CURRENCY OR IN EUROS.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16.
    JUDGMENT CURRENCY.</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: -1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: -1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CROSS-REFERENCE
TABLE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TIA
    SECTION</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDENTURE
    SECTION</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310(a)(1)(2)(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310(a)(3)(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8;
    7.10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">311(a)(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">311(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312(b)(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313(a)(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6;
    10.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2;
    4.4; 10.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(c)(1)(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4;
    10.5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(c)(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1,
    7.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5;
    10.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1;
    7.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">315(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(a)(last
    sentence)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(a)(1)(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(a)(1)(B)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(a)(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">316(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">317(a)(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">317(a)(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">317(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5;
    7.12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">318(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:
This Cross-Reference Table shall not, for any purpose, be deemed to be a part of the Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDENTURE,
dated as of _____________, _______, by and between Celcuity Inc., a Delaware corporation, as Issuer (the &ldquo;Company&rdquo;) _______________and
, a __________________organized under the laws of <U>______________</U>, as Trustee (the &ldquo;Trustee&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS
OF THE COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has duly authorized the execution and delivery of this Indenture to provide for the issuance from time to time of its debentures,
notes or other evidences of indebtedness to be issued in one or more series (the &ldquo;Securities&rdquo;), as herein provided, up to
such principal amount as may from time to time be authorized in or pursuant to one or more resolutions of the Board of Directors or by
supplemental indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
things necessary to make this Indenture a valid agreement of the Company in accordance with its terms have been done, and the execution
and delivery thereof have been in all respects duly authorized by the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE, THIS INDENTURE WITNESSETH:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and in consideration of the premises and the purchase of the Securities by the Holders thereof, it is mutually agreed, for the equal
and proportionate benefit of all Holders of the Securities of a Series thereof, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
DEFINITIONS AND INCORPORATION BY REFERENCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
DEFINITIONS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Affiliate&rdquo;
of any specified Person means any other Person which, directly or indirectly through one or more intermediaries, controls, or is controlled
by or is under common control with, such specified Person. For the purposes of this definition, &ldquo;control&rdquo; (including, with
correlative meanings, the terms &ldquo;controlling,&rdquo; &ldquo;controlled by&rdquo; and &ldquo;under common control with&rdquo;),
as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the
management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Agent&rdquo;
means any Registrar, Paying Agent, co-registrar or agent for service of notices and demands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Board
of Directors&rdquo; means the Board of Directors of the Company or any committee duly authorized to act therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Board
Resolution&rdquo; means a copy of a resolution certified pursuant to an Officers&rsquo; Certificate to have been duly adopted by the
Board of Directors of the Company and to be in full force and effect on the date of such certification which has been delivered to the
Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Capital
Stock&rdquo; means, with respect to any Person, any and all shares or other equivalents (however designated) of capital stock, partnership
interests or any other participation, right or other interest in the nature of an equity interest in such Person or any option, warrant
or other security convertible into any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Company&rdquo;
means the party named as such in the first paragraph of this Indenture until a successor replaces such party pursuant to Article 5 of
this Indenture, and thereafter means the successor and any other primary obligor on the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Company
Order&rdquo; means a written order signed in the name of the Company by two Officers, one of whom must be its Chief Executive Officer
or its Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Company
Request&rdquo; means any written request signed in the name of the Company by its Chief Executive Officer, its President, any Vice President,
its Chief Financial Officer or its Treasurer and attested to by its Secretary or any Assistant Secretary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Corporate
Trust Office&rdquo; means the office of the Trustee at which at any particular time its corporate trust business shall be principally
administered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Default&rdquo;
means any event that is, or that with the passing of time or giving of notice or both would be, an Event of Default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Depository&rdquo;
means, with respect to the Securities of any Series issuable or issued in whole or in part in the form of one or more Global Securities,
the Person designated as Depository for such Series by the Company, which Depository shall be a clearing agency registered under the
Exchange Act, until a successor Depository shall have become such pursuant to the applicable provisions of this Indenture, and thereafter
&ldquo;Depository&rdquo; shall mean each Person who is then a Depository hereunder, and if at any time there is more than one such Person,
such Persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Dollars&rdquo;
means the currency of the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Euro&rdquo;
means the single currency of participating member states of the economic and monetary union as contemplated in the Treaty on European
Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Exchange
Act&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Foreign
Currency&rdquo; means any currency or currency unit issued by a government other than the government of the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Foreign
Government Obligations&rdquo; means, with respect to Securities that are denominated in a Foreign Currency, (i) direct obligations of
the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged
or (ii) obligations of a Person controlled or supervised by, or acting as an agency or instrumentality of, such government, the timely
payment of which is unconditionally guaranteed as a full faith and credit obligation by such government, which, in either case under
clauses (i) and (ii), are not callable or redeemable at the option of the issuer thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;GAAP&rdquo;
means generally accepted accounting principles consistently applied as in effect in the United States of America from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Global
Security&rdquo; or &ldquo;Global Securities&rdquo; means a Security or Securities, as the case may be, in the form established pursuant
to Section 2.2, evidencing all or part of a Series of Securities issued to the Depository for such Series or its nominee, and registered
in the name of such Depository or nominee, and bearing the legend set forth in Section 2.15(c) (or such other legend(s) as may be applied
to such Securities in accordance with Section 2.2(24)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Holder&rdquo;
or &ldquo;Securityholder&rdquo; means the Person in whose name a Security is registered on the Registrar&rsquo;s books.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Indebtedness&rdquo;
means (without duplication), with respect to any Person, any indebtedness at any time outstanding, secured or unsecured, contingent or
otherwise, which is for borrowed money (whether or not the recourse of the lender is to the whole of the assets of such Person or only
to a portion thereof), or evidenced by bonds, notes, debentures or similar instruments, or representing the balance deferred and unpaid
of the purchase price of any property (excluding any balances that constitute accounts payable or trade payables, and other accrued liabilities
arising in the ordinary course of business), if and to the extent any of the foregoing indebtedness would appear as a liability upon
a balance sheet of such Person prepared in accordance with GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Indenture&rdquo;
means this Indenture as amended, restated or supplemented from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Interest
Payment Date,&rdquo; when used with respect to any Security, means the Stated Maturity of an installment of interest on such Security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Lien&rdquo;
means, with respect to any property or assets of any Person, any mortgage or deed of trust, pledge, hypothecation, assignment, deposit
arrangement, security interest, lien, charge, easement, encumbrance, preference, priority or other security agreement or preferential
arrangement of any kind or nature whatsoever on or with respect to such property or assets (including, without limitation, any capitalized
lease obligation, conditional sales or other title retention agreement having substantially the same economic effect as any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Maturity,&rdquo;
when used with respect to any Security, means the date on which the principal of such Security, or an installment of principal, becomes
due and payable as therein or herein provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption,
notice of option to elect payment or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Officer&rdquo;
means the Chief Executive Officer, the President, any Vice President, the Chief Financial Officer, the Treasurer or the Secretary of
the Company, or any other officer designated by the Board of Directors, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Officers&rsquo;
Certificate&rdquo; means, with respect to any Person, a certificate signed by the Chairman, Chief Executive Officer, President or any
Senior or Executive Vice President and the Chief Financial Officer or any Treasurer of such Person, that shall comply with applicable
provisions of this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Opinion
of Counsel&rdquo; means a written opinion from legal counsel, which counsel is reasonably acceptable to the Trustee. The counsel may
be an employee of or counsel to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Person&rdquo;
means any individual, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, unincorporated
organization or government (including any agency or political subdivision thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Redemption
Date,&rdquo; when used with respect to any Security to be redeemed, means the date fixed for such redemption pursuant to this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Responsible
Officer,&rdquo; when used with respect to the Trustee, means any officer within the corporate trust department or division of the Trustee
(or any successor group of the Trustee) or any other officer of the Trustee customarily performing functions similar to those performed
by any of the above designated officers, and also means, with respect to a particular corporate trust matter, any other officer to whom
such matter is referred because of his knowledge of and familiarity with the particular subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;SEC&rdquo;
means the United States Securities and Exchange Commission as constituted from time to time, or any successor performing substantially
the same functions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Securities&rdquo;
means the securities that are issued under this Indenture, as amended or supplemented from time to time pursuant to this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Securities
Act&rdquo; means the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Series&rdquo;
or &ldquo;Series of Securities&rdquo; means each series of debentures, notes or other debt instruments of the Company created pursuant
to Sections 2.1 and 2.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Significant
Subsidiary&rdquo; means (i) any direct or indirect Subsidiary of the Company that would be a &ldquo;significant subsidiary&rdquo; as
defined in Article 1, Rule 1-02 of Regulation S-X, promulgated pursuant to the Securities Act, as such regulation is in effect on the
date hereof, or (ii) any group of direct or indirect Subsidiaries of the Company that, taken together as a group, would be a &ldquo;significant
subsidiary&rdquo; as defined in Article 1, Rule 1-02 of Regulation S-X, promulgated pursuant to the Securities Act, as such regulation
is in effect on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Stated
Maturity,&rdquo; when used with respect to any Security or any installment of principal thereof or interest thereon, means the date specified
in such Security as the fixed date on which the principal of such Security, or such installment of principal or interest, is due and
payable, and when used with respect to any other Indebtedness, means the date specified in the instrument governing such Indebtedness
as the fixed date on which the principal of such Indebtedness, or any installment of interest thereon, is due and payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Subsidiary&rdquo;
of any specified Person means any corporation, limited liability company, partnership, joint venture, association or other business entity,
whether now existing or hereafter organized or acquired, (i) in the case of a corporation, of which more than 50% of the total voting
power of the Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors thereof
is held, directly or indirectly, by such Person or any of its Subsidiaries; or (ii) in the case of a partnership, joint venture, association
or other business entity, with respect to which such Person or any of its Subsidiaries has the power to direct or cause the direction
of the management and policies of such entity by contract or otherwise, or if in accordance with GAAP such entity is consolidated with
such Person for financial statement purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;TIA&rdquo;
means the Trust Indenture Act of 1939 (15 U.S. Code Section 77aaa-77bbbb) as in effect on the date of this Indenture (except as provided
in Section 8.3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Trustee&rdquo;
means the party named as such in this Indenture until a successor replaces it pursuant to this Indenture, and thereafter means the successor,
and if at any time there is more than one such Person, &ldquo;Trustee&rdquo; as used with respect to the Securities of any Series shall
mean the Trustee with respect to Securities of that Series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;U.S.
Government Obligations&rdquo; means direct non-callable obligations of, or non-callable obligations guaranteed by, the United States
of America for the payment of which obligation or guarantee the full faith and credit of the United States of America is pledged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
OTHER DEFINITIONS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
definitions of the following terms may be found in the sections indicated as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERM</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINED
    IN SECTION</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Bankruptcy
    Law&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Business
    Day&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Covenant
    Defeasance&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Custodian&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Event
    of Default&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Journal&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Judgment
    Currency&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Legal
    Defeasance&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Legal
    Holiday&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Market
    Exchange Rate&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;New
    York Paying Agent&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Paying
    Agent&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Place
    of Payment&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Registrar&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required
    Currency&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Service
    Agent&rdquo;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.
INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
this Indenture refers to a provision of the TIA, the portion of such provision required to be incorporated herein in order for this Indenture
to be qualified under the TIA is incorporated by reference in and made a part of this Indenture. The following TIA terms used in this
Indenture have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Commission&rdquo;
means the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;indenture
securities&rdquo; means the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;indenture
securityholder&rdquo; means a Holder or Securityholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;indenture
to be qualified&rdquo; means this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;indenture
trustee&rdquo; or &ldquo;institutional trustee&rdquo; means the Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;obligor
on the indenture securities&rdquo; means the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other terms used in this Indenture that are defined by the TIA, defined in the TIA by reference to another statute or defined by SEC
rule have the meanings therein assigned to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4.
RULES OF CONSTRUCTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
a term has the meaning assigned to it herein, whether defined expressly or by reference;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
&ldquo;or&rdquo; is not exclusive;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
words in the singular include the plural, and in the plural include the singular;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
words used herein implying any gender shall apply to each gender; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
the words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo; and other words of similar import refer to this Indenture
as a whole and not to any particular Article, Section or other subdivision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
THE SECURITIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.
ISSUABLE IN SERIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is $&nbsp;&nbsp;,&nbsp;&nbsp; ,&nbsp;&nbsp; . The Securities may be
issued in one or more Series. All Securities of a Series shall be identical except as may be set forth in a Board Resolution, a supplemental
indenture or an Officers&rsquo; Certificate detailing the adoption of the terms thereof pursuant to the authority granted under a Board
Resolution. In the case of Securities of a Series to be issued from time to time, the Board Resolution, Officers&rsquo; Certificate or
supplemental indenture may provide for the method by which specified terms (such as interest rate, Stated Maturity, record date or date
from which interest shall accrue) are to be determined. Securities may differ between Series in respect of any matters, PROVIDED, that
all Series of Securities shall be equally and ratably entitled to the benefits of the Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.
ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
or prior to the issuance of any Securities within a Series, the following shall be established (as to the Series generally, in the case
of Subsection 2.2(1) and either as to such Securities within the Series or as to the Series generally in the case of Subsections 2.2(2)
through 2.2(24)) by a Board Resolution, a supplemental indenture or an Officers&rsquo; Certificate, in each case, pursuant to authority
granted under a Board Resolution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the title of the Series (which shall distinguish the Securities of that particular Series from the Securities of any other Series);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
any limit upon the aggregate principal amount of the Securities of the Series which may be authenticated and delivered under this Indenture
(except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities
of the Series pursuant to Section 2.7, 2.8, 2.11, 3.6 or 8.5);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
the price or prices (expressed as a percentage of the principal amount thereof) at which the Securities of the Series will be issued;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
the date or dates on which the principal of the Securities of the Series is payable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
the rate or rates (which may be fixed or variable) per annum or, if applicable, the method used to determine such rate or rates (including,
but not limited to, any commodity, commodity index, stock exchange index or financial index) at which the Securities of the Series shall
bear interest, if any, the date or dates from which such interest, if any, shall accrue, the date or dates on which such interest, if
any, shall commence and be payable and any regular record date for the interest payable on any Interest Payment Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
the place or places where the principal of, and interest and premium, if any, on, the Securities of the Series shall be payable, or the
method of such payment, if by wire transfer, mail or other means;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
if applicable, the period or periods within which, the price or prices at which and the terms and conditions upon which the Securities
of the Series may be redeemed, in whole or in part, at the option of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
the obligation, if any, of the Company to redeem or purchase the Securities of the Series pursuant to any sinking fund or analogous provisions
or at the option of a Holder thereof, and the period or periods within which, the price or prices at which and the terms and conditions
upon which Securities of the Series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
the dates, if any, on which and the price or prices at which the Securities of the Series will be repurchased by the Company at the option
of the Holders thereof, and other detailed terms and provisions of such repurchase obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
if other than denominations of $1,000 and any integral multiple thereof, the denominations in which the Securities of the Series shall
be issuable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)
the forms of the Securities of the Series in bearer (if to be issued outside of the United States of America) or fully registered form
(and, if in fully registered form, whether the Securities will be issuable as Global Securities);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)
if other than the principal amount thereof, the portion of the principal amount of the Securities of the Series that shall be payable
upon declaration of acceleration of the Maturity thereof pursuant to Section 6.2;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)
the currency of denomination of the Securities of the Series, which may be Dollars or any Foreign Currency, including, but not limited
to, the Euro, and, if such currency of denomination is a composite currency other than the Euro, the agency or organization, if any,
responsible for overseeing such composite currency;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)
the designation of the currency, currencies or currency units in which payment of the principal of, and interest and premium, if any,
on, the Securities of the Series will be made;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)
if payments of principal of, or interest or premium, if any, on, the Securities of the Series are to be made in one or more currencies
or currency units other than that or those in which such Securities are denominated, the manner in which the exchange rate with respect
to such payments will be determined;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)
the manner in which the amounts of payment of principal of, or interest and premium, if any, on, the Securities of the Series will be
determined, if such amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity,
commodity index, stock exchange index or financial index;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)
the provisions, if any, relating to any collateral provided for the Securities of the Series;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)
any addition to or change in the covenants set forth in Articles 4 or 5 that applies to Securities of the Series;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)
any addition to or change in the Events of Default which applies to any Securities of the Series, and any change in the right of the
Trustee or the requisite Holders of such Securities to declare the principal amount thereof due and payable pursuant to Section 6.2;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)
the terms and conditions, if any, for conversion of the Securities into or exchange of the Securities for shares of common stock or preferred
stock of the Company that apply to Securities of the Series;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)
any depositories, interest rate calculation agents, exchange rate calculation agents or other agents with respect to Securities of such
Series if other than those appointed herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)
the terms and conditions, if any, upon which the Securities shall be subordinated in right of payment to other Indebtedness of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)
if applicable, that the Securities of the Series, in whole or any specified part, shall be defeasible pursuant to Article 9; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)
any other terms of the Securities of the Series (which terms shall not be inconsistent with the provisions of this Indenture, except
as permitted by Section 8.1, but which may modify or delete any provision of this Indenture insofar as it applies to such Series).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Securities of any one Series need not be issued at the same time, and may be issued from time to time, consistent with the terms of this
Indenture, if so provided by or pursuant to the Board Resolution, supplemental indenture or Officers&rsquo; Certificate referred to above,
however, the authorized principal amount of any Series may not be increased to provide for issuances of additional Securities of such
Series, unless otherwise provided in such Board Resolution, supplemental indenture or Officers&rsquo; Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.
EXECUTION AND AUTHENTICATION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities shall be executed on behalf of the Company by two Officers of the Company or an Officer and an Assistant Secretary of the
Company. Each such signature may be either manual or facsimile. The Company&rsquo;s seal may be impressed, affixed, imprinted or reproduced
on the Securities and may be in facsimile form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an Officer whose signature is on a Security no longer holds that office at the time the Security is authenticated, the Security shall
nevertheless be valid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Security shall not be valid until authenticated by the manual signature of the Trustee or an authenticating agent. The signature shall
be conclusive evidence that the Security has been authenticated under this Indenture. The Trustee shall at any time, and from time to
time, authenticate Securities for original issue in the principal amount provided in the Board Resolution, supplemental indenture hereto
or Officers&rsquo; Certificate, upon receipt by the Trustee of a Company Order. Such Company Order may authorize authentication and delivery
pursuant to oral or electronic instructions from the Company or its duly authorized agent or agents, which oral instructions shall be
promptly confirmed in writing. Each Security shall be dated the date of its authentication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate principal amount of Securities of any Series outstanding at any time may not exceed any limit upon the maximum principal amount
for such Series set forth in the Board Resolution, supplemental indenture hereto or Officers&rsquo; Certificate delivered pursuant to
Section 2.2, except as provided in Section 2.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the issuance of Securities of any Series, the Trustee shall have received and (subject to Section 7.1) shall be fully protected in
relying on: (a) the Board Resolution, supplemental indenture hereto or Officers&rsquo; Certificate establishing the form of the Securities
of that Series or of Securities within that Series and the terms of the Securities of that Series or of Securities within that Series,
(b) an Officers&rsquo; Certificate complying with Section 10.4, and (c) an Opinion of Counsel complying with Section 10.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee shall have the right to decline to authenticate and deliver any Securities of any Series: (a) if the Trustee, being advised in
writing by outside counsel, determines that such action may not lawfully be taken; or (b) if the Trustee in good faith by its board of
directors or trustees, executive committee or a trust committee of directors and/or vice-presidents shall reasonably determine that such
action would expose the Trustee to personal liability, or cause it to have a conflict of interest with respect to Holders of any then
outstanding Series of Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee may appoint an authenticating agent acceptable to the Company to authenticate Securities. An authenticating agent may authenticate
Securities whenever the Trustee may do so. Any appointment shall be evidenced by an instrument signed by an authorized officer of the
Trustee, a copy of which shall be furnished to the Company. Each reference in this Indenture to authentication by the Trustee includes
authentication by such agent. An authenticating agent has the same rights as an Agent to deal with the Company or an Affiliate of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.
REGISTRAR AND PAYING AGENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall maintain in each Place of Payment for any Series of Securities (i) an office or agency where such Securities may be presented
for registration of transfer or for exchange (&ldquo;Registrar&rdquo;), (ii) an office or agency where such Securities may be presented
for payment (&ldquo;Paying Agent&rdquo;) (PROVIDED that the Company shall at all times maintain a Paying Agent in the Borough of Manhattan,
City of New York, State of New York (the &ldquo;New York Paying Agent&rdquo;), and PROVIDED, FURTHER, that at the option of the Company
payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the register
for the Securities maintained by the Registrar), and (iii) an office or agency where notices and demands to or upon the Company in respect
of the Securities and this Indenture may be served (&ldquo;Service Agent&rdquo;). The Registrar shall keep a register of the Securities
and of their transfer and exchange. The Company may have one or more co-registrars and one or more additional paying agents. The Company
shall give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency. If at any
time the Company shall fail to maintain any such required office, or to furnish the Trustee with the address thereof, such presentations,
surrenders, notices and demands may be made or served at the address of the Trustee as set forth in Section 10.2. If the Company acts
as Paying Agent, it shall segregate the money held by it for the payment of principal of, and interest and premium, if any, on, the Securities
and hold it as a separate trust fund. The Company may change any Paying Agent, Registrar, co-registrar or any other Agent without notice
to any Securityholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may also from time to time designate one or more other offices or agencies where the Securities may be presented or surrendered
for any or all such purposes, and may from time to time rescind such designations; PROVIDED, HOWEVER, that no such designation or rescission
shall in any manner relieve the Company of its obligation to maintain an office or agency in each Place of Payment for Securities of
any Series for such purposes. The Company hereby initially designates the Corporate Trust Office of the Trustee as such office of the
Company. The Company shall give prompt written notice to the Trustee of such designation or rescission, and of any change in the location
of any such other office or agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall enter into an appropriate agency agreement with any Registrar or Paying Agent not a party to this Indenture. The agreement
shall implement the provisions of this Indenture that relate to such Agent. The Company shall notify the Trustee of the name and address
of any such Agent. If the Company fails to maintain a Registrar or Paying Agent, or agent for service of notices and demands, or fails
to give the foregoing notice, the Trustee shall act as such. The Company hereby appoints the Trustee as the initial Registrar, Paying
Agent and Service Agent for each Series unless another Registrar, Paying Agent or Service Agent, as the case may be, is appointed prior
to the time Securities of that Series are first issued. The Company designates [&#9679;], as the New York Paying Agent, with offices at
[&#9679;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.
PAYING AGENT TO HOLD ASSETS IN TRUST.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee as Paying Agent shall, and the Company shall require each Paying Agent other than the Trustee to agree in writing that each Paying
Agent shall, hold in trust for the benefit of the Holders of any Series of Securities or the Trustee all assets held by the Paying Agent
for the payment of principal of, or interest or premium, if any, on, such Series of Securities (whether such assets have been distributed
to it by the Company or any other obligor on such Series of Securities), and the Company and the Paying Agent shall notify the Trustee
in writing of any Default by the Company (or any other obligor on such Series of Securities) in making any such payment. The Company
at any time may require a Paying Agent to distribute all assets held by it to the Trustee and account for any assets disbursed, and the
Trustee may, at any time during the continuance of any payment default with respect to any Series of Securities, upon written request
to a Paying Agent, require such Paying Agent to distribute all assets held by it to the Trustee and to account for any assets distributed.
Upon distribution to the Trustee of all assets that shall have been delivered by the Company to the Paying Agent, the Paying Agent shall
have no further liability for such assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.
SECURITYHOLDER LISTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses
of Securityholders of each Series of Securities. If the Trustee is not the Registrar, the Company shall furnish to the Trustee as of
each regular record date for the payment of interest on the Securities of a Series and before each related Interest Payment Date, and
at such other times as the Trustee may request in writing, a list in such form and as of such date as the Trustee may reasonably require
of the names and addresses of Securityholders of each Series of Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7.
TRANSFER AND EXCHANGE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
Securities of a Series are presented to the Registrar with a request to register the transfer thereof, the Registrar shall register the
transfer as requested if the requirements of applicable law are met, and when such Securities of a Series are presented to the Registrar
with a request to exchange them for an equal principal amount of other authorized denominations of Securities of the same Series, the
Registrar shall make the exchange as requested. To permit transfers and exchanges, upon surrender of any Security for registration of
transfer at the office or agency maintained pursuant to Section 2.4, the Company shall execute and the Trustee shall authenticate Securities
at the Registrar&rsquo;s request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Securities are issued as Global Securities, the provisions of Section 2.15 shall apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Securities issued upon any registration of transfer or exchange of Securities shall be the valid obligations of the Company, evidencing
the same debt, and entitled to the same benefits under this Indenture, as the Securities surrendered upon such registration of transfer
or exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
Security presented or surrendered for registration of transfer or for exchange shall (if so required by the Company or the Registrar
or a co-registrar) be duly endorsed, or be accompanied by a written instrument of transfer in form satisfactory to the Company and the
Registrar or a co-registrar, duly executed by the Holder thereof or his attorney duly authorized in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
exchange or transfer shall be without charge, except that the Company may require payment by the Holder of a sum sufficient to cover
any tax or other governmental charge that may be imposed in relation to a transfer or exchange, but this provision shall not apply to
any exchange pursuant to Section 2.11, 3.6 or 8.5. The Trustee shall not be required to register transfers of Securities of any Series,
or to exchange Securities of any Series, for a period of 15 days before the record date for selection for redemption of such Securities.
The Trustee shall not be required to exchange or register transfers of Securities of any Series called or being called for redemption
in whole or in part, except the unredeemed portion of such Security being redeemed in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8.
REPLACEMENT SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a mutilated Security is surrendered to the Trustee, or if the Holder of a Security presents evidence to the satisfaction of the Company
and the Trustee that the Security has been lost, destroyed or wrongfully taken, the Company shall issue and the Trustee shall authenticate
a replacement Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.
An indemnity bond may be required by the Company or the Trustee that is sufficient in the reasonable judgment of the Company or the Trustee,
as the case may be, to protect the Company, the Trustee or any Agent from any loss which any of them may suffer if a Security is replaced.
The Company may charge such Holder for the Company&rsquo;s out-of-pocket expenses in replacing a Security, including the fees and expenses
of the Trustee. Every replacement Security shall constitute an original additional obligation of the Company, whether or not the destroyed,
lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally
and proportionately with any and all other Securities of that Series duly issued hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9.
OUTSTANDING SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
outstanding at any time are all Securities authenticated by the Trustee, except for those canceled by it, those delivered to it for cancellation
and those described in this Section 2.9 as not outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Security is replaced pursuant to Section 2.8 (other than a mutilated Security surrendered for replacement), it ceases to be outstanding
until the Company and the Trustee receive proof satisfactory to each of them that the replaced Security is held by a bona fide purchaser.
A mutilated Security ceases to be outstanding upon surrender of such Security and replacement thereof pursuant to Section 2.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Paying Agent holds on a Redemption Date or the Stated Maturity money sufficient to pay the principal of, premium, if any, and accrued
interest on, Securities payable on that date, and is not prohibited from paying such money to the Holders thereof pursuant to the terms
of this Indenture (PROVIDED, that if such Securities are to be redeemed, notice of such redemption has been duly given pursuant to this
Indenture or provision therefor satisfactory to the Trustee has been made), then on and after that date such Securities cease to be outstanding
and interest on them ceases to accrue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Security does not cease to be outstanding solely because the Company or an Affiliate holds the Security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10.
WHEN TREASURY SECURITIES DISREGARDED; DETERMINATION OF HOLDERS&rsquo; ACTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining whether the Holders of the required aggregate principal amount of the Securities of any Series have concurred in any direction,
waiver or consent, the Securities of any Series owned by the Company or any other obligor on such Securities, or by any Affiliate of
any of them, shall be disregarded, except that for the purposes of determining whether the Trustee shall be protected in relying on any
such direction, waiver or consent, only Securities of such Series which the Trustee actually knows are so owned shall be so disregarded.
Securities of such Series so owned which have been pledged in good faith shall not be disregarded if the pledgee establishes to the satisfaction
of the Trustee the pledgee&rsquo;s right so to act with respect to the Securities of such Series and that the pledgee is not the Company
or any other obligor on the Securities of such Series, or an Affiliate of any of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11.
TEMPORARY SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
definitive Securities are ready for delivery, the Company may prepare and execute, and the Trustee shall authenticate, temporary Securities.
Temporary Securities shall be substantially in the form, and shall carry all rights, of definitive Securities, but may have variations
that the Company considers appropriate for temporary Securities. Without unreasonable delay, the Company shall prepare and execute, and
the Trustee shall authenticate, definitive Securities in exchange for temporary Securities without charge to the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12.
CANCELLATION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Securities surrendered for payment, redemption or registration of transfer or exchange, or for credit against any sinking fund payment,
shall, if surrendered to any Person other than the Trustee, be delivered to the Trustee for cancellation. The Company may at any time
deliver to the Trustee for cancellation any Securities previously authenticated and delivered hereunder which the Company may have acquired
in any manner whatsoever, and may deliver to the Trustee (or to any other Person for delivery to the Trustee) for cancellation any Securities
previously authenticated hereunder which the Company has not issued and sold. The Registrar and the Paying Agent shall forward to the
Trustee any Securities surrendered to them for transfer, exchange or payment. The Trustee or, at the direction of the Trustee, the Registrar
or the Paying Agent, and no one else, shall cancel, and at the written request of the Company shall dispose of, all Securities surrendered
for transfer, exchange, payment or cancellation. If the Company shall acquire any of the Securities, such acquisition shall not operate
as a redemption or satisfaction of the Indebtedness represented by such Securities unless and until the same are surrendered to the Trustee
for cancellation pursuant to this Section 2.12. No Securities shall be authenticated in lieu of or in exchange for any Securities cancelled
as provided in this Section 2.12, except as expressly permitted by this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13.
PAYMENT OF INTEREST; DEFAULTED INTEREST; COMPUTATION OF INTEREST.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided as contemplated by Section 2.2 with respect to any Series of Securities, interest on any Security which is payable,
and is punctually paid or duly provided for, on any Interest Payment Date shall be paid to the Person in whose name that Security is
registered at the close of business on the regular record date for such interest, as provided in the Board Resolution, supplemental indenture
hereto or Officers&rsquo; Certificate establishing the terms of such Series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company defaults in a payment of interest on the Securities, it shall pay the defaulted amounts, plus any interest payable on defaulted
amounts pursuant to Section 4.1, to the Persons who are Securityholders on a subsequent special record date, which date shall be the
15th day next preceding the date fixed by the Company for the payment of defaulted interest, or the next succeeding Business Day if such
date is not a Business Day. At least 15 days before the special record date, the Company shall mail or cause to be mailed to each Securityholder,
with a copy to the Trustee, a notice that states the special record date, the payment date and the amount of defaulted interest, and
interest payable on such defaulted interest, if any, to be paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise specified as contemplated by Section 2.2 for Securities of any Series, interest on the Securities of each Series shall be
computed on the basis of a 360-day year of twelve 30-day months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14.
CUSIP NUMBER.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company in issuing the Securities may use one or more &ldquo;CUSIP&rdquo; numbers, and, if the Company does so, the Trustee shall use
the CUSIP number(s) in notices of redemption or exchange as a convenience to Holders, PROVIDED, that any such notice may state that no
representation is made as to the correctness or accuracy of the CUSIP number(s) printed in the notice or on the Securities, and that
reliance may be placed only on the other identification numbers printed on the Securities, and that any such redemption or exchange shall
not be affected by any defect in or omission of any such numbers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15.
PROVISIONS FOR GLOBAL SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
A Board Resolution, a supplemental indenture hereto or an Officers&rsquo; Certificate shall establish whether the Securities of a Series
shall be issued in whole or in part in the form of one or more Global Securities, and the Depository for such Global Securities or Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notwithstanding any provisions to the contrary contained in Section 2.7 and in addition thereto, if, and only if the Depository (i) at
any time is unwilling or unable to continue as Depository for such Global Security or ceases to be a clearing agency registered under
the Exchange Act and (ii) a successor Depository is not appointed by the Company within 90 days after the date the Company is so informed
in writing or becomes aware of the same, the Company promptly will execute and deliver to the Trustee definitive Securities, and the
Trustee, upon receipt of a Company Request for the authentication and delivery of such definitive Securities (which the Company will
promptly execute and deliver to the Trustee) and an Officers&rsquo; Certificate to the effect that such Global Security shall be so exchangeable,
will authenticate and deliver definitive Securities, without charge, registered in such names and in such authorized denominations as
the Depository shall direct in writing (pursuant to instructions from its direct and indirect participants or otherwise) in an aggregate
principal amount equal to the principal amount of the Global Security with like tenor and terms. Upon the exchange of a Global Security
for definitive Securities, such Global Security shall be canceled by the Trustee. Unless and until it is exchanged in whole or in part
for definitive Securities, as provided in this Section 2.15(b), a Global Security may not be transferred except as a whole by the Depository
with respect to such Global Security to a nominee of such Depository, by a nominee of such Depository to such Depository or another nominee
of such Depository or by the Depository or any such nominee to a successor Depository or a nominee of such a successor Depository.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Any Global Security issued hereunder shall bear a legend in substantially the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;This
Security is a Global Security within the meaning of the Indenture hereinafter referred to, and is registered in the name of the Depository
or a nominee of the Depository. This Security is exchangeable for Securities registered in the name of a Person other than the Depository
or its nominee only in the limited circumstances described in the Indenture, and may not be transferred except as a whole by the Depository
to a nominee of the Depository, by a nominee of the Depository to the Depository or another nominee of the Depository or by the Depository
or any such nominee to a successor Depository or a nominee of such a successor Depository.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Depository, as a Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization,
direction, notice, consent, waiver or other action which a Holder is entitled to give or take under the Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Notwithstanding the other provisions of this Indenture, unless otherwise specified as contemplated by Section 2.2, payment of the principal
of, and interest and premium, if any, on, any Global Security shall be made to the Depository or its nominee in its capacity as the Holder
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Except as provided in Section 2.15(e) above, the Company, the Trustee and any Agent shall treat a Person as the Holder of such principal
amount of outstanding Securities of any Series represented by a Global Security as shall be specified in a written statement of the Depository
(which may be in the form of a participants&rsquo; list for such Series) with respect to such Global Security, for purposes of obtaining
any consents, declarations, waivers or directions required to be given by the Holders pursuant to this Indenture, PROVIDED, that until
the Trustee is so provided with a written statement, it may treat the Depository or any other Person in whose name a Global Security
is registered as the owner of such Global Security for the purpose of receiving payment of the principal of, and any premium and (subject
to Section 2.13) any interest on, such Global Security and for all other purposes whatsoever, and none of the Company, the Trustee or
any agent of the Company or the Trustee shall be affected by notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16.
PERSONS DEEMED OWNERS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to due presentment of a Security for registration of transfer, the Company, the Trustee, the Registrar and any agent of the Company,
the Registrar or the Trustee may treat the Person in whose name such Security is registered as the owner of such Security for the purpose
of receiving payment of the principal of, and any premium and (subject to Section 2.13) any interest on, such Security and for all other
purposes whatsoever, and none of the Company, the Trustee, the Registrar or any agent of the Company, the Trustee or the Registrar shall
be affected by notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
REDEMPTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.
NOTICES TO TRUSTEE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may, with respect to any Series of Securities, reserve the right to redeem and pay the Series of Securities, or may covenant
to redeem and pay the Series of Securities or any part thereof, prior to the Stated Maturity thereof at such time and on such terms as
provided for in such Securities or the related Board Resolution, supplemental indenture or Officers&rsquo; Certificate. If a Series of
Securities is redeemable and the Company elects to redeem all or part of such Series of Securities, it shall notify the Trustee of the
Redemption Date and the principal amount of Securities to be redeemed at least 45 days (unless a shorter notice shall be satisfactory
to the Trustee) before the Redemption Date. Any such notice may be canceled at any time prior to notice of such redemption being mailed
to any Holder, and shall thereby be void and of no effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.
SELECTION BY TRUSTEE OF SECURITIES TO BE REDEEMED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated for a particular Series of Securities by a Board Resolution, a supplemental indenture or an Officers&rsquo; Certificate,
if fewer than all of the Securities of a Series are to be redeemed, the Trustee shall select the Securities of a Series to be redeemed
pro rata, by lot or by any other method that the Trustee considers fair and appropriate (unless the Company specifically directs the
Trustee otherwise) and, if such Securities are listed on any securities exchange, by a method that complies with the requirements of
such exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee shall make the selection from Securities of a Series outstanding and not previously called for redemption, and shall promptly
notify the Company in writing of the Securities selected for redemption and, in the case of any Security selected for partial redemption,
the principal amount thereof to be redeemed at least 35 but not more than 60 days before the Redemption Date. Securities of a Series
in denominations of $1,000 may be redeemed only in whole. The Trustee may select for redemption portions of the principal of Securities
of a Series that have denominations larger than $1,000. Securities of a Series and portions of them it selects shall be in amounts of
$1,000 or, with respect to Securities of any Series issuable in other denominations pursuant to Section 2.2(10), the minimum principal
denomination for each Series and integral multiples thereof. Provisions of this Indenture that apply to Securities called for redemption
also apply to portions of Securities called for redemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.
NOTICE OF REDEMPTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated for a particular Series by Board Resolution, a supplemental indenture hereto or an Officers&rsquo; Certificate, at
least 30 days, and no more than 60 days, before a Redemption Date, the Company shall mail, or cause to be mailed, a notice of redemption
by first-class mail to each Holder of Securities to be redeemed at his or her last address as the same appears on the registry books
maintained by the Registrar. The notice shall identify the Securities to be redeemed and shall state:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Redemption Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
the redemption price, and that such redemption price shall become due and payable on the Redemption Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
if any Security of a Series is being redeemed in part, the portion of the principal amount of such Security of a Series to be redeemed
and that, after the Redemption Date and upon surrender of such Security of a Series, a new Security or Securities in principal amount
equal to the unredeemed portion will be issued;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
the name and address of the Paying Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
that Securities of a Series called for redemption must be surrendered to the Paying Agent to collect the redemption price, and the place
or places where each such Security is to be surrendered for such payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
that, unless the Company defaults in making the redemption payment, interest on the Securities of a Series called for redemption ceases
to accrue on the Redemption Date, and the only remaining right of the Holders of such Securities is to receive payment of the redemption
price upon surrender to the Paying Agent of the Securities redeemed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
if fewer than all of the Securities of a Series are to be redeemed, the identification of the particular Securities of a Series (or portion
thereof) to be redeemed, as well as the aggregate principal amount of Securities of a Series to be redeemed and the aggregate principal
amount of Securities of a Series to be outstanding after such partial redemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
the CUSIP number, if any, printed on the Securities being redeemed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
that no representation is made as to the correctness or accuracy of the CUSIP number, if any, listed in such notice or printed on the
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Company&rsquo;s request, the Trustee shall give the notice of redemption in the Company&rsquo;s name and at the Company&rsquo;s sole
expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.
EFFECT OF NOTICE OF REDEMPTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the notice of redemption described in Section 3.3 is mailed, Securities of a Series called for redemption become due and payable on the
Redemption Date and at the redemption price, plus interest, if any, accrued to the Redemption Date. Upon surrender to the Trustee or
Paying Agent, such Securities of a Series shall be paid at the redemption price, plus accrued interest, if any, to the Redemption Date;
PROVIDED, that if the Redemption Date is after a regular interest payment record date and on or prior to the next Interest Payment Date,
the accrued interest shall be payable to the Holder of the redeemed Securities registered on the relevant record date, as specified by
the Company in the notice to the Trustee pursuant to Section 3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.
DEPOSIT OF REDEMPTION PRICE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
or prior to the Redemption Date (but no later than 11:00 A.M. Eastern Time on such date), the Company shall deposit with the Paying Agent
money sufficient to pay the redemption price of and accrued interest, if any, on all Securities to be redeemed on that date other than
Securities or portions thereof called for redemption on that date which have been delivered by the Company to the Trustee for cancellation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
and after any Redemption Date, if money sufficient to pay the redemption price of, and accrued interest on, Securities called for redemption
shall have been made available in accordance with the preceding paragraph and the Company and the Paying Agent are not prohibited from
paying such moneys to Holders, the Securities called for redemption will cease to accrue interest and the only right of the Holders of
such Securities will be to receive payment of the redemption price of and, subject to the proviso in Section 3.4, accrued and unpaid
interest on such Securities to the Redemption Date. If any Security called for redemption shall not be so paid, interest will be paid,
from the Redemption Date until such redemption payment is made, on the unpaid principal of the Security and any interest or premium,
if any, not paid on such unpaid principal, in each case, at the rate and in the manner provided in the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6.
SECURITIES REDEEMED IN PART.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
surrender of a Security of a Series that is redeemed in part, the Company shall execute, and the Trustee shall authenticate, for a Holder
a new Security of the same Series equal in principal amount to the unredeemed portion of the Security surrendered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
COVENANTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.
PAYMENT OF SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay the principal of, and interest and premium, if any, on, each Series of Securities on the dates and in the manner provided
in such Securities and this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
installment of principal or interest shall be considered paid on the date it is due if the Trustee or Paying Agent holds on that date
money designated for and sufficient to pay such installment and is not prohibited from paying such money to the Holders pursuant to the
terms of this Indenture or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay interest on overdue principal, and overdue interest, to the extent lawful, at the rate specified in the Series of Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.
SEC REPORTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will deliver to the Trustee within 15 days after the filing of the same with the SEC, copies of the quarterly and annual reports
and of the information, documents and other reports, if any, which the Company is required to file with the SEC pursuant to Section 13
or 15(d) of the Exchange Act; PROVIDED, HOWEVER, that each such report or document will be deemed to be so delivered to the Trustee if
the Company files such report or document with the SEC through the SEC&rsquo;s EDGAR database no later than the time such report or document
is required to be filed with the SEC pursuant to the Exchange Act. Notwithstanding that the Company may not be subject to the reporting
requirements of Section 13 or 15(d) of the Exchange Act, the Company will file with the SEC, to the extent permitted, and provide the
Trustee with, such quarterly and annual reports and such information, documents and other reports specified in Sections 13 and 15(d)
of the Exchange Act. The Company will also comply with the other provisions of TIA Section 314(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.
WAIVER OF STAY, EXTENSION OR USURY LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants (to the extent that it may lawfully do so) that it will not at any time insist upon, or plead (as a defense or otherwise)
or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension, usury or other law which would prohibit or
forgive the Company from paying all or any portion of the principal of, and/or interest and premium, if any, on, the Securities as contemplated
herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Indenture;
and the Company hereby expressly waives (to the extent that they may lawfully do so) all benefit or advantage of any such law, and covenants
that it will not hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution
of every such power as though no such law had been enacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.
COMPLIANCE CERTIFICATE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company shall deliver to the Trustee, within 120 days after the end of each fiscal year of the Company, an Officers&rsquo; Certificate
which complies with TIA Section 314(a)(4) stating that a review of the activities of the Company and its Subsidiaries during such fiscal
year has been made under the supervision of the signing Officers with a view to determining whether the Company has kept, observed, performed
and fulfilled its obligations under this Indenture, and further stating, as to each such Officer signing such certificate, that to the
best of his or her knowledge the Company has kept, observed, performed and fulfilled each and every covenant contained in this Indenture
and that there is no default in the performance or observance of any of the terms, provisions and conditions hereof (or, if a Default
or Event of Default shall have occurred, describing all such Defaults or Events of Default of which he or she may have knowledge and
what action the Company is taking or proposes to take with respect thereto) and that to the best of his or her knowledge no event has
occurred and remains in existence by reason of which payments on account of the principal of, or interest or premium, if any, on, the
Securities is prohibited, or if such event has occurred, a description of the event and what action the Company is taking or proposes
to take with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(i) If any Default or Event of Default has occurred and is continuing or (ii) if any Holder seeks to exercise any remedy hereunder with
respect to a claimed Default under this Indenture or the Securities, within five Business Days after the Company becoming aware of such
occurrence the Company shall deliver to the Trustee an Officers&rsquo; Certificate specifying such event, notice or other action and
what action the Company is taking or proposes to take with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.
CORPORATE EXISTENCE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to Article 5, the Company shall do or cause to be done all things necessary to preserve and keep in full force and effect its corporate
existence, in accordance with the organizational documents (as the same may be amended from time to time) of the Company and the rights
(charter and statutory), licenses and franchises of the Company; PROVIDED, HOWEVER, that the Company shall not be required to preserve
any such right, license or franchise, or its corporate existence, if the Board of Directors shall determine that the preservation thereof
is no longer desirable in the conduct of the business of the Company and that the loss thereof is not adverse in any material respect
to the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
5</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
SUCCESSOR CORPORATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.
LIMITATION ON CONSOLIDATION, MERGER AND SALE OF ASSETS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company will not, in any transaction or series of transactions, merge or consolidate with or into, or sell, assign, convey, transfer,
lease or otherwise dispose of all or substantially all of its properties and assets (as an entirety or substantially as an entirety in
one transaction or a series of related transactions), to any Person or Persons, unless at the time of and after giving effect thereto
(i) either (A) if the transaction or series of transactions is a merger or consolidation, the Company shall be the surviving Person of
such merger or consolidation, or (B) the Person formed by such consolidation or into which the Company is merged or to which the properties
and assets of the Company are transferred (any such surviving Person or transferee Person being the &ldquo;Surviving Entity&rdquo;) shall
be a corporation organized and existing under the laws of the United States of America, any state thereof or the District of Columbia,
or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and shall expressly assume by a supplemental
indenture executed and delivered to the Trustee, in form reasonably satisfactory to the Trustee, all of the obligations of the Company
(including, without limitation, the obligation to pay the principal of, and premium and interest, if any, on, the Securities and the
performance of the other covenants) under the Securities of each Series and this Indenture, and in each case, this Indenture shall remain
in full force and effect; and (ii) immediately before and immediately after giving effect to such transaction or series of transactions
on a pro forma basis (including, without limitation, any Indebtedness incurred or anticipated to be incurred in connection with or in
respect of such transaction or series of transactions), no Default or Event of Default shall have occurred and be continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In connection with any consolidation, merger or transfer of assets contemplated by this Section 5.1, the Company shall deliver, or cause
to be delivered, to the Trustee, in form and substance reasonably satisfactory to the Trustee, an Officers&rsquo; Certificate and an
Opinion of Counsel, each stating that such consolidation, merger or transfer, and the supplemental indenture in respect thereto, comply
with this Section 5.1, and that all conditions precedent herein provided for relating to such transaction or transactions have been complied
with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.
SUCCESSOR PERSON SUBSTITUTED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
any consolidation, merger or transfer of all or substantially all of the assets of the Company in accordance with Section 5.1 above,
the successor corporation formed by such consolidation, or into which the Company is merged or to which such transfer is made, shall
succeed to, and be substituted for, and may exercise every right and power of, the Company under this Indenture with the same effect
as if such successor corporation had been named as the Company herein, and thereafter (except with respect to any such transfer which
is a lease) the predecessor corporation shall be relieved of all obligations and covenants under this Indenture and the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
6</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
DEFAULTS AND REMEDIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.
EVENTS OF DEFAULT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Events
of Default,&rdquo; wherever used herein with respect to Securities of any Series, means any one of the following events, unless in the
establishing Board Resolution, supplemental indenture or Officers&rsquo; Certificate, it is provided that such Series shall not have
the benefit of said Event of Default:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
there is a default in the payment of any principal of, or premium, if any, on, the Securities when the same becomes due and payable at
Maturity, upon acceleration, redemption or otherwise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
there is a default in the payment of any interest on any Security of a Series when the same becomes due and payable, and the Default
continues for a period of 30 days;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
the Company defaults in the observance or performance of any other covenant in the Securities of a Series or in this Indenture for 60
days after written notice from the Trustee or the Holders of not less than 25% in the aggregate principal amount of the Securities of
such Series then outstanding, which notice must specify the Default, demand that it be remedied and state that the notice is a &ldquo;Notice
of Default&rdquo;;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
the Company or any Significant Subsidiary pursuant to or within the meaning of any Bankruptcy Law:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
commences a voluntary case,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
consents to the entry of an order for relief against it in an involuntary case,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)
consents to the appointment of a Custodian of it or for all or substantially all of its property,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)
makes a general assignment for the benefit of its creditors, or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(E)
generally is not paying its debts as they become due;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
is for relief against the Company or any Significant Subsidiary in an involuntary case;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
appoints a Custodian of the Company or any Significant Subsidiary, or for all or substantially all of the property of the Company or
any Significant Subsidiary; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)
orders the liquidation of the Company or any Significant Subsidiary, and the order or decree remains unstayed and in effect for 90 consecutive
days; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
any other Event of Default provided with respect to Securities of that Series, which is specified in a Board Resolution, a supplemental
indenture hereto or an Officers&rsquo; Certificate, in accordance with Section 2.2(19).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;Bankruptcy Law&rdquo; means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors. The term
&ldquo;Custodian&rdquo; means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee may withhold notice of any Default (except in the payment of the principal of, or interest or premium, if any, on, the Securities)
to the Holders of the Securities of any Series in accordance with Section 7.5. When a Default is cured, it ceases to exist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.
ACCELERATION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an Event of Default with respect to Securities of any Series at the time outstanding (other than an Event of Default arising under Section
6.1(4) or (5)) occurs and is continuing, the Trustee by written notice to the Company, or the Holders of not less than 25% in aggregate
principal amount of the Securities of that Series then outstanding by written notice to the Company and the Trustee, may declare that
the entire principal amount of all the Securities of that Series then outstanding plus accrued and unpaid interest to the date of acceleration
are immediately due and payable, in which case such amounts shall become immediately due and payable; PROVIDED, HOWEVER, that after such
acceleration but before a judgment or decree based on such acceleration is obtained by the Trustee, the Holders of a majority in aggregate
principal amount of the outstanding Securities of that Series may rescind and annul such acceleration and its consequences if (i) all
existing Events of Default, other than the nonpayment of accelerated principal, interest or premium, if any, that has become due solely
because of the acceleration, have been cured or waived, (ii) to the extent the payment of such interest is lawful, interest on overdue
installments of interest and overdue principal, which has become due otherwise than by such declaration of acceleration, has been paid
and (iii) the rescission would not conflict with any judgment or decree. No such rescission shall affect any subsequent Default or impair
any right consequent thereto. In case an Event of Default specified in Section 6.1(4) or (5) with respect to the Company occurs, such
principal, premium, if any, and interest amount with respect to all of the Securities of that Series shall be due and payable immediately
without any declaration or other act on the part of the Trustee or the Holders of the Securities of that Series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.
REMEDIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an Event of Default with respect to Securities of any Series at the time outstanding occurs and is continuing, the Trustee may pursue
any available remedy by proceeding at law or in equity to collect the payment of the principal of, or interest and premium, if any, on,
the Securities of that Series, or to enforce the performance of any provision of the Securities of that Series or this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee may maintain a proceeding even if it does not possess any of the Securities of that Series or does not produce any of them in
the proceeding. A delay or omission by the Trustee or any Securityholder in exercising any right or remedy accruing upon an Event of
Default shall not impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default. No remedy is exclusive
of any other remedy. All available remedies are cumulative to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.
WAIVER OF PAST DEFAULTS AND EVENTS OF DEFAULT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to Sections 6.2, 6.7 and 8.2, the Holders of a majority in principal amount of the Securities of any Series then outstanding have the
right to waive any existing Default or Event of Default with respect to such Series or compliance with any provision of this Indenture
(with respect to such Series) or the Securities of such Series. Upon any such waiver, such Default with respect to such Series shall
cease to exist, and any Event of Default with respect to such Series arising therefrom shall be deemed to have been cured for every purpose
of this Indenture; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent
thereto. This Section 6.4 shall be in lieu of TIA Section 316(a)(1)(B), and TIA Section 316(a)(1)(B) is hereby expressly excluded from
this Indenture and Section as permitted by the TIA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.
CONTROL BY MAJORITY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to Sections 6.2, 6.7 and 8.2, the Holders of a majority in principal amount of the Securities of any Series then outstanding may direct
the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred
on the Trustee by this Indenture with respect to such Series. The Trustee, however, may refuse to follow any direction that conflicts
with law or this Indenture, or that the Trustee determines may be unduly prejudicial to the rights of another Securityholder, or that
may involve the Trustee in personal liability; PROVIDED, that the Trustee may take any other action deemed proper by the Trustee which
is not inconsistent with such direction. This Section 6.5 shall be in lieu of TIA Section 316(a)(1)(A), and TIA Section 316(a)(1)(A)
is hereby expressly excluded from this Indenture and Section as permitted by the TIA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6.
LIMITATION ON SUITS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to Section 6.7, a Securityholder may not institute any proceeding or pursue any remedy with respect to this Indenture or the Securities
of a Series unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Holder gives to the Trustee written notice of a continuing Event of Default with respect to the Securities of that Series;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
the Holders of at least 25% in aggregate principal amount of the Securities of such Series then outstanding make a written request to
the Trustee to pursue the remedy;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
such Holder or Holders offer to the Trustee indemnity reasonably satisfactory to the Trustee against any loss, liability or expense to
be incurred in compliance with such request;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
the Trustee does not comply with the request within 60 days after receipt of the request and the offer of indemnity; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
no direction inconsistent with such written request has been given to the Trustee during such 60-day period by the Holders of a majority
in aggregate principal amount of the Securities of such Series then outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Securityholder may not use this Indenture to prejudice the rights of another Securityholder, or to obtain a preference or priority over
another Securityholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7.
RIGHTS OF HOLDERS TO RECEIVE PAYMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any other provision of this Indenture, the right of any Holder of a Security of a Series to receive payment of the principal of, and
interest and premium, if any, on, the Security of such Series on or after the respective due dates expressed in the Security of such
Series, or to bring suit for the enforcement of any such payment on or after such respective dates, is absolute and unconditional, and
shall not be impaired or affected without the consent of the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8.
COLLECTION SUIT BY TRUSTEE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an Event of Default in payment of principal, interest or premium, if any, specified in Section 6.1(1) or (2) with respect to Securities
of any Series at the time outstanding occurs and is continuing, the Trustee may recover judgment in its own name and as trustee of an
express trust against the Company (or any other obligor on the Securities of that Series) for the whole amount of unpaid principal and
premium, if any, and accrued interest remaining unpaid, together with interest on overdue principal and premium, if any, and, to the
extent that payment of such interest is lawful, interest on overdue installments of interest, in each case at the rate then borne by
the Securities of that Series, and such further amounts as shall be sufficient to cover the costs and expenses of collection, including
the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, as set forth in Section 7.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9.
TRUSTEE MAY FILE PROOFS OF CLAIM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee may file such proofs of claim and other papers or documents, and take other actions (including sitting on a committee of creditors),
as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agents and counsel) and the Securityholders allowed in any judicial proceedings relative
to the Company (or any other obligor on the Securities), any of their respective creditors or any of their respective property, and the
Trustee shall be entitled and empowered to collect and receive any monies or other property payable or deliverable on any such claims,
and to distribute the same after deduction of its charges and expenses to the extent that any such charges and expenses are not paid
out of the estate in any such proceedings, and any custodian in any such judicial proceeding is hereby authorized by each Securityholder
to make such payments to the Trustee, and in the event that the Trustee shall consent to the making of such payments directly to the
Securityholders, to pay to the Trustee any amount due to it for the reasonable compensation, expenses, disbursements and advances of
the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 7.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
herein contained shall be deemed to authorize the Trustee to authorize or consent to, or accept or adopt on behalf of any Securityholder,
any plan of reorganization, arrangement, adjustment or composition affecting the Securities of a Series or the rights of any Holder thereof,
or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10.
PRIORITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Trustee collects any money pursuant to this Article 6, it shall pay out the money in the following order:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST:
to the Trustee for amounts due under Section 7.7;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECOND:
to Securityholders for amounts then due and unpaid for the principal of, and interest and premium, if any, on, the Securities in respect
of which, or for the benefit of which, such money has been collected, ratably, without preference or priority of any kind, according
to the amounts due and payable on such Securities; for principal and any premium and interest, respectively; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIRD:
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee may fix a record date and payment date for any payment to Securityholders pursuant to this Section 6.10. At least 15 days before
such record date, the Trustee shall mail to each Securityholder a notice that states the record date, the payment date and amount to
be paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11.
UNDERTAKING FOR COSTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or
omitted by it as Trustee, a court in its discretion may require the filing by any party litigant in the suit of an undertaking to pay
the costs of the suit, and the court in its discretion may assess reasonable costs, including reasonable attorneys&rsquo; fees, against
any party litigant in the suit, having due regard to the merits and good faith of the claims or defenses made by the party litigant.
This Section 6.11 does not apply to a suit by the Trustee, a suit by a Holder pursuant to Section 6.7 or a suit by Holders of more than
10% in principal amount of the Securities of a Series then outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
7</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
TRUSTEE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.
DUTIES OF TRUSTEE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If an Event of Default has occurred and is continuing, the Trustee shall exercise such of the rights and powers vested in it by this
Indenture and use the same degree of care and skill in their exercise as a prudent Person would exercise or use under the same circumstances
in the conduct of his own affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except during the continuance of an Event of Default:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Trustee need perform only those duties that are specifically set forth in this Indenture, and no covenants or obligations shall be
implied in this Indenture against the Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
In the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of
the opinions expressed therein, upon certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture,
but, in the case of any such certificates or opinions which by any provision hereof are specifically required to be furnished to the
Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Trustee may not be relieved from liability for its own negligent action, its own negligent failure to act or its own willful misconduct,
except that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
This paragraph does not limit the effect of paragraph (b) of this Section 7.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it is proved that the Trustee
was negligent in ascertaining the pertinent facts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The Trustee shall not be liable with respect to any action it takes or omits to take in good faith in accordance with a direction received
by it pursuant to Sections 6.2 and 6.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
No provision of this Indenture shall require the Trustee to expend or risk its own funds, or otherwise incur any financial liability,
in the performance of any of its rights or powers if it shall have reasonable grounds for believing that repayment of such funds or adequate
indemnity satisfactory to it against such risk or liability is not reasonably assured to it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Whether or not therein expressly so provided, paragraphs (a), (b), (c) and (d) of this Section 7.1 shall govern every provision of this
Indenture that in any way relates to the Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Trustee and Paying Agent shall not be liable for interest on any money received by either of them, except as the Trustee and Paying
Agent may agree in writing with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the
extent required by the law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Paying Agent, the Registrar and any authenticating agent shall be entitled to the protections, immunities and standard of care set
forth in paragraphs (a), (b), (c), (d) and (f) of this Section 7.1 and in Section 7.2 with respect to the Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.
RIGHTS OF TRUSTEE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to Section 7.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Trustee may rely on, and shall be protected in acting or refraining from acting upon, any document reasonably believed by it to be
genuine and to have been signed or presented by the proper Person. The Trustee need not investigate any fact or matter stated in the
document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Before the Trustee acts or refrains from acting, it may require an Officers&rsquo; Certificate or an Opinion of Counsel, or both, which
shall conform to the provisions of Section 10.5. The Trustee shall be protected and shall not be liable for any action it takes or omits
to take in good faith in reliance on such certificate or opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The Trustee may act through agents and attorneys, and shall not be responsible for the misconduct or negligence of any agent appointed
by it with due care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
The Trustee shall not be liable for any action it takes or omits to take in good faith which it reasonably believes to be authorized
or within its rights or powers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
The Trustee may consult with counsel reasonably acceptable to the Trustee, which may be counsel to the Company, and the advice or opinion
of such counsel as to matters of law shall be full and complete authorization and protection from liability in respect of any action
taken, omitted or suffered by it hereunder in good faith and in accordance with the advice or opinion of such counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order
or direction of any of the Holders pursuant to the provisions of this Indenture, unless such Holders shall have offered to the Trustee
reasonable security or indemnity against the costs, expenses and liabilities which may be incurred therein or thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
The Trustee shall not be deemed to have knowledge of any fact or matter (including, without limitation, a Default or Event of Default)
unless such fact or matter is known to a Responsible Officer of the Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
Unless otherwise expressly provided herein or in the Securities of a Series or the related Board Resolution, supplemental indenture or
Officers&rsquo; Certificate, the Trustee shall not have any responsibility with respect to reports, notices, certificates or other documents
filed with it hereunder, except to make them available for inspection, at reasonable times, by Securityholders, it being understood that
delivery of such reports, information and documents to the Trustee is for informational purposes only and the Trustee&rsquo;s receipt
of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein,
including the Company&rsquo;s compliance with any of its covenants hereunder (except as set forth in Section 4.4).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3.
INDIVIDUAL RIGHTS OF TRUSTEE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee in its individual or any other capacity may become the owner or pledgee of Securities, and may make loans to, accept deposits
from, perform services for or otherwise deal with the Company, or any Affiliate thereof, with the same rights it would have if it were
not Trustee. Any Agent may do the same with like rights. The Trustee, however, shall be subject to Sections 7.10 and 7.11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4.
TRUSTEE&rsquo;S DISCLAIMER.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee makes no representation as to the validity or adequacy of this Indenture or the Securities (except that the Trustee represents
that it is duly authorized to execute and deliver this Indenture and authenticate the Securities and perform its obligations hereunder),
and the Trustee shall not be accountable for the Company&rsquo;s use of the proceeds from the sale of Securities or any money paid to
the Company pursuant to the terms of this Indenture, and the Trustee shall not be responsible for any statement in the Securities other
than its certificates of authentication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5.
NOTICE OF DEFAULT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Default or an Event of Default occurs and is continuing with respect to the Securities of any Series, and if it is known to the Trustee,
the Trustee shall mail to each Securityholder of the Securities of that Series notice of the Default or the Event of Default, as the
case may be, within 90 days after it occurs or, if later, after a Responsible Officer of the Trustee has knowledge of such Default or
Event of Default (except if such Default or Event of Default has been validly cured or waived before the giving of such notice). Except
in the case of a Default or an Event of Default in payment of the principal of, or interest or premium, if any, on, any Security of any
Series, the Trustee may withhold the notice if and so long as the Board of Directors of the Trustee, the executive committee or any trust
committee of such board and/or its Responsible Officers in good faith determine(s) that withholding the notice is in the interests of
the Securityholders of that Series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.
REPORTS BY TRUSTEE TO HOLDERS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
and to the extent required by the TIA, within 60 days after April 1 of each year, commencing the April 1 following the date of this Indenture,
the Trustee shall mail to each Securityholder a brief report dated as of such April 1 that complies with TIA Section 313(a). The Trustee
also shall comply with TIA Sections 313(b) and 313(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of each report at the time of its mailing to Securityholders shall be filed with the SEC and any stock exchange on which the Securities
of that Series are listed. The Company shall promptly notify the Trustee when the Securities of any Series are listed on any stock exchange
or any delisting thereof, and the Trustee shall comply with TIA Section 313(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.
COMPENSATION AND INDEMNITY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay to the Trustee from time to time reasonable compensation for its services. The Trustee&rsquo;s compensation shall not
be limited by any provision of law on compensation of a trustee of an express trust. The Company shall reimburse the Trustee within 45
days after receipt of request for all reasonable out-of-pocket disbursements and expenses incurred or made by it in connection with its
duties under this Indenture, including the reasonable compensation, disbursements and expenses of the Trustee&rsquo;s agents and counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall indemnify the Trustee for, and hold it harmless against, any and all loss or liability incurred by it in connection with
the acceptance or performance of its duties under this Indenture including the reasonable costs and expenses of defending itself against
any claim or liability in connection with the exercise or performance of any of its powers or duties hereunder. The Trustee shall notify
the Company promptly of any claim asserted against the Trustee for which it may seek indemnity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure by the Trustee to so notify the Company shall not however relieve the Company of its obligations. Notwithstanding the foregoing,
the Company need not reimburse the Trustee for any expense or indemnify it against any loss or liability incurred by the Trustee through
its negligence or bad faith. To secure the payment obligations of the Company in this Section 7.7, the Trustee shall have a lien prior
to the Securities of any Series on all money or property held or collected by the Trustee except such money or property held in trust
to pay the principal of, interest and premium, if any, on particular Securities of that Series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Trustee incurs expenses or renders services after an Event of Default specified in Section 6.1(4) or (5) occurs, the expenses and
the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section 7.7, the term &ldquo;Trustee&rdquo; shall include any trustee appointed pursuant to this Article 7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8.
REPLACEMENT OF TRUSTEE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee may resign with respect to the Securities of one or more Series by so notifying the Company in writing at least 90 days in advance
of such resignation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Holders of a majority in principal amount of the outstanding Securities of any Series may remove the Trustee with respect to that Series
by notifying the removed Trustee in writing and may appoint a successor Trustee with respect to that Series with the consent of the Company,
which consent shall not be unreasonably withheld. The Company may remove the Trustee with respect to that Series at its election if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Trustee fails to comply with, or ceases to be eligible under, Section 7.10;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
the Trustee is adjudged a bankrupt or an insolvent, or an order for relief is entered with respect to the Trustee, under any Bankruptcy
Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
a Custodian or other public officer takes charge of the Trustee or its property; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
the Trustee otherwise becomes incapable of acting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
If the Trustee resigns or is removed, or if a vacancy exists in the office of Trustee, with respect to any Series of Securities for any
reason, the Company shall promptly appoint, by Board Resolution, a successor Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a successor Trustee with respect to the Securities of one or more Series does not take office within 60 days after the retiring Trustee
resigns or is removed, the retiring Trustee, the Company or the Holders of at least 10% in principal amount of the outstanding Securities
of the applicable Series may petition any court of competent jurisdiction for the appointment of a successor Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Trustee with respect to the Securities of one or more Series fails to comply with Section 7.10, any Securityholder of the applicable
Series may petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
successor Trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the Company. Immediately following
such delivery, (i) the retiring Trustee with respect to one or more Series shall, subject to its rights under Section 7.7, transfer all
property held by it as Trustee with respect to such Series to the successor Trustee, (ii) the resignation or removal of the retiring
Trustee shall become effective and (iii) the successor Trustee with respect to such Series shall have all the rights, powers and duties
of the Trustee under this Indenture. A successor Trustee with respect to the Securities of one or more Series shall mail notice of its
succession to each Securityholder of such Series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9.
SUCCESSOR TRUSTEE BY CONSOLIDATION, MERGER OR CONVERSION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Trustee, or any Agent, consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust assets
to, another corporation, subject to Section 7.10, the successor corporation without any further act shall be the successor Trustee or
Agent, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10.
ELIGIBILITY; DISQUALIFICATION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Indenture shall always have a Trustee who satisfies the requirements of TIA Sections 310(a)(1), (2) and (5) in every respect. The Trustee
(or in the case of a Trustee that is a Person included in a bank holding company system, the related bank holding company) shall have
a combined capital and surplus of at least $100,000,000 as set forth in its most recent published annual report of condition. The Trustee
shall comply with TIA Section 310(b), including the provision in Section 310(b)(1). In addition, if the Trustee is a Person included
in a bank holding company system, the Trustee, independently of such bank holding company, shall meet the capital requirements of TIA
Section 310(a)(2). If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section 7.10, it shall
resign immediately in the manner and with the effect specified in this Article 7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11.
PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee shall comply with TIA Section 311(a), excluding any creditor relationship listed in TIA Section 311(b). A Trustee who has resigned
or been removed shall be subject to TIA Section 311(a) to the extent indicated therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12.
PAYING AGENTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall cause each Paying Agent other than the Trustee to execute and deliver to it and the Trustee an instrument in which such
agent shall agree with the Trustee, subject to the provisions of this Section 7.12:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
that it will hold all sums held by it as agent for the payment of the principal of, or interest or premium, if any, on, the Securities
(whether such sums have been paid to it by the Company or by any obligor on the Securities) in trust for the benefit of Holders of the
Securities or the Trustee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
that it will at any time during the continuance of any Event of Default, upon written request from the Trustee, deliver to the Trustee
all sums so held in trust by it together with a full accounting thereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
that it will give the Trustee written notice within three Business Days after any failure of the Company (or by any obligor on the Securities)
in the payment of any installment of the principal of, or interest or premium, if any, on, the Securities when the same shall be due
and payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
8</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
AMENDMENTS, SUPPLEMENTS AND WAIVERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.
WITHOUT CONSENT OF HOLDERS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, when authorized by a Board Resolution, and the Trustee may amend or supplement this Indenture or the Securities of one or more
Series without notice to or consent of any Securityholder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
to comply with Section 5.1;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
to provide for certificated Securities in addition to uncertificated Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
to comply with any requirements of the SEC under the TIA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
to cure any ambiguity, defect or inconsistency, or to make any other change herein or in the Securities that does not materially and
adversely affect the rights of any Securityholder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
to provide for the issuance of, and establish the form and terms and conditions of, Securities of any Series as permitted by this Indenture;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
to evidence and provide for the acceptance of appointment hereunder by a successor Trustee with respect to the Securities of one or more
Series, and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration
of the trusts hereunder by more than one Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee is hereby authorized to join with the Company in the execution of any supplemental indenture authorized or permitted by the terms
of this Indenture, and to make any further appropriate agreements and stipulations which may be therein contained, but the Trustee shall
not be obligated to enter into any such supplemental indenture which adversely affects its own rights, duties or immunities under this
Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.
WITH CONSENT OF HOLDERS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company, when authorized by a Board Resolution, and the Trustee may amend or supplement this Indenture or the Securities of one or
more Series with the written consent of the Holders of not less than a majority in aggregate principal amount of the outstanding Securities
of such Series affected by such amendment or supplement without notice to any Securityholder. The Holders of not less than a majority
in aggregate principal amount of the outstanding Securities of each such Series affected by such amendment or supplement may waive compliance
by the Company in a particular instance with any provision of this Indenture or the Securities of such Series without notice to any Securityholder.
Subject to Section 8.4, without the consent of each Securityholder affected, however, an amendment, supplement or waiver may not:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
reduce the amount of Securities whose Holders must consent to an amendment, supplement or waiver to this Indenture or the Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
reduce the rate of, or change the time for payment of, interest on any Security;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
reduce the principal, or change the Stated Maturity, of any Security, or reduce the amount of, or postpone the date fixed for, the payment
of any sinking fund or analogous obligation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
make any Security payable in money other than that stated in the Security;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
change the amount or time of any payment required by the Securities, or reduce the premium payable upon any redemption of the Securities,
or change the time before which no such redemption may be made;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
waive a Default or Event of Default in the payment of the principal of, or interest or premium, if any, on, any Security (except a rescission
of acceleration of the Securities of any Series by the Holders of at least a majority in principal amount of the outstanding Securities
of such Series and a waiver of the payment default that resulted from such acceleration);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
waive a redemption payment with respect to any Security, or change any of the provisions with respect to the redemption of any Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
make any changes in Section 6.6 or this Section 8.2, except to increase any percentage of Securities the Holders of which must consent
to any matter; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
take any other action otherwise prohibited by this Indenture to be taken without the consent of each Holder affected thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Upon the request of the Company, accompanied by a Board Resolution authorizing the execution of any such supplemental indenture, and
upon the receipt by the Trustee of evidence reasonably satisfactory to the Trustee of the consent of the Securityholders as aforesaid
and of the documents described in Section 8.6, the Trustee shall join with the Company in the execution of such supplemental indenture,
unless such supplemental indenture affects the Trustee&rsquo;s own rights, duties or immunities under this Indenture, in which case the
Trustee may in its discretion, but shall not be obligated to, enter into such supplemental indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
It shall not be necessary for the consent of the Holders under this section to approve the particular form of any proposed amendment,
supplement or waiver, but it shall be sufficient if such consent approves the substance thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
an amendment or supplement under this Section becomes effective, the Company shall mail to Securityholders a notice briefly describing
the amendment or supplement. Any failure of the Company to mail any such notice, or any defect therein, shall not, however, in any way
impair or affect the validity of any supplemental indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.
COMPLIANCE WITH TRUST INDENTURE ACT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
amendment to, or supplement of, this Indenture or the Securities shall comply with the TIA as then in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.
REVOCATION AND EFFECT OF CONSENTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
an amendment, supplement, waiver or other action becomes effective, a consent to it by a Holder of a Security is a continuing consent
conclusive and binding upon such Holder and every subsequent Holder of the same Security or portion thereof, and of any Security issued
upon the transfer thereof or in exchange therefor or in place thereof, even if notation of the consent is not made on any such Security.
Any such Holder or subsequent Holder, however, may revoke the consent as to his Security or portion of a Security, if the Trustee receives
the notice of revocation before the date the amendment, supplement, waiver or other action becomes effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may, but shall not be obligated to, fix a record date for the purpose of determining the Holders entitled to consent to any amendment,
supplement or waiver, which record date shall be at least 30 days prior to the first solicitation of such consent. If a record date is
fixed, then, notwithstanding the preceding paragraph, those Persons who were Holders at such record date (or their duly designated proxies),
and only such Persons, shall be entitled to consent to such amendment, supplement or waiver, or to revoke any consent previously given,
whether or not such Persons continue to be Holders after such record date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
an amendment, supplement, waiver or other action becomes effective, it shall bind every Securityholder, unless it makes a change described
in any of clauses (1) through (9) of Section 8.2. In that case, the amendment, supplement, waiver or other action shall bind each Holder
of a Security who has consented to it and every subsequent Holder of a Security or portion of a Security that evidences the same debt
as the consenting Holder&rsquo;s Security; PROVIDED, that any such waiver shall not impair or affect the right of any Holder to receive
payment of the principal of, and interest and premium, if any, on, a Security, on or after the respective due dates expressed in such
Security, or to bring suit for the enforcement of any such payment on or after such respective dates without the consent of such Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5.
NOTATION ON OR EXCHANGE OF SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an amendment, supplement or waiver changes the terms of a Security of any Series, the Trustee may request the Holder of such Security
to deliver it to the Trustee. In such case, the Trustee shall place an appropriate notation on such Security about the changed terms
and return it to the Holder. Alternatively, the Company, in exchange for such Security, may issue, and the Trustee shall authenticate,
a new security that reflects the changed terms. Failure to make the appropriate notation or issue a new Security shall not affect the
validity and effect of such amendment, supplement or waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6.
TRUSTEE TO SIGN AMENDMENTS, ETC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee shall sign any amendment, supplement or waiver authorized pursuant to this Article 8 if the amendment, supplement or waiver does
not adversely affect the rights, duties, liabilities or immunities of the Trustee. If it does, the Trustee may, but need not, sign it.
In signing or refusing to sign such amendment, supplement or waiver the Trustee shall be entitled to receive and, subject to Section
7.1, shall be fully protected in relying upon an Officers&rsquo; Certificate and an Opinion of Counsel stating that such amendment, supplement
or waiver is authorized or permitted by this Indenture. The Company may not sign an amendment or supplement until the Board of Directors
of the Company approves it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
9</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
DISCHARGE OF INDENTURE; DEFEASANCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.
DISCHARGE OF INDENTURE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may terminate its obligations under the Securities of any Series and this Indenture with respect to such Series, except the obligations
referred to in the last paragraph of this Section 9.1, if there shall have been canceled by the Trustee, or delivered to the Trustee
for cancellation, all Securities of such Series theretofore authenticated and delivered (other than any Securities of such Series that
are asserted to have been destroyed, lost or stolen and that shall have been replaced as provided in Section 2.8) and the Company has
paid all sums payable by it hereunder or deposited all required sums with the Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
such delivery the Trustee upon request shall acknowledge in a writing prepared by or on behalf of the Company the discharge of the Company&rsquo;s
obligations under the Securities of such Series and this Indenture, except for those surviving obligations specified below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the satisfaction and discharge of this Indenture, the obligations of the Company in Sections 7.7, 9.5 and 9.6 shall survive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.
LEGAL DEFEASANCE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may at its option, by Board Resolution, be discharged from its obligations with respect to the Securities of any Series on the
date upon which the conditions set forth in Section 9.4 below are satisfied (hereinafter, &ldquo;Legal Defeasance&rdquo;). For this purpose,
such Legal Defeasance means that the Company shall be deemed to have paid and discharged the entire indebtedness represented by the Securities
of such Series and to have satisfied all its other obligations under such Securities and this Indenture insofar as such Securities are
concerned (and the Trustee, at the expense of the Company, shall, subject to Section 9.6, execute proper instruments acknowledging the
same, as are delivered to it by the Company), except for the following, which shall survive until otherwise terminated or discharged
hereunder: (A) the rights of Holders of outstanding Securities of such Series to receive solely from the trust funds described in Section
9.4 and as more fully set forth in such section, payments in respect of the principal of, and interest and premium, if any, on, the Securities
of such Series when such payments are due, (B) the Company&rsquo;s obligations with respect to the Securities of such Series under Sections
2.4, 2.5, 2.6, 2.7, 2.8 and 2.9, (C) the rights, powers, trusts, duties and immunities of the Trustee hereunder (including claims of,
or payments to, the Trustee under or pursuant to Section 7.7) and (D) this Article 9. Subject to compliance with this Article 9, the
Company may exercise its option under this Section 9.2 with respect to the Securities of any Series notwithstanding the prior exercise
of its option under Section 9.3 below with respect to the Securities of such Series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.
COVENANT DEFEASANCE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the option of the Company, pursuant to a Board Resolution, the Company shall be released from its obligations with respect to the outstanding
Securities of any Series under Sections 4.2 through 4.5, inclusive, and Section 5.1, with respect to the outstanding Securities of such
Series, on and after the date the conditions set forth in Section 9.4 are satisfied (hereinafter, &ldquo;Covenant Defeasance&rdquo;).
For this purpose, such Covenant Defeasance means that the Company may omit to comply with and shall have no liability in respect of any
term, condition or limitation set forth in any such specified section or portion thereof, whether directly or indirectly by reason of
any reference elsewhere herein to any such specified Section or portion thereof or by reason of any reference in any such specified section
or portion thereof to any other provision herein or in any other document, but the remainder of this Indenture and the Securities of
any Series shall be unaffected thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.
CONDITIONS TO LEGAL DEFEASANCE OR COVENANT DEFEASANCE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following shall be the conditions to application of Section 9.2 or Section 9.3 to the outstanding Securities of a Series:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Company shall irrevocably have deposited or caused to be deposited with the Trustee (or another trustee satisfying the requirements
of Section 7.10 who shall agree to comply with the provisions of this Article 9 applicable to it) as funds in trust for the purpose of
making the following payments, specifically pledged as security for, and dedicated solely to, the benefit of the Holders of the Securities,
(A) money in an amount, or (B) U.S. Government Obligations or Foreign Government Obligations which through the scheduled payment of principal
and interest in respect thereof in accordance with their terms will provide, not later than the due date of any payment, money in an
amount, or (C) a combination thereof, sufficient, in the opinion of a nationally recognized firm of independent public accountants expressed
in a written certification thereof delivered to the Trustee, to pay and discharge, and which shall be applied by the Trustee (or other
qualifying trustee) to pay and discharge, the principal of, and accrued interest and premium, if any, on, the outstanding Securities
of such Series at the Stated Maturity of such principal, interest or premium, if any, or on dates for payment and redemption of such
principal, interest and premium, if any, selected in accordance with the terms of this Indenture and of the Securities of such Series;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
no Event of Default or Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such
deposit, or shall have occurred and be continuing at any time during the period ending on the 91st day after the date of such deposit
or, if longer, ending on the day following the expiration of the longest preference period under any Bankruptcy Law applicable to the
Company in respect of such deposit as specified in the Opinion of Counsel identified in paragraph (8) below (it being understood that
this condition shall not be deemed satisfied until the expiration of such period);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
such Legal Defeasance or Covenant Defeasance shall not cause the Trustee to have a conflicting interest for purposes of the TIA with
respect to any securities of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
such Legal Defeasance or Covenant Defeasance shall not result in a breach or violation of, or constitute default under, any other agreement
or instrument to which the Company is a party or by which it is bound;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
the Company shall have delivered to the Trustee an Opinion of Counsel stating that, as a result of such Legal Defeasance or Covenant
Defeasance, neither the trust nor the Trustee will be required to register as an investment company under the Investment Company Act
of 1940, as amended;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
in the case of an election under Section 9.2, the Company shall have delivered to the Trustee an Opinion of Counsel stating that (i)
the Company has received from, or there has been published by, the Internal Revenue Service a ruling to the effect that or (ii) there
has been a change in any applicable Federal income tax law with the effect that, and such opinion shall confirm that, the Holders of
the outstanding Securities of such Series or Persons in their positions will not recognize income, gain or loss for Federal income tax
purposes solely as a result of such Legal Defeasance and will be subject to Federal income tax on the same amounts, in the same manner,
including as a result of prepayment, and at the same times as would have been the case if such Legal Defeasance had not occurred;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
in the case of an election under Section 9.3, the Company shall have delivered to the Trustee an Opinion of Counsel to the effect that
the Holders of the outstanding Securities of such Series will not recognize income, gain or loss for Federal income tax purposes as a
result of such Covenant Defeasance, and will be subject to Federal income tax on the same amounts, in the same manner and at the same
times as would have been the case if such Covenant Defeasance had not occurred;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
the Company shall have delivered to the Trustee an Officers&rsquo; Certificate and an Opinion of Counsel, each stating that all conditions
precedent provided for in this Article 9 relating to either the Legal Defeasance under Section 9.2 or the Covenant Defeasance under Section
9.3 (as the case may be) have been complied with;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
the Company shall have delivered to the Trustee an Officers&rsquo; Certificate stating that the deposit under clause (1) was not made
by the Company with the intent of defeating, hindering, delaying or defrauding any creditors of the Company or others; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
the Company shall have paid, or duly provided for payment under terms mutually satisfactory to the Company and the Trustee, all amounts
then due to the Trustee pursuant to Section 7.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5.
DEPOSITED MONEY AND U.S. AND FOREIGN GOVERNMENT OBLIGATIONS TO BE HELD IN TRUST; OTHER MISCELLANEOUS PROVISIONS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
money, U.S. Government Obligations and Foreign Government Obligations (including the proceeds thereof) deposited with the Trustee pursuant
to Section 9.4 in respect of the outstanding Securities shall be held in trust and applied by the Trustee, in accordance with the provisions
of such Securities and this Indenture, to the payment, either directly or through any Paying Agent as the Trustee may determine, to the
Holders of such Securities, of all sums due and to become due thereon in respect of principal, accrued interest and premium, if any,
but such money need not be segregated from other funds except to the extent required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay and indemnify the Trustee against any tax, fee or other charge imposed on or assessed against the U.S. Government Obligations
and Foreign Government Obligations deposited pursuant to Section 9.4 or the principal, interest and premium, if any, received in respect
thereof other than any such tax, fee or other charge which by law is for the account of the Holders of the outstanding Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anything
in this Article 9 to the contrary notwithstanding, but subject to payment of any of its outstanding fees and expenses, the Trustee shall
deliver or pay to the Company from time to time upon Company Request any money, U.S. Government Obligations or Foreign Government Obligations
held by the Trustee as provided in Section 9.4 which, in the opinion of a nationally-recognized firm of independent public accountants
expressed in a written certification thereof delivered to the Trustee, are in excess of the amount thereof which would then be required
to be deposited to effect an equivalent Legal Defeasance or Covenant Defeasance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6.
REINSTATEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Trustee or Paying Agent is unable to apply any money, U.S. Government Obligations or Foreign Government Obligations in accordance
with Section 9.1, 9.2, 9.3 or 9.4 by reason of any legal proceeding or by reason of any order or judgment of any court or governmental
authority enjoining, restraining or otherwise prohibiting such application, the Company&rsquo;s obligations under this Indenture and
the Securities shall be revived and reinstated as though no deposit had occurred pursuant to this Article 9 until such time as the Trustee
or Paying Agent is permitted to apply all such money, U.S. Government Obligations or Foreign Government Obligations, as the case may
be, in accordance with Section 9.1, 9.2, 9.3 or 9.4; PROVIDED, HOWEVER, that if the Company has made any payment of principal of, or
accrued interest or premium, if any, on, any Securities because of the reinstatement of its obligations, the Company shall be subrogated
to the rights of the Holders of such Securities to receive such payment from the money, U.S. Government Obligations or Foreign Government
Obligations held by the Trustee or Paying Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7.
MONEYS HELD BY PAYING AGENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the satisfaction and discharge of this Indenture, all moneys then held by any Paying Agent under the provisions of this
Indenture shall, upon demand of the Company, be paid to the Trustee, or, if sufficient moneys have been deposited pursuant to Section
9.1, to the Company, and thereupon such Paying Agent shall be released from all further liability with respect to such moneys.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8.
MONEYS HELD BY TRUSTEE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
moneys deposited with the Trustee or any Paying Agent or then held by the Company in trust for the payment of the principal of, or interest
or premium, if any, on, any Security that are not applied but remain unclaimed by the Holder of such Security for two years after the
date upon which the principal of, or interest or premium, if any, on, such Security shall have respectively become due and payable shall
be repaid to the Company upon Company Request, or if such moneys are then held by the Company in trust, such moneys shall be released
from such trust; and the Holder of such Security entitled to receive such payment shall thereafter, as an unsecured general creditor,
look only to the Company for the payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money
shall thereupon cease; PROVIDED, HOWEVER, that the Trustee or any such Paying Agent, before being required to make any such repayment,
may, at the expense of the Company, either mail to each Securityholder affected, at the address shown in the register of the Securities
maintained by the Registrar, or cause to be published once a week for two successive weeks, in a newspaper published in the English language,
customarily published each Business Day and of general circulation in the City of New York, New York, a notice that such money remains
unclaimed and that, after a date specified therein, which shall not be less than 30 days from the date of such mailing or publication,
any unclaimed balance of such moneys then remaining will be repaid to the Company. After payment to the Company or the release of any
money held in trust by the Company, Securityholders entitled to the money must look only to the Company for payment as general creditors,
unless applicable abandoned property law designates another Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
10</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.
TRUST INDENTURE ACT CONTROLS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any provision of this Indenture limits, qualifies or conflicts with another provision which is required to be included in this Indenture
by the TIA, the required provision shall control. If any provision of this Indenture modifies or excludes any provision of the TIA which
may be so modified or excluded, the latter provision shall be deemed to apply to this Indenture as so modified or to be excluded, as
the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.
NOTICES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice or communication shall be given in writing and delivered in Person, sent by facsimile (and receipt confirmed by telephone or electronic
transmission report), delivered by commercial courier service or mailed by first-class mail, postage prepaid, addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">to the Company:</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
  Inc.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16305
  36th Avenue N., Suite 100</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Minneapolis,<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MN 55446</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Fax: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(763)
  ___-____</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
  Secretary</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Copy</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">to:</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fredrikson
  &amp; Byron, P.A.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">200
  South Sixth Street, Suite 4000</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,MN 55402</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:(612) 492-7077</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
  Eric O. Madson, Esq.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">to the Trustee:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">___________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">___________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">___________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">___________________________</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company or the Trustee by written notice to the other may designate additional or different addresses for subsequent notices or communications.
Any notice or communication to the Company or the Trustee shall be deemed to have been given or made as of the date so delivered if personally
delivered; when receipt is confirmed by telephone or electronic transmission report, if sent by facsimile; and three Business Days after
mailing if sent by registered or certified mail, postage prepaid (except that a notice of change of address shall not be deemed to have
been given until actually received by the addressee).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice or communication mailed to a Securityholder shall be mailed to such Securityholder by first-class mail, postage prepaid, at such
Securityholder&rsquo;s address shown on the register kept by the Registrar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to mail, or any defect in, a notice or communication to a Securityholder shall not affect its sufficiency with respect to other Securityholders.
If a notice or communication to a Securityholder is mailed in the manner provided above, it shall be deemed duly given, three Business
Days after such mailing, whether or not the addressee receives it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case by reason of the suspension of regular mail service, or by reason of any other cause, it shall be impossible to mail any notice
as required by this Indenture, then such method of notification as shall be made with the approval of the Trustee shall constitute a
sufficient mailing of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of Global Securities, notices or communications to be given to Securityholders shall be given to the Depository, in accordance
with its applicable policies as in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the manner provided for in the foregoing provisions, notices or communications to Securityholders shall be given by the Company
by release made to Reuters Economic Services and Bloomberg Business News.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.
COMMUNICATIONS BY HOLDERS WITH OTHER HOLDERS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securityholders
of any Series may communicate pursuant to TIA Section 312(b) with other Securityholders of that Series or any other Series with respect
to their rights under this Indenture or the Securities of that Series or any other Series. The Company, the Trustee, the Registrar and
any other Person shall have the protection of TIA Section 312(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4.
CERTIFICATE AND OPINION AS TO CONDITIONS PRECEDENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
an Officers&rsquo; Certificate (which shall include the statements set forth in Section 10.5 below) stating that, in the opinion of the
signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
an Opinion of Counsel (which shall include the statements set forth in Section 10.5 below) stating that, in the opinion of such counsel,
all such conditions precedent have been complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5.
STATEMENT REQUIRED IN CERTIFICATE AND OPINION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
certificate and opinion with respect to compliance with a condition or covenant provided for in this Indenture (other than pursuant to
Section 4.4) shall include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
a statement that the Person making such certificate or opinion has read such covenant or condition;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such
certificate or opinion are based;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
a statement that, in the opinion of such Person, it or he has made such examination or investigation as is necessary to enable it or
him to express an informed opinion as to whether or not such covenant or condition has been complied with; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
a statement as to whether or not, in the opinion of such Person, such covenant or condition has been complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6.
RULES BY TRUSTEE AND AGENTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Trustee may make reasonable rules for action by or at meetings of Securityholders. The Registrar and Paying Agent may make reasonable
rules for their functions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.
BUSINESS DAYS; LEGAL HOLIDAYS; PLACE OF PAYMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;Business Day&rdquo; is a day that is not a Legal Holiday. A &ldquo;Legal Holiday&rdquo; is a Saturday, a Sunday, a federally-recognized
holiday or a day on which banking institutions are not authorized or required by law, regulation or executive order to be open in the
State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a payment date is a Legal Holiday at a Place of Payment, payment may be made at that place on the next succeeding day that is not a Legal
Holiday, and no interest shall accrue for the intervening period. &ldquo;Place of Payment&rdquo; means the place or places where the
principal of, and interest and premium, if any, on, the Securities of a Series are payable as specified as contemplated by Section 2.2.
If the regular record date is a Legal Holiday, the record date shall not be affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8.
GOVERNING LAW.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
INDENTURE AND THE SECURITIES SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, AS APPLIED TO CONTRACTS
MADE AND PERFORMED WITHIN THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9.
NO ADVERSE INTERPRETATION OF OTHER AGREEMENTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Indenture may not be used to interpret another indenture, loan, security or debt agreement of the Company or any Subsidiary thereof.
No such indenture, loan, security or debt agreement may be used to interpret this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10.
NO RECOURSE AGAINST OTHERS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director, officer, employee, stockholder or incorporator, as such, of the Company shall not have any liability for any obligations of
the Company under the Securities or the Indenture. Each Securityholder by accepting a Security waives and releases all such liability.
Such waiver and release are part of the consideration for the issuance of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11.
SUCCESSORS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
covenants and agreements of the Company in this Indenture and the Securities shall bind the Company&rsquo;s successors and assigns, whether
so expressed or not. All agreements of the Trustee, any additional trustee and any Paying Agents in this Indenture shall bind their respective
successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.
MULTIPLE COUNTERPARTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties may sign multiple counterparts of this Indenture. Each signed counterpart shall be deemed an original, but all of them together
represent one and the same agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13.
TABLE OF CONTENTS, HEADINGS, ETC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table of contents, cross-reference sheet and headings of the Articles and Sections of this Indenture have been inserted for convenience
of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14.
SEVERABILITY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
provision of this Indenture shall be considered separable, and if for any reason any provision which is not essential to the effectuation
of the basic purpose of this Indenture or the Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired thereby, and a Holder shall have no claim therefor against any
party hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15.
SECURITIES IN A FOREIGN CURRENCY OR IN EUROS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officers&rsquo; Certificate delivered pursuant to Section
2.2 with respect to a particular Series of Securities, whenever for purposes of this Indenture any action may be taken by the Holders
of a specified percentage in aggregate principal amount of Securities of all Series or all Series affected by a particular action at
the time outstanding and, at such time, there are outstanding Securities of any Series which are denominated in a coin or currency other
than Dollars (including Euros), then the principal amount of Securities of such Series which shall be deemed to be outstanding for the
purpose of taking such action shall be that amount of Dollars that could be obtained for such amount at the Market Exchange Rate at such
time. For purposes of this Section 10.15, &ldquo;Market Exchange Rate&rdquo; shall mean the noon Dollar buying rate in New York City
for cable transfers of that currency as published by the Federal Reserve Bank of New York; PROVIDED, HOWEVER, in the case of Euros, Market
Exchange Rate shall mean the rate of exchange determined by the Commission of the European Union (or any successor thereto) as published
in the Official Journal of the European Union (such publication or any successor publication, the &ldquo;Journal&rdquo;). If such Market
Exchange Rate is not available for any reason with respect to such currency, the Trustee shall use, in its sole discretion and without
liability on its part, such quotation of the Federal Reserve Bank of New York or, in the case of Euros, the rate of exchange as published
in the Journal, as of the most recent available date, or quotations or, in the case of Euros, rates of exchange from one or more major
banks in New York City or in the country of issue of the currency in question or, in the case of Euros, in Luxembourg or such other quotations
or, in the case of Euros, rates of exchange as the Trustee, upon consultation with the Company, shall deem appropriate. The provisions
of this paragraph shall apply in determining the equivalent principal amount in respect of Securities of a Series denominated in currency
other than Dollars in connection with any action taken by Holders of Securities pursuant to the terms of this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
decisions and determinations of the Trustee regarding the Market Exchange Rate or any alternative determination provided for in the preceding
paragraph shall be in the Trustee&rsquo;s sole discretion, and shall, in the absence of manifest error, be conclusive to the extent permitted
by law for all purposes and irrevocably binding upon the Company and all Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16.
JUDGMENT CURRENCY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agrees, to the fullest extent that it may effectively do so under applicable law, that (a) if for the purpose of obtaining judgment
in any court it is necessary to convert the sum due in respect of the principal of, or interest or premium, if any, or other amount on,
the Securities of any Series (the &ldquo;Required Currency&rdquo;) into a currency in which a judgment will be rendered (the &ldquo;Judgment
Currency&rdquo;), the rate of exchange used shall be the rate at which, in accordance with normal banking procedures, the Trustee could
purchase in The City of New York the Required Currency with the Judgment Currency on the day on which final unappealable judgment is
entered, unless such day is not a Business Day, in which instance, the rate of exchange used shall be the rate at which, in accordance
with normal banking procedures, the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on
the Business Day preceding the day on which final unappealable judgment is entered and (b) its obligations under this Indenture to make
payments in the Required Currency (i) shall not be discharged or satisfied by any tender or any recovery pursuant to any judgment (whether
or not entered in accordance with subsection (a)) in any currency other than the Required Currency, except to the extent that such tender
or recovery shall result in the actual receipt, by the payee, of the full amount of the Required Currency expressed to be payable in
respect of such payments, (ii) shall be enforceable as an alternative or additional cause of action for the purpose of recovering in
the Required Currency the amount, if any, by which such actual receipt shall fall short of the full amount of the Required Currency so
expressed to be payable and (iii) shall not be affected by judgment being obtained for any other sum due under this Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed, and their respective corporate seals to be hereunto
affixed and attested, all as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
    INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Name
    of Trustee]</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
17, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16305
36th Avenue N., Suite 100</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
MN 55446</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
Celcuity Inc. Registration Statement on Form S-3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Celcuity Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the Company&rsquo;s Registration
Statement on Form S-3 (the &ldquo;Registration Statement&rdquo;) to be filed with the Securities and Exchange Commission pursuant to
the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), for the registration of the sale from time to time of (i) shares of common
stock, par value $0.001, of the Company (the &ldquo;Common Stock&rdquo;); (ii) shares of preferred stock of the Company (the &ldquo;Preferred
Stock&rdquo;); (iii) debt securities (the &ldquo;Debt Securities&rdquo;), which may be issued pursuant to an indenture to be entered
into between the Company and a trustee, as amended from time to time (the &ldquo;Indenture&rdquo;); (iv) warrants to purchase Common
Stock, Preferred Stock, Debt Securities and other securities or rights (the &ldquo;Warrants&rdquo;); and (v) units (the &ldquo;Units&rdquo;)
consisting of one or more shares of Common Stock, shares of Preferred Stock, Warrants, Debt Securities, or any combination of such securities
(collectively, the Common Stock, the Preferred Stock, the Debt Securities, the Warrants and the Units are referred to herein as the &ldquo;Securities&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have examined originals or copies, certified and otherwise identified to our satisfaction, of such documents, corporate records, certificates
of public officials and other instruments as we have deemed necessary for the purposes of rendering this opinion. In addition, as to
certain factual matters relevant to the opinions expressed below, we have relied upon representations, statements and certificates of
officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the foregoing and the other provisions set forth herein, we are of the opinion as of this date that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
When the necessary corporate action on the part of the Company has been taken to authorize the issuance and sale of shares of Common
Stock proposed to be sold by the Company, and when such shares of Common Stock are issued and delivered in accordance with the applicable
underwriting or other agreement against payment therefor (in excess of par value thereof) or upon conversion or exercise of any security
offered under the Registration Statement (the &ldquo;Offered Security&rdquo;), in accordance with terms of such Offered Security or the
instrument governing such Offered Security providing for such conversion or exercise as approved by the Board of Directors, for the consideration
approved by the Board of Directors (which consideration is not less than the par value of the Common Stock), such shares of Common Stock
will be validly issued, fully-paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Upon proper designation of the relative rights, preferences and limitations of any series of Preferred Stock by the Board of Directors
of the Company and the proper filing with the Secretary of State of the State of Delaware of a Certificate of Designation relating to
such series of Preferred Stock, when the necessary corporate action on the part of the Company has been taken to authorize the issuance
and sale of such series of Preferred Stock proposed to be sold by the Company, and when such shares of Preferred Stock are issued and
delivered in accordance with the applicable underwriting or other agreement against payment therefor (in excess of par value thereof),
such shares of Preferred Stock will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
When the specific terms of a particular series of Debt Securities have been duly authorized and established in accordance with the Indenture
and such Debt Securities have been duly authorized, executed, authenticated, issued and delivered in accordance with the Indenture and
the applicable underwriting or other agreement, such Debt Securities will constitute binding obligations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
When the Warrants have been duly authorized and established by the Company, the applicable warrant agreement and the applicable warrant
certificates have been duly authorized, executed and delivered, and the Warrants have been duly issued and delivered by the Company,
the Warrants will constitute binding obligations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
When the Units have been duly authorized and established by the Company, the necessary corporate action on the part of the Company has
been taken to authorize and execute and deliver or issue the securities underlying such Units, and the applicable Unit agreement has
been duly authorized, executed and delivered, the Units will constitute binding obligations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have assumed, among other things, the genuineness of all signatures and authenticity of all documents submitted to us as originals and
the conformity to original documents of all documents submitted to us as copies. In examining documents, we have assumed that parties,
other than the Company, have all necessary power to enter into and perform all of their obligations thereunder and have also assumed
the due authorization by all requisite action of the execution, delivery and performance of such documents by such parties, that such
documents are legal, valid, binding and enforceable obligations of such parties in accordance with their respective terms and that the
representations and warranties made in such documents by any parties are true and correct. We have also assumed that each natural person
executing any document relating to the matters covered by this opinion letter has the capacity and is legally competent to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the opinions expressed above, we have assumed that, at or prior to the time of the delivery of any such security, (i)
the Board of Directors shall have duly established the terms of such security and duly authorized the issuance and sale of such security
and such authorization shall not have been modified or rescinded; (ii) the Registration Statement shall be effective and such effectiveness
shall not have been terminated or rescinded; and (iii) there shall not have occurred any change in law affecting the validity, binding
nature or enforceability of such security. We have also assumed that none of the terms of any security to be established subsequent to
the date hereof, nor the issuance and delivery of such security, nor the compliance by the Company with the terms of such security will
violate, or fail to comply with, any applicable law affecting the validity, binding nature or enforceability of such security, or will
result in a violation of any provision of any instrument or agreement then binding upon the Company, or any restriction imposed by any
court or governmental body having jurisdiction over the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinions expressed above are specifically subject to the following additional limitations, exceptions, qualifications and assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
The legality, validity, binding nature and enforceability of the Company&rsquo;s obligations under the Securities may be subject to or
limited by (1) bankruptcy, insolvency, reorganization, arrangement, fraudulent transfer or conveyance, equitable subordination, moratorium
and other similar laws affecting the rights of creditors generally; (2) general principles of equity (whether relief is sought in a proceeding
at law or in equity), including, without limitation, concepts of materiality, reasonableness, good faith, fair dealing, commercial practice,
estoppel, diligence, unconscionability, right to cure, election of remedies, and the discretion of any court of competent jurisdiction
or of any arbiter in awarding specific performance or injunctive relief and other equitable remedies different from that provided in
the Securities; (3) the limitations or restrictions on a party&rsquo;s ability to enforce contractual rights or bring a cause of action
under state law or within the courts of such state if such party has failed to comply with applicable qualification, authorization, registration,
notice or similar filing requirements of such state; and (4) without limiting the generality of the foregoing, (a) principles requiring
the consideration of the impracticability or impossibility of performance of the Company&rsquo;s obligations at the time of the attempted
enforcement of such obligations, (b) the effect of court decisions and statutes that indicate that any provisions of the Securities that
permit a party to take action or make determinations may be subject to a requirement that such action be taken or such determinations
be made on a reasonable basis in good faith or that it be shown that such action is reasonably necessary for the party&rsquo;s protection,
and (c) public policy considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
We express no opinion as to the enforceability of provisions (i) to the effect that rights or remedies may be exercised without notice
and failure or delay to exercise is not a waiver of rights or remedies, that every right or remedy is cumulative, not exclusive, and
may be exercised in addition to or with any other right or remedy, or that election of a particular remedy or remedies does not preclude
recourse to one or more remedies, (ii) prohibiting waivers of any terms of the Securities other than in writing, or prohibiting oral
modifications thereof or modification by course of dealing, or (iii) that may be unenforceable under certain circumstances but the inclusion
of which does not affect the validity of the Security taken as a whole. In addition, our opinions are subject to the effect of judicial
decisions that may permit the introduction of extrinsic evidence to interpret the terms of written contracts such as the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing opinion is limited to the corporate laws of the states of Delaware and New York and the federal laws of the United States of
America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our name under the caption
&ldquo;Legal Matters&rdquo; in the prospectus. In giving such consent, we do not thereby admit that we are in the category of persons
whose consent is required under Section 7 of the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FREDRIKSON
    &amp; BYRON, P.A.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Eric O. Madson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    O. Madson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statement filed on Form S-3 and related Prospectus of our report
dated February 16, 2021, with respect to the financial statements of Celcuity Inc. on Form 10-K as of and for the year ended December
31, 2020. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Boulay PLLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
Minnesota</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
17, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ] . # 2(  A$! Q$!_\0
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M9GD4"LW0/%&C^)K);_P]K6B^(; M) -3T.^M]2T^2ZMG"742W-C<WELC1,Z
MP-=M.C;U=3L)'Q1_P5'@6?\ X)T?MMB1XHXU_9A^,DCO,N]42'P1K$[.%*MF
M5%C+0GC;,(V/"X/XR_\ !KY\4_A=X+_X):>&K#Q9\1O /A/6+KXU_&+46TSQ
M1XL\)>']6BLK[5M.;3FO+6]U:WO/WL,3/:.\2!H X*L54UTX;*?KN28C,Z57
M%.M"K2IJC1A*<8*<%-RO&G-QY6^62::T5W'<Y:V/JT\TPV#2H1I5)3<I5)J,
MFM+*SDM%KRM6OYZV_J.\V3@84G&3C/'/3[U2>8?0?D?\:\FTCXX?!S7M2L=%
MT3XM_"_6=:U.=+/3=+TGQ[X2U+4KZ\E.(K>SL+/6I+J\F<_=M[>-I7 .T9%=
MMK?B/2?#VE7FNZ]J>E:%H-E;->W>M:UJ,.F:=I]HL2NUSJ=W>_9K.R@5V57E
MGO(T1'\QCMCDQYBC7A.,9T*BYJ=.RJ1E&7-9IMIQB[2:O>UGT/24Z:E.4ZU-
MQC.44H2BX)1:5FTW[VOO)/<Z$2DG&!C!['UX[^GZT[>?0?K_ (URGA;Q;X<\
M96"ZOX6UO1?$.D3O/';:IH6KZ9K>GSO:-%#>P1W^D7VH63W&GWC2V5[&EP6A
MN(]N"&!/44_9U*=XU+\UW*SNFHRUBM4GHM-BE.$_>IM..UUM=;]Q^\^@_7_&
MI%.0#_GK7.>(_$>A>$M(N=?\3:WI'AS0K%K?^T-;U_4;/2=(L$N;F*T@:]U"
M_N+6UMEN+J>"S@>64 W5S @5RVTV/#?B+0_%FB6/B#PUK6D>(=$U%9GL=8T+
M4K'6-*O%@N9K6;[)J6G7%U970@N8)K69X)W5;B&6-MDB.BJU6[DZ5J.BC6UL
MZF[AM:Z6MKWMK:VH<\.;V=U[1+F:Z\O1V_X!\Q_MV?M4>#?V)OV3_C-^U#X[
M@;4-#^$GA@ZY::#'<_8I?%GBR^O;70_ /@Z*\P39OXL\=:IX<\/B\8-!:#4#
M=7L<UC#=02?Q_P#[$O\ P2W_ &A_^"ZT<7[??_!3S]H#XHV'P@\>ZMK%_P#!
M7X-> KL:?:7?A>TUF\TN\O/#T&IVVOZ#\//!5K<6)T7P_)HVC#7?&<:WGBJX
MUA+4007GZ=_\';'BO6?#W_!+CPOI&DO,D/CG]K'X4^&M9\I@$;3-*\!_%_XA
M1"XC?,4\*:UX&TB40S1RHUQ' RH)4C=/V\_81\%:)\/_ -B_]DWPAX?AAMM'
M\-_LY_!?3[.&RW0VK'_A77AV:XE2*(I"ZW5Q+->8V>6DEQ*8U0-M'UU/%5>'
M.%J6=8.,7F6<8S&8##5HTX2KX:."G2IRE2<XU(J4Y5HMN5.:48NRO9KYJM!9
MAGU7+\0O:X6CA<+6="3?LU*I"I*4FHN$KRY4M)_<?B/XT_X-2?\ @E_K?AF^
MT[PG-^T%\._%!A":-XLT_P")]MXRN])O+>19[:YDT;Q=X6UG2=6M9?)!OM'N
M+:*&6)F:TELKJ&VNXOVY_8H_9FA_8V_9?^#'[,EEXZ\0_$^#X1^&+CPU:>._
M%\-Q#XA\36TNLS:J;R]@?5-3CTU[:"]%E]ACE2V3[/;BR@MX4> _5[Q[]H8L
MP(PQW>69 =O+F'RR<;0.-N5)# [L4+;K&I2,*%:0'R]J1Q9:1&+%85CR5 PI
M/)Z-N'7Y['YSFV-PRHYECL1C+>Q<:E?V-XU9Z3:=+#4$K.32T::M?4]>AEN"
MP6*A7P=&G14E.G.G3<[2<$]^:I4OOW6OX?S&?\%YOVY_VE;7XF?LZ?\ !+7]
MAOQ#<>%_VCOVNM2MSXH^(&C$6.K> _A_J&I7.AV%C:ZX;F67PM=:E<6NK:[K
M6O06OV[_ (1SPY=:?ID^FS:JUTN)\&/^#5#_ ()[:%X*L8OVD/$?QG^/?Q:U
M5Y-7\<>.+OXB:IX3TC4?$^I);W&KW6B:38VYU:>P^WK(EA>^*=>\1:M+!),S
M7T0N)+5/RQ_;^_:VU3]E7_@Y<\2?M #X'_$#]I*]^#OP;\(^'/#/PO\ A_'>
MS>*&7Q+\#=6M)-;TRVL_#OB420>'KKQ?J^KW3R:4(H80;G[1'<P1O/\ H@G_
M  <S?$J-$0_\$?\ ]M&6&2)G$;P^(6Q&;F[@2.4S?".250WV=KFV2-T2.VN(
M@J@ 9^]JX#B?+LNR"EPY.C@HXRC#$XC&0ED<<77G72G.E.68XJ-;V=.*A&-Z
M-.-I6ISG%2:^,I8S)<3F>/JYS#&5)1KU*,*<(5G0C3I/DIN/LW%.24I-IR^+
MLY77R!^W_P#\$A_B3_P1ET%O^"B/_!*SX\_%+P5X>^#VKZ%?_%KX0^-M>BUW
M1H_#6LZI!I=WJ\D%O8:/I?C#P+'>3:3I_BKPIKNFZQJ4UEJ,FN6FNV#Z&UPO
M]9/[ _[5GA[]MG]D?X(?M-^'--30E^)O@BUOM>\,Q3>=%X1\::--+X<\;^$@
MZ2R1M%X>\6:5K&GVDBDB:UBCN(V\N89_F!_:>_X. _B!^T3^SK\;O@-/_P $
MCOVP-$B^,/PM\;_#9-9UBRU[4]-T6[\9>'-1\/:;J]UIMS\+(1?QZ;J6H6EV
M;>"6.X B\V&2-HC(OZA?\&T/@7X@?#G_ ()3_#+PY\1?"WBGP;J<?Q)^,UQI
M6@>,=&U/0=;L_#\GCF^CTYYM/U6."[6UO&BN)].D>!&EML/++<3-),_FY]@\
M3/)75SNM2KYY2SRA0G7C/ RJ3P53 5*M*C/^SJM3#-1G&<I-?O>;WI--V/3R
MRO2_M:EALKIUXY34BY<M6-1+VSUK/]ZY32YE"RYVK/1JSO\ G3_P=*L1\=_^
M"2O3_DO/BG_QWQQ\"<?_ %Z_L8 W'GO#%G_ON4_UK^./_@Z8)'QW_P""2A'_
M $7KQ5_ZF_P*K^QR,Y*_]<(3^;3?X5Y&;V?#'!T[6G4HXN=5]9U7B[3J2_O2
MY(7LDO=6BUOTY6_^%GB"%_=C'#J,>D4HST7I?N]SS'XV?%3P9\#OA-\1/C#\
M1=571/ ?PP\'^(/'?B[4BZK)!H7AG3;K5[^*V1I(A=7MY':_8K"P5C+J-Y<0
M6, ,]Q'C^(K]FK]E3]JC_@Y2^)WQ"_:M_:[^,?C_ .!W[#OA/QO>>$?@[\%/
MA\;64ZL=.F,]YX=\/077VOP]8W/A+1[RST;QS\1]?TCQ+<:IXPO]2TCP_8Z+
M:Z;K%M<?T$_\'&/C+4_!?_!(+]K&;2R8Y/$VG_#KP+>SJ6!M])\8_%#PAH>K
M2#:Z$%]/NKBW#@EHC,)H]LD:.O8?\$&/"6A^%O\ @DO^Q?::+96MO;:O\-M0
M\5:Q'#"JP:AK_BWQ9KGB+5]1=) Q,UU>W\\L[9^:XDDW9;@=6"Q$\@X2S/B*
MA'GQM7.L+EV%JJ,)U,)3<E[>5+GA.,/;<RYFX5.90LK+0TQ%\3G.#P$FY8=8
M>G5K47\$TX2=I6L[:=)Q/BO4/^#4_P#X)57VC76G6.G_ +0FC:S/8-9+KUG\
M7K:[U2UD:-H5NO[+U'PO>>%;A_(+W,EA-HLNG2R(C+:!TCV?JS_P3;_8,T/_
M ()R_LWVW[-OASXI>,?BUHEOXW\9^+[#Q1XWAB@UH:?XHNM+2PT<6UM))865
MMHMC:16Z0Z=%86LL\LLT=C$A"#] (T7Y$9F;:K$#(5"A*_(4C"(\8QM 96^7
M*DX)S((DC4*BJB[U.U$1%_UBE1M15 V@!1@9*CYBS<UY&.SC-LP52EF&98C'
M4G6G4A"M[+EIQER\M.*IX:@U&%GR\S;]YW;T:]7#8# X6MB*F$PM*A*+E!RI
M^T3]W?XZM1;OMNC^1#_@[T^7]F3]C?!<%?VI[FZ4B65,3V_@75YX7PDBJ=C,
MZ+N!Q'(X&&;?7]:'A&)(_"_AN) 0D?A[1U102%5191( (UQ&,+&H!" J,J"%
M)%?R6_\ !WP2/V8?V/&'5?VH+['IS\/M6/-?UK^%1_Q3/AUNYT#2,_\ @'&?
MYL?TKOQL(1X6R-QC%.IF>;1FTM91C4PJC%O5V2;2VM?<\7+I2EQ!G,I-MT\#
M@G!M_"W"K=I:*[LMT]C:D42*0Q("ESP<9VQOP<Y!!SR/H1@BOXWO^#8^&.+]
MLO\ X+'QQJ0D?QQTY5#N]PX,?Q7^/UN66>Y::XB66*U@$L$,T=J[11L( T<9
M3^R,_=?_ +:?^BVK^.#_ (-D_P#D\[_@LG_V7.R_]6[^T-6F11C4R;BN4TI2
MP^%HNC)J[I-U8I\FUKK36Y&93G#-^'E"3BL5B*D<2D[>VC%:*>]TNEN7U/['
M"-X5R2"%=A@D#(C88(S@CDY5LC/.-P!'\8G_  ;,Q(G[??\ P6%8 LZ?$V.,
M2RLTTN(_C1\;;<A99C))$DL=I;>;#"T=N[0QMY(\M-O]G8^XONDG_HMC_2OX
MRO\ @V< '[?'_!8<_P#541^OQN^.QI</0@LBXIDHQYE@,-44K7:J5*J<YIN]
MG)I-M6]%L7G$Y0SW((0DXQGC<1"44])0C&'+%K717=NNN[/Z1_\ @J(HD_X)
MQ?MPEC(/^,5_C<#Y62_S_#_78\J.=S*)"R@Y7>%+JZ@J?XY/^"+O_! O]CW_
M (*+_L3:1^TI\9_&_P =_#7CK4OB9\0/!ES8?#?Q)X2T+P^=-\)W.G6^GW*:
M;J_@;7KL:A=+<RR:G.=2>":5(#;6UJ!*C_V/?\%/\'_@G'^V^",@_LM?&H=2
M.O@361G*D'(ZCGJ.<C(/Y4_\&L/S_P#!*'PUNYQ\??C*HR V!_:&D]-P/^2:
M]#)\=C,KX'QV(R[$3PE>?$^4X:56DJ?-+#XG+L15Q%%^UI5U[.K4IPG./*KN
M*M*"O%Y8_!X7%<79=#$T(5H2P&93<9.I9SH.FJ,FH5:>M/GERNZM?52>JM?L
MV?\ !LO^PK^R[\?_ (0?M&> OB9^TKJ?C;X+^.=+\?\ A;3_ !;XT\$WGAF\
MUC1?-%M;ZW8Z?\.M-O;_ $^07$GG6EMJ-C*^%9+A"O/[U?&+X3>"_CA\*_B'
M\'OB'I(\1^!/BMX0UOP!XRT>Z=Q%J/ASQ-IL^CZPBKS';3'3[FXDAFBC1DNT
M@<98 'TN)0&!& <2\A5R,-'C^'WZ'(I+E 48;F\R0,L;X4[)$1YD<@KLPCQ!
MQE2"P (*D@_*8W-,;C)RQ6,Q56O6I1HQ56?LU)4Z<ZG)%<E&E&T8W2O"]MW+
MI[>'P&$I814J5"$%4I>TLG-WK5>=U*EY59/FFXQ;?-9-*T4?QV?\&Z_Q-\9_
ML6_M7?MH_P#!&[XTZ@$UKX<^./$WQ/\ @=/>K%;Q^(+:-;&7Q%;:2^R%[Q?%
MOP[N_A_\5--*_P"CQ:8=>A4&\MKJ1O[$S< [MK#<<>4#&2&WR>3$^X2?.FY6
MD<J!^Z>/&""S_P >G_!Q1\*/&'[''[5/[%__  65^!^CS+K?PK\>^#OA?\;8
M--#1#7-)LK^]OO"*:NEHMM+]A\7^$IO&/PEU>YNKPK,OB#PA;0M9)8,+O^KO
MX0_%#P?\:_A9\-_C)X!U>WU?P)\2O!7AWQWX5U.!XC%/X<\5:-::QIS2%9&5
MI8+.\B6\"LOD7$<D#@26\M>WQ%AZ5:EDN=X)Q6&Q^!GA<=3C\-#-<'%4:$9O
M5*>/BXU$O=<G'FC%W;7%DDY4*F,RK&S<:F'Y\52K2DE*=+$7G""NDK4_9M)6
M;M+[_P"93_@Z*_:&\3^(?AK^R]_P3;^$3SWOQ;_;+^,?AE]2T'3_ #FO;SP=
MH7BK3_#?A/1[OR)HW@L/&GQ(UG2WCE5?,:W\(ZBR2PK#.U?TA?LB?L^>&/V4
M?V8/@-^SAX/C@&A?!KX7^$O J75O$L0UG5-'TJ"/Q#XEN%1(U-_XI\0OJOB3
M4Y1'&)M1U6ZF\N/S-@_D[_8<A_X>I_\ !PA^TA^V?J$2ZY^S[^PM8KX%^#]U
M/')=Z1J/B/0I]>^'7@#4-.1VN(8[NZUN/XE?%>P>"2U475UH5YY96,PW7]H]
MHK);1"1464KNF$>?+$[DO-LW%CM,K.0"QP#C-7GM)Y9@,ER:<O\ :(X*&:9A
M2T4J.-QZE.6&FK74L+3A!6;O%UMO>,LFJ5L9B<;CJE^3VE3"4;V^##5%%25D
ME>::;WV6O0_";_@Y$_9P\1?M'?\ !*OXP0^$-,N]:\3_  3\3^#_ -H'3]*T
M^S.H7UWI?P^.JVGC:6VM%E@DF.E_#SQ%XNUF=(IDD-IIMP$64GR9.V_X(5?M
MM_#W]L/_ ()[_ &UT?Q1I%_\3?@G\-O"?P9^+/A6"^\[5]!\0_#S2H/#6D:W
M=+<+!=W>D>//#&G:/XKT75K6P?3IH[ZYM1=FYMG@3]F-8L+'4]/N+'4H+6YT
M^YCD@O;>]BBGM)[6:*2&XM[F"=)()[:ZAD>UNH)D:*>UFFBD!1V!_E9_:7_X
M-KDL?C1KW[17_!-+]JOXA?L,_$'Q+?7NJ:QX*TRZ\4R_#TZA>2PW,J:!K'@[
M7M+\0:)X:EN[:WG7PAJ8\1:!:2Q0SV5A91VEI:PK XK!YAEE'),?6C@XX+$8
MG%X+&.G*7LZF*Y)5:<N5MM.5-24N6\6^6ZTO>,PV)PN85,VPT93E.A1HU*<?
MMQHQDDMFOM']43R.QS')",!D+[?.\J12&96C$T,LC%5=555CP2)"QV[';'=-
M,655*MNDVF,--&!!</"(GNT46<=R\L4L+6XG>6"1HPZ-@@_R,?\ #HS_ (.
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M*\7VNG7FG-<-8SW%C'J^CZOIEW>:?KFDK>6=Q<03BYL[NTN[6WGB_+#]A/\
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MBT;LN9MV;^%=#CJ_7,RSC):RP3P]#+JLZM;2R<9IJ-[MNW7O?5NQ^P>]ML7
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ('!0(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U?XB>)+SP
MCX$U+7+"."2ZM?*V).I*'=*B'(!!Z,>]>?V'B_XU:GIUM?V?A'0Y+6ZB2:%_
M, W(P!4X-QD9!'6NH^-O_)(==_[=_P#THCKH/ G_ "3SPU_V"K7_ -%+0!Y_
M_P )#\<_^A,T/_O\O_R11_PD/QS_ .A,T/\ [_+_ /)%>P44 >/_ /"0_'/_
M *$S0_\ O\O_ ,D4?\)#\<_^A,T/_O\ +_\ )%>P44 >/_\ "0_'/_H3-#_[
M_+_\D4?\)#\<_P#H3-#_ ._R_P#R17L%% 'C_P#PD/QS_P"A,T/_ +_+_P#)
M%'_"0_'/_H3-#_[_ "__ "17L%% 'C__  D/QS_Z$S0_^_R__)%'_"0_'/\
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M^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!X_\ \)#\<_\ H3-#_P"_R_\
MR11_PD/QS_Z$S0_^_P O_P D5[!10!X__P )#\<_^A,T/_O\O_R11_PD/QS_
M .A,T/\ [_+_ /)%>P44 >/_ /"0_'/_ *$S0_\ O\O_ ,D4?\)#\<_^A,T/
M_O\ +_\ )%>P44 >/_\ "0_'/_H3-#_[_+_\D4?\)#\<_P#H3-#_ ._R_P#R
M17L%% 'C_P#PD/QS_P"A,T/_ +_+_P#)%'_"0_'/_H3-#_[_ "__ "17L%%
M'C__  D/QS_Z$S0_^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!X_\ \)#\
M<_\ H3-#_P"_R_\ R11_PD/QS_Z$S0_^_P O_P D5[!10!X__P )#\<_^A,T
M/_O\O_R11_PD/QS_ .A,T/\ [_+_ /)%>P44 >/_ /"0_'/_ *$S0_\ O\O_
M ,D4?\)#\<_^A,T/_O\ +_\ )%>P44 >/_\ "0_'/_H3-#_[_+_\D4?\)#\<
M_P#H3-#_ ._R_P#R17L%% 'C_P#PD/QS_P"A,T/_ +_+_P#)%'_"0_'/_H3-
M#_[_ "__ "17L%% 'C__  D/QS_Z$S0_^_R__)%'_"0_'/\ Z$S0_P#O\O\
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ML%% 'C__  D/QS_Z$S0_^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!X_\
M\)#\<_\ H3-#_P"_R_\ R11_PD/QS_Z$S0_^_P O_P D5[!10!X__P )#\<_
M^A,T/_O\O_R11_PD/QS_ .A,T/\ [_+_ /)%>P44 >/_ /"0_'/_ *$S0_\
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MS_Z$S0_^_P O_P D5[!10!X__P )#\<_^A,T/_O\O_R11_PD/QS_ .A,T/\
M[_+_ /)%>P44 >/_ /"0_'/_ *$S0_\ O\O_ ,D4?\)#\<_^A,T/_O\ +_\
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M >/_ /"0_'/_ *$S0_\ O\O_ ,D4?\)#\<_^A,T/_O\ +_\ )%>P44 >/_\
M"0_'/_H3-#_[_+_\D4?\)#\<_P#H3-#_ ._R_P#R17L%% 'C_P#PD/QS_P"A
M,T/_ +_+_P#)%'_"0_'/_H3-#_[_ "__ "17L%% 'C__  D/QS_Z$S0_^_R_
M_)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!X_\ \)#\<_\ H3-#_P"_R_\ R11_
MPD/QS_Z$S0_^_P O_P D5[!10!X__P )#\<_^A,T/_O\O_R14GPU^)?B;Q3X
MZU/PYX@L--M7L+>5I%M4;<LJ2HA4DNP(^9NGH.:]<KY_^%G_ "<+XU_[?O\
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MJQCS,[BN,9QU![UL:!KEGXDT2VU:P\P6UP"4$B[6&"0<CZ@UXKJ'_)M6G_\
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MSFK:]YKLE^(NE_-GMUCXKT+4M-NM1L]3@EL[7)GF!.V/ SSGVK,_X67X,/\
MS,-I^;?X5EZYI_AZR^%GB"3PW':+9SVLC%[5@R.0,=03Z8KS_P"%&@>$]5\*
MZG/XCALBT=P5$MQ+Y91-@Z'(QSGFEU?D'1>9[AI>M:7K<#3:7J%M>1J<,8)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO:B9P"WS C=C\>E4WH[=24M4F:.E1:9#8K'I"6:68)VK:!1&#WP%XK'^(/\
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M*LIZ@BH=-TNQT>R6STZUBM;922(HEPH)Y-6Z* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.
MJZ-INMVJVVIV4-W K!PDJ[@&Z9_4U:M[>&TMH[>WB6*&)0B(@P%4<  5)10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?/_P +/^3A?&O_ &_?^E:5] 5\_P#P
ML_Y.%\:_]OW_ *5I0!] 4444 >?_ !M_Y)#KO_;O_P"E$==!X$_Y)YX:_P"P
M5:_^BEKG_C;_ ,DAUW_MW_\ 2B.N@\"?\D\\-?\ 8*M?_12T =!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S_\ "S_DX7QK
M_P!OW_I6E?0%?/\ \+/^3A?&O_;]_P"E:4 ?0%%%% 'G_P ;?^20Z[_V[_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0,  8 %+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9^MZWIWAW2)]5U6X
M^SV4&WS)=C/MW,%'"@D\D#I0!H45Q%C\7? NIZA;6%IKGF7-S*L,*?9)QN=B
M HR4P,DCK7;T %%%% !1110 4444 8'B'_D-^%/^PJ__ *17-;]8'B'_ )#?
MA3_L*O\ ^D5S6_0 4444 %%%% !1110 5@>!?^2?>&O^P5:_^BEK?K \"_\
M)/O#7_8*M?\ T4M &_1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR$X[9S^?K7!7GB#0;[PG<^$_#<,TUU=:OYNGQQQMB--RD'+<] 1WI1U=O/\
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M@ HID4T4\?F0R)(F2-R,",@X(R/0@BGT %%%% !14<-Q!<JS031RJKE&*,&
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M1110!P45Y\0Y==N]+%UX7#VUM#<%_L=Q@B1I5 _UO;RC^8KO:P+/_DH.L_\
M8*L/_1MW6GJ.IVFDVIN+R81IG '4L?0#O0!R'C+Q/;%_[*2&1I+>\M9WDR,?
MNIHY2H^NS'MFM"WAE\8B&]NG$>DJQ*6BGYI&!QES]>U<]J7A35]8OI=3M[=8
MXKE]ZQRN Z@]-P[?2NW\.:6^CZ'!:2L#*,LY4Y&2<\4 ::(L:*B*%11A548
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS:0W"@@2HK@'MD9J6F]R5J@HHHI#"BBB@ HHHH **** *<O_ "&K7_KWF_\
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M%% !1110 44R66."%YI6"1QJ69CT ')-<G_PM+P/_P!#+8_]]'_"@#KZ***
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MO[2!;Q6$]TJH&.QP %R3SDGGTJ)325SKP^"J5:JIR7+?O_D['I&A?\B]IO\
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M''SKHF='2$A022 !U)KG/^$?UFX_X_?$MR0?X;:)8L?B*4>"M+?'VN6]O/\
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MD:::/S(Q@@2*,9*$\,!D=":.EP>G]?UW-"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KY_\ A9_R<+XU_P"W[_TK2OH"OG_X6?\ )POC7_M^_P#2M* /
MH"BBB@#S_P"-O_)(==_[=_\ THCKH/ G_)//#7_8*M?_ $4M<_\ &W_DD.N_
M]N__ *41UT'@3_DGGAK_ +!5K_Z*6@#H**** ,R+3]$T:>6[2VLK.:YD+23$
M*C2.QR<L>2>M:=<)\5]&O=:\+P1:;IDM]?172R0F*0(82 ?GYX([8]ZP[;Q1
M\5TM8TD\'VLKJN#(SA2Q]2-_%"8VCU>BH;1YY+*![F,1SM&ID0=%;'(_.IJ;
M5G8E.ZN%%%%(84444 %%%% !1110!3E_Y#5K_P!>\W_H4=7*IR_\AJU_Z]YO
M_0HZN4 %%%% !1110 4444 %8'@[_D"7/_85U'_TMFJUXBU<Z)HTMVJ!Y,A(
MP>FX^M<#X>\4ZG;YTRVA@D>ZGD>-GR-DDLC.Q/J-SL<?_JH ]-N;JWLXC+<S
M1Q(/XG8"N?DU75M;<P:/:O:VIX:]N5VG'^PO]?Y58T_PQ!#<B^U&9]0O^OFR
M_=7_ '5Z#_/2MZ@#C;SX>6=QM:&^GCE_Y:/(/,WGN>W-=-IFFP:3I\5G; A$
M')/5CW)JY10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MD>(]1UG3-/CFT/0O[9N6E"-;_:TM]J8)+[G&#@@#'O[5C^#O%/B'Q+Y5SJ'A
M/^RM,N+47-O=_P!HQS^9NVE5V !AE6)R>F,=ZZ^L#P+_ ,D^\-?]@JU_]%+0
M!OUY3<_"+P+'XQTVP70\6TVGW<TB?:Y^722W"G._/ D?\_85ZM6!>?\ )0=&
M_P"P5?\ _HVTH WZS]9_X\8_^OJV_P#1R5H5GZS_ ,>,?_7U;?\ HY* -"BF
MR2QPQM)*ZHBC)9C@#\:YR_\ &NGPL8-+BFU>[/"QV2[U!_VG'R@>OI2;2W-*
M=*=1VBK_ -?<=+7C$WQ7\WQ#9ZK_ &+C[-:SVWE?:OO>:\+;L[.,>3C&.=W;
M'/83Z#XK\0V\AU?5(K&%E.RPLR0&/822=2.Q S[8KS__ (5#XO\ ^>FA_P#@
M9+_\9K.;F_A/2PE/ PNL3)-^5_S6Y[I%-%,NZ*1)%]48$4^N6NOA[X=GE\Z"
MTDL9P/EELY6C*_0 X_2H?^$<\46!!TWQ6\T8'$6H0"3/U?K5W:W1Q>RHR^&=
MO5?JKG7UGZ%_R+VF_P#7K%_Z *\K^(&N>+K'^SH[UAI[8DQ-IUTRI/\ =SD9
MR,>_]ZF_#SQ)XACBOXK>PO-;"B)41[O:L &_@;LXSZ#^[4>U7-RV.O\ LJI[
M#VZDOO\ .V^Q[-17(_VAXZN%S%H>EVA/3[1=&3'UV4"R\=W*'S=6TBS)'_+O
M;M)M_P"^JOF\CD^K6^*<5\[_ ))G75QGQ$\0Z59>&=9T:XNMFH7FF3K!#Y;'
M>71U7D# RPQR:E7POXAFYO/&5XQ/:WMDB_E7 ^)OA_XFNM<E^R6][?VT2JD=
MW>7T;O+P&) )!4 L5P<_=)SS4RE)+1'1A<-AIU.6K55O*Z_%Z'I]IXS\.7MF
M]U%J]LL*L4)F;RCG / ?!/452N?&\3R^5H^D:EJKG@20P%(L^[L/UQ5'X<>%
MI]"TB?\ M73H8;\W+,CG8[^7M7'S*3@9#<9KN*:YFM=#*LL/2JRC!<R7GI^!
MQ_D^-]9^:2YL]"@;HD:BXF'U)^7\JEMOA_I'G"YU1[G5[K_GK>RE@/8+TQ[<
MUU=%/D774AXJHM(>ZO+3\=_Q/+W^&VB7WC35K,RW<,"6MO=HL+(H5I9)PR@;
M>% B7 [<\GMZ186<>G:=:V,+,T5M$D*%SEB%  SCOQ619_\ )0=9_P"P58?^
MC;NM^A12V1-7$UJR4:DFT@HHHJC P/ O_)/O#7_8*M?_ $4M;]8'@7_DGWAK
M_L%6O_HI:WZ "N6\;Z;87&FVUS/96TL_]H:?#YKQ*S;&NX@RY(SM(9@1T()]
M:ZFL#QC_ ,@2V_["NG?^EL- XR<7>+L:]G86>G0F&QM(+6(MN*01A%)Z9P!U
MX'Y58HHH!MMW84444""L"\_Y*#HW_8*O_P#T;:5OU@7G_)0=&_[!5_\ ^C;2
M@#?HHHH **** "BBB@ HHIDLL<$32RR+'&HRS,< ?C0!2T+_ )%[3?\ KUB_
M] %:%9?ARY@N/#]B()DE\N!(WV'.&"@$'\JTV95&68#ZFFTT[,$[ZBT57>_L
MXSA[N!2/[T@%5Y-=TB+[^J68/IYZY_G349/9"YEW-"BL=_%.CITNS)_URB=\
M_D#4#^+;4?ZG3]4N!V,5HW/YXJE2F^@N>/<WZR/%'ARS\6^'+O0[^2>.VN=F
M]X& <;75Q@D$=5':J7_"2ZC,/]%\-:@W_7;$7\ZKWM]XNNK*46VD16C%3AC<
M*[@>W;--49=;+YHGVBZ?D<=X>^!_AC3_ !#]O@O]6:72[Z*2$--$58HL<@W8
MCY^8D<8XKUVO'_#5KK[ZQ)%I\DUM(WRW$KKP@_V@1U].]=Y_PA\=SSJ>J7]Z
M3U5I=J'_ ("/\:TJT(TW9R)A5E-743=FOK2W_P!==01_[\@'\ZSYO$^CPG"W
MBSMZ6ZF7_P!!!%+:>&=%L0/(TV#(Z-(N\_FV36JJJBA54*HZ # K+W%W?X&G
MO'.OXGNYR5T[0-0G/]Z9?)4_B:3/BZ]Z+8:<GHQ,KC\N*Z2BG[1+:*_,7(WN
MSFO^$8O;K_D)^(+V8==D $*_B!G-6;7PAH5JQ86"2N>K3DR9_ \5N44G6GM?
M]/R#V<>QR'BO1-/N;S0+40+#]JO6MR\2A2$$,LI'_D+'MFNJMK:&SMH[>WC6
M.&,855Z 5B^(?^0WX4_["K_^D5S6_4N<FE%O1#44G=(****DH**CEN(;==TT
MT<8]78#^=9TVO0YV6<$]Y(>!Y2';^+'C%9SK4X?$_P#/[M_P-(4IS^%&K3)9
MHH5W2R)&OJ[ "LCRM<O^)I8K"$]5B^:3\^@_"IK;0+"WD$KHUQ-_STG;<?\
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M]-KVI7MS9H6BMWCA"Q%H\,KB.)2O'&&(Y'K4FDW-U8^)8=-L9S>Z/<)-,P:
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M\9\K>-V/7'6L71?$KZUI\5W'8B,-?2VCJTX^4(6&\9 W9VCY1SS[4XO9=O\
MAA/J^_\ PYPWBVRNI[CX@".VE<S6UBL85"=Y!Y ]:["2YAU'6/#:V:ONMVDE
MF7RRIA3R67:XQ\I+,O!P>/:KNE^)8;_4M6LYDCMOL%V+56>8?OB4#9 (&#ST
MYK<I+X5\OU_S*;N_Z\O\@HHHH$%%%% !1110 4444 %%%% !1110 4444 %?
M/_PL_P"3A?&O_;]_Z5I7T!7S_P#"S_DX7QK_ -OW_I6E 'T!1110!Y_\;?\
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M"]1U(X.:ZNL#P]_R&_%?_853_P!(K:@#9N[J*QLY[N<LL,$;22%4+$*HR<
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M!X8%XOA721J 87@M(A,'^\&VC.?>M:BDM%;T_#_AQO5_?^-O\@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^?\ X6?\G"^-?^W[_P!*TKZ KY_^%G_)
MPOC7_M^_]*TH ^@**** //\ XV_\DAUW_MW_ /2B.N@\"?\ )//#7_8*M?\
MT4M<_P#&W_DD.N_]N_\ Z41UT'@3_DGGAK_L%6O_ **6@#H**** /.?C,E@O
MA&VN[R95EM;Q);>%TW+<. <HP]",\^U<[!\5?#;6\9/@:;)4$^7:QE>G8XY%
M=?\ %72;[5_"\,6F:6]]?1W220F-PIA(!._G@CMCWK#@\4_%80(K>#+1V"@%
MC(%R?7&_BE'KZ_H-]/ZZGIUE,MS8V\Z1F-)(E=488*@C.,>U3U#://)90/<Q
MB.=HU,B#HK8Y'YU-5/=DQV04444AA1110 4444 %%%% %.7_ )#5K_U[S?\
MH4=7*IR_\AJU_P"O>;_T*.KE !115>_^V?V=<_V?Y'VWRF^S_:,^7YF#MWXY
MVYQG'.* +%17-S#9VLES.X2*-2S,>PKR:?QI\0K>[:W-SX)<JC,SHMV5!&/E
MSW)R<8XX/(XSV]A:7NOWB:GJB-#9)\UM9$\-Z.X[_P"?Q &VB7?BB[2]NE:'
M1T.8;9AS/CHSCT]O_P!==0JA5"J  !@ =J7I10 45GZWK>G>'=(GU75;C[/9
M0;?,EV,^W<P4<*"3R0.E8&B?%#P=XBU>#2M*UC[1>S[O+B^S3)NVJ6/+( .
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M>/K**QV:/+YUS)D>88V41CU^8#)]/U]^TV+_ '1^54=6T6RUFR:VNHAR/DD
M^9#Z@U,)45)-I_?_ , J2J-:,X[PKXLFCT:#2X-)FNI;2-8HUMP HC4 +GTQ
MTK=\[Q9?8V6MEIJ=S*_FO^&./SK4T;1K71+%;6U7W>0_><^IK0HJ5(<S<(A"
M$N5*3.<7PU?7!W:GX@OIO]BWQ"OXXZU@>+/"%E:PV=U:%XQ)=0VT[.Y<DRR+
M&K<GLSC/M7H58'C'_D"6W_85T[_TMAI1KU(NZ8W2@U9HMV'A[2M/M8X(K*%]
MHYDDC#,Q]2<5=2RM8_N6T*_2,"IZ*S<I/5LM12V0U45?NJ!]!3J**D85SUY'
M&?B!I ,:'.G7DA)49W+);!3GV#N/^!&NAKYRF^)_CI_$-G>M!X.^TQ6L\487
M4X#'L=X2VYOM. V43 R,C=P<'#3:V"Q]&T5GZ%=W&H>'M-O;L0"YN+6*686[
MAXP[("VQ@2"N2<$$Y'<UH4@"BBB@ HHHH *Y#QSXOU?PK]@_LKPG?:_]I\SS
M/LI?]SMVXSM1NNX^GW3UKKZ"0!DG H X[P'XRU3Q?'>R:CX6O-#2$1-"UPS$
M7 ?=DJ61>FT=,_>%=C6?H1']@:>,C*V\:GV(4 C\Q6A0U;<2::N@HH) &2<"
MJ\E_9Q</=0J?0N,TTF]@<E'=EBBLU]>TU#C[1N/HJD_TJK+XILHVVB.9CTY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/\
M\+/^3A?&O_;]_P"E:5] 5\__  L_Y.%\:_\ ;]_Z5I0!] 4444 >?_&W_DD.
MN_\ ;O\ ^E$==!X$_P"2>>&O^P5:_P#HI:Y_XV_\DAUW_MW_ /2B.N@\"?\
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M9M$N?&=WIQ!?-K#>)%L^=L8[C/7\:ATZR5W!V.R5'"I:5TWI?1O?SZGJU%<
M-%T)&!E\<ZM+ZJ=6&#^0_K3IM)\&O T=UKES<QN"'234G<..X(!YHY*G\O\
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MDJK4)<R3[O\ X:Y0\.>+-%N-,W7VMRZ?,#\T"LP'?D<$<X/Z9[5M+XE\&_\
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M?%#=XINH;/39;BVN D=M"=L;F4=<_4G'KP*Z+[3X\U+F&QTO28CVN)#-(/\
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M2!(V<MC'WCDY/7DU<HH AM[.ULPPMK:& .<L(D"[CZG%3444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MS_\ "S_DX7QK_P!OW_I6E?0%?/\ \+/^3A?&O_;]_P"E:4 ?0%%%% 'G_P ;
M?^20Z[_V[_\ I1'70>!/^2>>&O\ L%6O_HI:Y_XV_P#)(==_[=__ $HCKH/
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M6[*>H,8(_E6&/ ^CC5_MOD Q;?\ CV/W-WK]/;I72T41J3CLP<(O=" !0
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M_P!B^*9]"\C?YOE6XE\[=MQGYAC&#_WU5?P#HVN:;I[W>M>)I]:^VQ0R1++
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MP4XZX)K).'7\O^";*4^L5]__  #S+P5XO\0317>GV9TQY3+)=;KUS& 7;<^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7&:QJ7AWQAHXB@\6W>FK"_VAI-.N_LTY"J0001DKSG&.H%8/PVTN*^D.M_\
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M15"@!0 !V I:**ZCG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX?2*U9MJZK9$R6^3W/\ %'V&?T K">$C-\T'K]S_ ,_S]"U4J4U:+T[/5?\
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MBBB@ HHHH **** "BBL_4]/N;[ROL^LWVF[,[OLJ0-YF<=?-C?ICMCJ<YXP
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MXJUJQBU+3EAN;>:^TRZ^T26ZR@O'NA=!O4<C*RL1G'8UU%G>VVH6J7-G/'/
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M4E[UO/\ R_S-K0]<N]:MM/O!I?E65W8I=&?[0&V2-C]UMP">#G=TI_AC7/\
MA)- @U3[-]G\UY%\O?OQM=DZX'7;GIWKA/!?_(Q^&/\ L5%_]#6L>RMK:V^&
MVFZGIR*OB(:GY-M*G^M+&X/[OU*%"25Z<YQWK2VMOZ^)H7V;_P!;7/:Z*K7B
M7LEJ5L9[>"XR,// 94'K\H=3^M<WX,BU91J#75[92V_V^Y#)%9O&Y?S#DAC*
MP ]L?C47UL+I<WM4UBST>*)[IVWS2"*&*-"[RN?X54<G^@Y-,T_59KR8Q3Z1
MJ%@VW<IN!&RL..\;L >>AP?RKG]?8:?\0M!U2].W3S;S6JRM]R&=BI4D]MP!
M4'\.]7+C4]0@\9#2H+CSHIM-FND215RL@=54 @#CD]<TUM?U_ 'O;T_$Z:J>
MK7XTK1[W4#&9!:P/-L!QNVJ3C/;I7F_@_2[[4].TS79];L;:_P#M9^U.;1A<
MR.&(:!W,V"#T"[,#C %/U:&"^T[QU<:T%^WVLCP6DF2KQQ&(&)4(YPQ)R!]X
MD@YI3T7]>7^94$G)>J_/_@'HNDW_ /:FCV6H>7Y7VF!)O+W;MNY0<9XSUJ/5
M=8M](:Q6X25C>W26D?E@'#L"03DCC@^M<?;+;W^@:#IK:+8:G*NDQ7##49]D
M,:;0,CY'^;/?;P.]<_!%%K'@SPHVHPP7B1Z^;?=+B91%OD4+N8?,O"CGK@5I
M*/OM+O\ JT9Q?N)^7Z7/8*R-<UP:+-I2&W,WV^^2SR'V^7N5CNZ'/W>G'6L:
MXTNRN_%\6DWVGV<FC0:;YEG:O"IB$@?#D+C&0-@'' 8^IKD89;B2/2D,KRZ?
M%XN\O3W=BV80K\!CR5!W ?2IA:37]=;%2T3?];7/4[6XO);R\BN+'R((G403
M>:&\\%02=HY7!R,'KC-274MQ%Y/V>V\_?*JR?O OEH>K<]<>E>?1::=7\1^-
MK);F*!Y+NS*B9=\<A$8;8ZY&Y3C!&>E+'=1R65K8KI]M926'B"""1+-B;=FP
M#F,8&T<\KV.:(J]OD*3M<Z[2]>_M+7=:TS[-Y?\ 9DD2>9OSYF]-V<8XQTZF
MMFO*Y[;1[GQ)X^.JLN84BFB#2%=FV$?O%YX8';AAR,^_/<^#YK^X\'Z3-JA8
MWKVJ-*7&&)QU/OC&:2U5_)?C?_(;T?W_ *?YFW1110 4444 %%%% !1110 4
M444 %%%% !1110 5\_\ PL_Y.%\:_P#;]_Z5I7T!7S_\+/\ DX7QK_V_?^E:
M4 ?0%%%% 'G_ ,;?^20Z[_V[_P#I1'70>!/^2>>&O^P5:_\ HI:Y_P"-O_)(
M==_[=_\ THCKH/ G_)//#7_8*M?_ $4M '04444 %%%% !1110 4444 %%%%
M !1110 4444 4Y?^0U:_]>\W_H4=7*IR_P#(:M?^O>;_ -"CJY0 4444 %%%
M% !3)88KB%X9HTDB<%71U!5@>H(/44^B@#A=4\$Z?X?T_4]9\-276DWT5O),
M([:7]S(ZJ2 T; J1D= ![5XWH?Q5\16>O_:Y'M)%N9 )P]MQM)Y(VX/OQ^M?
M3K*KJ58 J1@@]"*YO2OA_P"%M%U5M2T_2(8KLYVN69@F>NT$D+^%;0G"S]HK
MOH8SI-M..EB2S3PQXIMOM=@UI=(>3);MM8'WQ@@_6KHTF:!"MIJ=TGHLI$J_
MJ,_K6)J?PYT6[OQJ6G&?1M2!R+K3F\LL<Y^9?NL">O'-,O;_ ,:Z @D>QL_$
M%H@_>/:YM[G'<["2K'V4C/H*Q=*#=X_Y#Y$M6ON,;Q$MW:ZN(;JT)_<B3[3;
M6K+ ?F(PSXVA_;.<8J?1+A+/S9+ZYU"WMY IB6*,JH/.6+9.[(*C&.-O4YXY
MKQE\:;!K>73=+THW:S6V3-<2-$UO-EAM:/;SM(4G##.<9[UWG@+Q#J7B+1Q<
MW?AY=*L1%']CD%\EQYZ\@\* 5Q@<$9Y]C7 \JC"M[:UK_P!>1T?7<1*/L8S7
M*O*[^\O0W]I,!]G\1'GH)A'G]5!JUY.L ;HM0M90>A>'&?R-6)](TZY),UE
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M2/7O[9K&M0E6M[B=GZ_H34Q&(I)<CY;OHSWO[5;_ //Q%_WV*/M5O_S\1?\
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M-<6>GVMO/.<RR0PJC2?[Q R?QJ:*ZMYYIH8IXI)8"%E1'!:,D9 8=N.>:FH
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MJU_]%+7/_&W_ ))#KO\ V[_^E$==!X$_Y)YX:_[!5K_Z*6@#H**** "BBB@
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MCG_L'BS_ *&#2O\ P4O_ /'Z/L'BS_H8-*_\%+__ !^N@HJ.8OE.?^P>+/\
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M!@"DOAMZ?\$;W^;_ $.:T[QI'?>*[S2S;7BVZ1P&%CIERK[G+;M^4^5>!@D
M=>3CC0\4SRII]M:Q-)&+Z[BM9)8FVLB.?F((Y!(&,CIFKL&DP6^M7FJH\AGN
MXHXI%)&T!-V,#&<_,<\T_5-.CU73WM)))(MQ5TEC(#QNK!E9<@C((!Y%#V0=
M6<W+!H.@:]91KX7>WDN+A8(=2A2$!Y""V&8/YIZ'.Y>2.]46\>W=Q_;36-C/
M*UA<26\%O'IMQ.;AD SF5!L3)R.<XX)KI+K0I]0N-/DOK_S$L;@7$8BA",[@
M$#<<D$8)Z 4RT\.'3+[49]-OGMX]0F,\T1B5PDA !9#V)QDYW#/:A>?];?\
M!&[6T_K?_@%9?$%]?>+6T2TBAMQ#8I=SR3HSMN<X" !EQC!R>?I67\/9S;>
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M_)POC7_M^_\ 2M*^@*^?_A9_R<+XU_[?O_2M*0SZ HHHH \_^-O_ "2'7?\
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M@"G]MN/^@7=_]]1?_%T?;;C_ *!=W_WU%_\ %U<HH I_;;C_ *!=W_WU%_\
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M;<?] N[_ .^HO_BZN44 4_MMQ_T"[O\ [ZB_^+H^VW'_ $"[O_OJ+_XNKE%
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MM_.EMI-V/)D+XQU^1EQ_X]G\*FH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 5#<M<J@-K##*^>1+*4 'U"M4U5=3O&T_3+F[2VFN7BC++# A=Y#V
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M 4444 >?_&W_ ))#KO\ V[_^E$==!X$_Y)YX:_[!5K_Z*6N?^-O_ "2'7?\
MMW_]*(ZZ#P)_R3SPU_V"K7_T4M '04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '*WN@Z<-8TZQ, :&XCNGES]YV.P[B?7/3TKJ(T$421@DA5"Y/
M4XJO-8QS:A:WC,P>W5U51T._&<_]\U:K2<W))7(C&S9#=VL5[;/;SKNB?&Y?
M49SBL#2=.M;C4]2D:("2VO\ ="R\%?W:C ]B.,5TM5+.PCLYKN5&9C<R^:P;
ML< 8'Y4HSM%H;C=IENBD8;E(/0C%8]MX:LK72X]/22X,*3B<%G&[<"#UQTXI
M)+JQN_0V:*S1HEL-6N=2WS>=<0^2XW?*%XZ#'7BH!X9LAIEC8>9<>59S":,[
MQN+ D\\=.>V*=H]_P%>78V:*RET"T6?4YA)/NU%-DOS#"C!'R\<=>^:'T"TD
METR0R3YTX8A ?KP!\W'/3VHM'O\ A_74+R[&K16*OABR33;ZP$MQY5Y(9)#O
M&X$D'CCVJP=#M6U2TU O-YMK%Y4:[OE(P1SQR>:+1[_A_74+R[?U_P ,:5%8
MDGA>QDT:32S+<>1),9BP<;MQ.?3&/PJU'HMM%K$^IJ\QGFB$3*6^4 8Z#'7B
MBT>_X!>78T:*Q3X8LFLK"T,MQY=C+YL9WC).<\\>_;%3?V#:[M3;S)LZB,3?
M,/EXQ\O''7WHM#O^ 7EV-2BL@>'+,-I9\RX_XEHQ#\X^;I][CGIVQ2R^'K26
MSU"V:2<)?RF64AQD'C[O' X]Z+0[_AY_Y:_@%Y=C6JK>Z=;:@T'VE/,6"3S%
M0]"V"!D=^M5(- M(-1M;U'G,EM;BV0%_E*CN>.3S6K2=D_=8*[7O(YGP=80+
MIL=^JD3OYL3D'A@)6(S[C^M=-5/3-/CTNQ2TB=W169@7QGYF)_K5RG4ES2;"
M"Y8I&!XJLX&T74+QHP9UM3&K'^$9R<?6M*PL+>S\R6W38;C:\BCH6QUQZFI-
M0LDU'3Y[.5F5)EVL5Z@585=B*HZ 8HY_<Y0Y?>N+7'>)[N"+78XKS5[ZPA-I
MN3[*[#<^X]0 >W_ZZ[&J?V#_ (G/]H>9_P N_D>7M_VMV<TZ4E&5V*:;5D<K
M;?VKJ=MHEMJ%Y>VLDQFW/"_E2.J@%2?_ -50ZEJ6J>'Q?:<M_)<Y2,V\TN"\
M89B#D]SQ73ZOI5UJ$]I/9ZA]BGMR^'\D29W  \$XJC_PB,,]I>+?7LUS=787
M?<$!2NWIM X SVK=58.SEMVMYF7LY*Z6_?Y%=+2]TZ^N+!=6OYDEL_/$C_O9
M$96 ;8/<'@53T:>Z.NWUA%J6HB(VI9!?J3,K\?,H(Z=:V+?P]>(9YKG6IYKQ
MXUBCG2)4\M0<XQR#D]?6FV_ANY^V2WM]K$UQ=M"88Y4B6+RP><@#/-+GC9W?
M3M_P/\A\KTLOZ^\RM*FN5\2&SBU'5 DUJS8U%3NW]F12 ,#TJ6S-U;>*Y+:S
MU.\U!([=FN5G?<J2?P@=ASV%:$?AV^:[-W>:U)<7"0O%;N(%3RBPQNP#R?RI
MNA^&[[19 HUD2VQ+-)%]D52Y(ZE\D]>?PIRG!IZ]/ZZ?Y:@HR5M.O]=3"T?5
MY6U"RDDU.]FU&6=H[JRD#") 0V,#& 1@=_6F:?J\[W]K+/JEZ-3:\$<]BRL(
MDC+;<8Q@=1SFNIM-&ODOHI[_ %B2]2 DPQ&%4"D@C)(^\<$TV+0[YKV*6^UF
M6ZMX9/,B@\E4Y'3<1][%-U:=W_7RV_KN3R3M_7^?]=BE>M?6WC/24?4)GAN#
M,?)7Y$"A>!@?>/N?TK2\28?2?LQ) N9HH#]&< _IFJEWX>U"ZUR#43K6!;NS
M0Q?95^13U7.>>.,D5H:[#+-IA,$9DFBECF1!U8JX./R!K*ZO"S_JYHT_>T_J
MQR7B*^:#Q)<P'5+ZUV6JFUBMV;:\O92H!&#^%:MWXIFT72K ZC;JU[+$&D5I
M AS] "<_@![UKPZ5LU^;5O.SYT"Q>44QC!SG.?TQ575O#TFH:DM];:@]I*83
M!)B(/N0]0,]#[U:G3?+&73^OZW)Y))N2_K8R]0NTO]?T*[C#!)K.=U#=0"G>
MC1-;FTS0=(6XL&%G+MA%P)02&)./E]/Q_"M)/#6R32W^UY^PV[P8\O[^Y<9Z
M\?3FJUMX0EB^PPSZM-/96C+(MN8@,N.^[.<9[<U7/2<>6^GS\_\ @$\L^;F_
MK9$J^*)9;7^T8M,=M,W[3.9@'QNV[@F.F?>K,&N3WM[-'8Z<TUO!,899FE"$
M,.NU3UQ]15)/",L0^RQZM,NE>;YAL_*!/7.-_7&:G'AN>#4IY[+5IK:UN)/-
MFMUC!W-WPQY7-0_8]/U_'S_ O]Y_5OP_ K66O"VM!&D5S<W5Q>RQ0QRSALE3
MS\Q VK[8./>B\>67QCH#S0^3*89MT>X-M.WU'6II/"8:S5$OGBN8KI[F&=8_
MN%CG!&>15E-"D_M'3;V:_>:2S216+IS*7[\'@#/3%'-33NO/\A<LVK/^M3GU
MN97U;PW/#%-<2&"<JLLP+'KU<@?RJ[KMZ=1\,3WHA\B\TZY!*EMVQU89P>XP
M:LOX5DQIS0ZF\,UC&Z)(D0Y+'K@G&/;O46J:+=0^&7TVW9[JYO+@&>?;MR6;
M+,1V' &*OG@Y1L]G^K_07+)7OM;]/\R]K^LR:=X9?4+=1YKJFS(X4MCD_3-8
MVH1ZCX;@LM3_ +7N[HO*B7,,S[D;=UV#^&NGO=+M[_2GTZ8'R&0)QP1CH1^5
M<Y>^%]6,=LXU1=0%G(KPVUQ&$4@=BP/)Z<FHI2@M'IK]Z'.,VOE^(Z'3;O5;
MO5ITUG4+:6&Z:.%$F_=   C*_C6IX>O)]8\.1R73D3,'B>2,[22"1N!'0_2J
M2^'M4E:XD76'LHKQO-FMD@5F5B!D"3/MC(K9M=,33](%A8N80B%4=AN()_B(
MXSR<TJDHN-K]OEW_ *U'33O>W?\ X!RFE75_>:S!HDNH2$:?(\DTRRG=< 'Y
M5SU(&>:L7O\ :-OXPLX;+4[JYED8R7,#']U'%GCCH.,CU_.KL/A-+9=-DM[P
MI=6;LSSF/)F#'+ C/?/J:(?#VJV^H7%U!KVP7$OF2*;-&)'9=Q.< <5ISPYK
MIK;MU^[Y_@2XRM:W]?>,O)+N'QYIT1O9C;SQR'R <(,*>W<YYR:VM3L/[1MA
M$;R[M0K;M]M+L8\="<=*RM1\.ZA>ZVFIPZU]G:(%84^RJ_E@C!&2><\]1WK7
MU&TEO=-GM8KCR'E39YNW=C/7C([5C)JT;/4TBG>5UH<.FH7EMIE[+9:A>2PW
M-Y':6TUU(9&4<[F'UK9^U3>&6U))+BZU".*WCN$^TRY8$L5(W8Z< UH3>&K:
M7PY#I D9%A"E)5&"''.['US^=0-X:N)]/OX;S5&N+J[18S<&$+L53D *#[GO
M6KJ4W]_W[6_7[R%"2M_5M_\ @#TU^]EG$$>CL99(1/"&N% *=#N/8].!GK59
MO&$9TVUNHK5 TWF92>X6)5*8! 8@Y/(P.]:T&E^3?P77G9\JT^S;=O7D'=G/
MMTKE=0\.WEA!96L DN8X_-8RI9QS<LP.-CM@=/O=:452D[?UU_X -U$K_P!=
M/UN:5[KL][X229;;R+G46^SV\8?=G=QG.!CC)JO-<0>&-5LX-AD8:>((D!QY
MDA<=2>!DYY-6]-MM4O)M*;5K<(]JLDA(  +<*F0. <%CQ5W5O#T.KS2O/)A7
MMO) "\JV[<&!SVQTH<H1?*]M=ON0)2DK]2IJ_BI]'\N.:R0W)A\YT:X"J!G&
MU6(^9O8"MRQGDNK&&XEA\EY$#&/=NVY]\"N*U?2=:CU*!XUDN7AM5C2Y%M'+
MYC@DC*NWR=OF'-=IIS7;Z=;M?(J710>:J] U34C!03CN.$I.=F6:***YS8**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KS31?B)XE\1O?/I'A."Y@LYS"Y;4 C$
MCTROI7I9Z5Y3\$R%LO$C,0 -18DGMQ26LGZ?JAO2-_/]&=?X3\<:;XL-U!#%
M<6E]9G%S:W"X:,Y(ZC@C((K3A\2Z%<7WV&'6M.DN\X\A+I"^?3:#G->3^&Y[
M*_\ BEXTUB)]^@K92+<3Q9VD87.".N=KGBLKQ+;Z1_PC>FZEHO@JYTJ 7,#V
M^I22(&92W&0&+'/J:KI%][?B["MJUV_RN>]17UI-<R6T5U!)<1?ZR)) 63ZC
MJ*2._LYI9HHKN!Y(/]:BR F/_>';\:\J\4./ WQ<LO$K_N]+U6$P73]@X&.?
MR0_@:H>&?"FK:[\+_$%]$WE:KK\YF4L=N^,-G;GL&._\Q4K6/-_5[V_X([>]
M;^MOZ1Z]I^LZ7JWF?V=J-I>>6</]GF63;]<'BKU>:?#Z]T.#6VTI_#9T'Q'#
M:!98]ORS)QE@1P>0#S^!/->EU31*"BBBD,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOG_X6?\ )POC7_M^_P#2M*^@*^?_ (6?\G"^-?\ M^_]*TH ^@**** //_C;
M_P DAUW_ +=__2B.N@\"?\D\\-?]@JU_]%+7/_&W_DD.N_\ ;O\ ^E$==!X$
M_P"2>>&O^P5:_P#HI: .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** .!U#7O%$?BNS>'3F&GL)@ED6 EG1-NY_0'Y@5&>Q]:[Q&WHKX(W '##!'
MUK$U&WF?QAH<Z12-#'#="20*2J$B/&3VS@X^E;M5)[#84445(@K+U^ZOK;2W
M&F0F2\E/EQ-C*Q$@DNWH  3[G [UJ5'.";>0 9)4X ^E" Y/P+JNMW>FVT6K
MP-,LL F@OEY#K_=?T89_$?3GL*Q/"$$UMX1TN"XB>*5+=0\<BE64^A!Z5MU4
MMQO<****D0A.%)P3@=J\\L]<\6Q^*+R:XL_/LUCB>33XN9(8W+;2H[N,?,,\
MY]N/1*P;&WF3QMJ]PT,BPR6MNJ2%2%8@OD ]"1D?G51>XT;U%%%2(**** (;
MJ<VMI-.(I)C&A81Q+EGP.@'K7$^']:\3MKMZ=1LC+9272Q-%$P9[)F12N?5<
M, 2.A!/U[RL71()HM5UYY(G19;U6C9E(#CR8QD>HR"/PJD]&-&U1114B"BBB
M@#C?'>H:_;0Q1Z.1;1*T1ENF[LT@547\>6]L>N#T&AWE_>6!_M.R:TO(G,<J
MYRCD ?,A[J<_AR.U4_&%O-<Z$([>&25_M5NVV-2QP)5).!V YK>JF_='T"LO
M4M=M]-N$M1!=7=VZ>8MO:Q;WV9QN.< #/J16I7*ZJLUKXDN9I(+\V=]8+;_:
MK*-GD@=6;H%!(R'R#@\BDE=@C8L]9BN;::>YMKK3UA&7^W((P!SSNR5/3L>*
ML0ZE87%HUW#>VTELN=TR2J4&.N6!Q7E5]I&NW=M=0+)K5SIR:C"\4E]"\TGE
MA7RWE. 6 ./EQSQQ3[CPQ>0Z1?&U-Y?137%L]Q!'I9L@\:EMP6/C)Z9PH[=:
MTY%W'RH]$MO$-K>:TUC;/#- +3[3]JCF#*?G*D<<=NN:F/B#1A;7%P-5LWBM
MAF9DG5MG;G!]>*XF\T]8[S6+C0O#LH@ETL1"%[1X4ED\SD;3M.0O;C..]9NE
M>&[IM5N/,M&N(9]*E0YTC[(BRY!"8V@,0<$,?3VJ>56;_KJ5RK3^NW^9Z/9^
M(='O]/:_MM2MFM4 +R&0*(\]-V<%?QQ4&J>)+6RT=-2LVAOXFGCA!AF!7+,%
MSN&>F>E<AIVFP)X6T2*?0[C;!=*=3@^P.&DPCA6(VYD )4\9JI=:+<-=:O/I
M6DW5OILUS:&*'[.T>YE<;F$9&5 Y["K4(\UOZZ?F9]+_ -=3T&/7K)K_ %"T
MD;R?L 5II970( PR/XLC\0*=+K=DJ64D4JW,5Y,((Y()$9=Q!/7//3MD^U<1
MJFB37NN>*1<0W<5O.UHT,Z6;3*Q49^Z!\XR,$#-/TZTU"2UTI7T46ODZT')M
M[9HD= A'FF,\H.G7%3RJR?H4TK_UV.FT3Q5::LLHG,-G,MW):Q1/."TI3'*@
M@9Z]!FMF[NX+&TENKF01P1*7=SV KRZUT0C3-4C.AW2ZU-J9>TN6M&R%$BD,
M),80#!/)&?>N]\36&I:EI<<&F-9^:)TDD6[W>6ZJ<X.T9ZA:4HK3Y?D@:7-;
MU':!XCMO$*71M[>Z@:VD\N1+E K XST!-1WGBFSM[Z6QMK:\U&ZAQYT5G$'\
MK/3<20!],YK$\#VFO6VM:Z^J6]O%%-<%V9$==\GK'NZIC//7-+I N/#OB?Q
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MOTK.NM>D>72]>AL3(YT>XN!;"3G[T)(W8]/:AS2_KU_R+CA:C_KRNOP.VHK
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MJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\
MX_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/R
MF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA
M_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_
MPJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\
MC]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%
M9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#Q
MA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%%
M !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\
MIO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5
MG7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_P
MJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\
MX_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/R
MF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA
M_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_
MPJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\
MC]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%
M9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#Q
MA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%%
M !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\
MIO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5
MG7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_P
MJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\
MX_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/R
MF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA
M_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_
MPJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\
MC]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%
M9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#Q
MA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%%
M !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\
MIO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5
MG7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_P
MJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\
MX_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/R
MF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA
M_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_
MPJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\
MC]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%
M9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#Q
MA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%%
M !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\
MIO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5
MG7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_P
MJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\
MX_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/R
MF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA
M_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_
MPJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\
MC]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%
M9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#Q
MA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%%
M !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\
MIO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5
MG7/RF_\ C]%% !_PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C]%% !_P
MJ#QA_P!%9US\IO\ X_6I\/\ X33>"?%5YKUQXBDU6>[MWBD\RV*,S,ZN7+%V
0).5_'/6BB@#TRBBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_003.jpg
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  7H# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "N"USQIJ6GZ]K=C =/5+&WBEB%PRJ6W;=QR9!G )P,
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M(_&NRK@_BW;M-X,$J@GR+J-V]@<K_45I#XD1'<\R\.SQ'2+RV;2(=1G%S"\
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M8RC#/"C[V"!UIC(\P!N96E(VG'10R]"!VH7,]BE&VY\_C[5HVK _*MW9S9'
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MEA'.FTL!U*D9!Q[&K-.\2/$QT^ 8-V;E7B ZJH^^WTVY'XBJGDWG_/Y'_P"
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MW'H>G(^][?SY/[]PQD/_ (]6K2N9INPC:[IX;9#,UR_]VVC,A_3BC[=J4_\
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M[" )"LD31H N%7(]!5NBE<H@LX#:V-O;LP8Q1JA8=#@8J>BBD 4444 %%%%
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M^]5ZJ.F_ZN3_ 'JO5E+<A[A1112$%%%% !1110 4444 %%%% !1110 4444
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MYX_SQ7O7PZ@LX/!.FM9A1YJ;IF7JTF><_2M*U;D6B,J5%3O=['@7]CZG_P!
MV\_[\-_A4$]I<VI N+>6$GH)$*Y_.OH7^T=<40[C+ECNP8\[AZ<+]>#@^]1?
M$J"TG\$7\EV%+1 - S=0^1@ ^]<U/&N3LT==7 1I]3Q_X>P&X^(&BH!G;<;S
M]%!/]*^F*\&^#.G&Z\837I&4L[9CG_:?Y1^F:]YJ\0_?L3A5:%PHHHKG.D**
M** -'3?]7)_O5>JCIO\ JY/]ZKU92W(>X4444A!1110 4444 %%%% !1110
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90]PHHHI""BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_004.jpg
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $% IH# 2(  A$! Q$!_\0
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M[Z-QALX7 H ]!!R,BH+N\M;"V:YO+B*W@3[TDKA%'XFO/[W1?$T[ZM)!;WD
MFOXF$7VP2+);+D$(/,!5F8[B,J,8 Z5IW^B:K_8_AN3R9=3GTN<37%M<R())
MAL9<YR5+J6!&3VZYYH ZBSU6QU&6:.SNHYVA"%S&<@!AE2#T.1SQ5RN!;PKJ
M<_B'^VXK2.RF-S:R)&+C_5QJC+*A"_*<Y'U]:I:;X,UN20)J<426<MW#-/;Q
M7+!<+%*LF,<X+,AP3D@<T >EU'//%:V\EQ/(L<,2EW=C@*H&237DT.EZS#XA
MT^QO$NWN;>VA@BF3>P23RG'F;B,&-203SDL!Z5T6A^%]4M?"&M:?=;_M=Y;&
M)5DG5XR_E%2PP!C<>23R>IH>P'6Z9K6F:S&\FFWT%TL9 ?RG!*D\C([5;$T9
MF:$2(954,R!AN .<$CTX/Y5Y[/X:U^\5[R6QLHY6M;:R-KY^\O&C%F<M@+NY
M 4'(QG/I4-MX/URTA\TV=I=7\FCPVDDTMPQ_>)(=P/3=N0C!Z97G@TP/2Z*P
MO"&FWVD>'TL]0(,J32LH#[MJ,Y*C/L"!@<#M6[2 **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\1VM_+'!L>.Y=F41$9X&[YL^GRGGUXH V**** "BBB@ HHHH **** "BBB@
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MV;7#?/<B21F7Y,;@Q9E'+\Y RN>AY +Z>$(Q/;RR:A<2&*=9RNU%5F79MX
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M2D][,LC0F':LRKP1*,DC)W<Q<Y['WR =!-I!NK:)+B]G-Q#,9HKB,*K1DY&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC/8CLO\ EJO^Z?Z42=4_WJ4_ZU?]T_TH 3_EL?\ =%,$*'SE557?P2![4_\
MY;'_ '10OWW^O]*&K@8MMH/V;0+NPCN-YFR0[KC' ';Z5S'CCP-J7B'P%::)
M8SVHN(;D3,\S,JE</Z G/S"O0%_U)_&D;_CW'T%8T</3HSC.FK.*LO3<UJ5I
MU8N,WN[_ #/&?BU;O:7O@&VDP7AE$;%>F0T(-=GXG_Y'SP_]5_\ 0Z[2558I
MN4'#<9&:BFM+::[AFEMXGECSL=D!9?H>U;5OWD%'M_G<XJM!S5D^J?W'(?\
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M618UW;2% YQ[US7Q%('QF\#@D9WQ_P#HVM\&FJLO3]#YRFFIRO\ W?R.J/\
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M_CUO\,OR-?1O^2F:M_US/_LE6=)_Y"^O_1_YM5;1O^2F:M_US/\ [)5G2?\
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M\:LZ3*HU;7CA^2Z_</7<WZ>]>+7^.G_BE_Z2SERG^#6]?_;D.T3_ )$K4/\
MMI_Z"*XCXE?\D;A_Z_U_FU=GHLJKX*U'(?@N#A"?X17%?$EP?@\B@-E;],Y4
MXZMT/>C*OX^'_P #_,]#'_PJW^)?D;FN_P#(J>#O^N$7_H"4GC#_ )*]X6_W
M4_\ 0WINNR >%O""X;*VT3'Y3C[B=/7Z4>+V#?%SPJ0#RB'D$?QM7?/^)/U1
MP9-_OE7_  O_ -(9U$?_ "4"3_KE_P"RBL[PK_R.'B+_ 'V_]#-7895?Q^Q
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M0GEF+;Y6T[ONXZ_A6-/#U(U)R:WDG\K6/0QS]K"C&&O+:_WLR/#'_([^(?\
M>;_T,UQOPQ_Y))XK_P"NUS_Z)6O2=(\/RZ?X@U34'N(W2[)*H%(*Y;/)KE/"
M'@[5_#?PZ\0Z7>QQ27=TT\D26[[]VZ,*!T'.17=17+0E%[W_ ,S' PE"<.96
M]Y_^E(I>'O\ DB\O_7PW_HT5F_$__DF?A7_K\B_] :MS2M,O[#X1RVEW9S0W
M/GEO*9/FP9 0<5A_%$&/X:^%5<%6%Y$"&&"/D:IPB_VB/I_F7F33S"JUM;]3
M=^)7_(Y>$O\ KO\ ^U(ZZ6Z_Y'VU_P"N?]&KFOB5_P CEX2_Z[_^U(ZZ6Z_Y
M'VU_ZY_T:N#&_9_QQ/H(_P "G_@G^90\+_\ (]^(/]YO_0ZL^'?NZY]3_P"S
MU6\+_P#(]^(/]YO_ $.K/AW[FN?4_P#L]95?XE+UG^3/&RG_ '6KZ_\ MYRW
MC'_DB&H_]=4_]')5'6?^2 ^'_P#=@_DU7O&/_)$-2_ZZI_Z.2J.L_P#) ?#_
M /NP?R:O0PG_ "+8>GZ'=1_Y&R_Q?YC?C1_Q[>#/^NY_E'6SJW_)==)_Z]Q_
MZ#)6-\:/^/;P9_UW/\HZV=6_Y+KI/_7N/_09*ZJ_\*'K^IGEW\>M_AE^1KZ-
M_P E,U;_ *YG_P!DJSI/_(7U_P"C_P VJMHW_)3-6_ZYG_V2K.D_\A?7_H_\
MVKQ:_P =/_%+_P!)9RY1_!K>O_MR$T3_ )$K4/\ MI_Z"*XCXE?\D;A_Z_U_
MFU=OHG_(E:A_VT_]!%<1\2O^2-P_]?Z_S:C*OX^'_P #_,]#'_PJW^)?D;6N
M_P#(J>#O^N$7_H"4GC#_ )*]X6_W4_\ 0WI==_Y%3P=_UPB_] 2D\8?\E>\+
M?[J?^AO7?/\ B3]4<&3?[Y5_PO\ ](9TT?\ R4"3_KE_[**SO"O_ ".'B+_?
M;_T,UHQ_\E D_P"N7_LHK.\*_P#(X>(O]]O_ $,UQ87XI?XY$9G_ !L/Z+\F
M4)?^2:>*O^O6;_T6:X>/_DV>3_K[_P#;@5W$O_)-/%7_ %ZS?^BS7#Q?\FSR
M?]??_MP*]')O]RI^O^9>9_[U/T_R.VM/^26>%_\ KWB_] J'X@?\CQX/_P"N
MJ_\ HQ*FM/\ DEGA?_KWB_\ 0*A^('_(\>#_ /KJO_HQ*XW_ +Y6_P"W?U/6
MR_X*7I/_ -).GG_Y'^W_ .N7_LK4FE_\CCJO^XW\UI9_^1_M_P#KE_[*U)I?
M_(XZK_N-_-:XH_QE_P!?7_Z21+^$_P#KVOS,OP)_R -9_P!X_P#H%6;#_D0K
MW_?/\UJMX$_Y &L_[[?^@59L/^1"O?\ ?/\ -:=?>/\ @F>?DW^Y1_Q1_-DE
MW_R3Z#_@/_H1KE/B;_R&OAU_U_+_ .A0UU=W_P D^@_X#_Z$:Y3XF_\ (:^'
M7_7\O_H4-=N5_P"\+_KW'\F:X_\ @O\ QR_0[.X_Y'ZV_P"N7_LK4NE?\CIJ
M?^Z?YK27'_(_6W_7+_V5J72O^1UU/_=/\UKAC_&7_7U_^DG6_P"$_P#KVOS.
M<\"_\A3QS_U]-_.2M;3_ /D0[[_?/_LM9/@3_D*>.?\ KZ;^<E:VG_\ (AWW
M^^?_ &6M,7_$7^"9T5?CE_BI_DBEXA_Y)Q8_]=5_]FH\7?\ 'AX8_P" _P D
MH\0_\DXL?^NR_P#LU'B[_CP\,?\  ?Y)6M/^"O\ #']#Y#,_]XK_ "_]*+7B
MO_D=/#W^^O\ Z&*[BN'\6?\ (Z>'O]]?_0Q7<5WTOCGZ_H:X?^+5]5^04445
ML=84444 5[V>2WM7DBCWR8.WT!QU;OCUQS69I&KWE_=>7/;B-?*W'",.>.03
MP5.3CO\ +[\;3NJ(SNP55&22< "JUMJ5G>2>7;W"2/L#[1UVGO\ R_,>M $>
MF,S&\+)L;[0WRYSV6K?_ "V_X#573^7O<?\ /P?_ $%:M?\ +;_@-  /]:_T
M']:(^C?[Q_G0/]:_T']:(^C?[Q_G0 B?Z@_C0W_'N/H*$_U!_&AO^/<?04 +
M)U3_ 'J4_P"M7_=/]*23JG^]2G_6K_NG^E "?\MC_NBA?OO]?Z4?\MC_ +HH
M7[[_ %_I0 B_ZD_C2-_Q[CZ"E7_4G\:1O^/<?04 .D_@_P!X4-_K4^AHD_@_
MWA0W^M3Z&@ _Y;'_ '10OWW^H_E1_P MC_NBA?OO]1_*@ C_ (_]XTW_ )=?
M^ ?TIT?\?^\:;_RZ_P# /Z4 /D^Z/]X?SI&_UJ?C2R?='^\/YTC?ZU/QH /^
M6P_W30O^M?Z"C_EL/]TT+_K7^@H (^K_ .]2+_Q[GZ&ECZO_ +U(O_'N?H:
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M?='^\/YT 8^M>&--UO4M.O;U93-9/NAV2;0#D-R._*BKDFF6TFL1W[!_/1,
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MZ^__ &X%>CDW^Y4_7_,O,_\ >I^G^1VUI_R2SPO_ ->\7_H%0_$#_D>/!_\
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M?[Z_^ABNXKA_%G_(Z>'O]]?_ $,5W%=]+XY^OZ&N'_BU?5?D%%%%;'6%%%%
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M0O\ K7^@H_Y;#_=-"_ZU_H* "/J_^]2+_P >Y^AI8^K_ .]2+_Q[GZ&@ /\
MJD^J_P Z5_OI]?Z&D/\ JD^J_P Z5_OI]?Z&@ /^N'^Z?Z4+_K7^@H/^N'^Z
M?Z4+_K7^@H (^K_[U-_Y=F^AIT?5_P#>IO\ R[-]#0 Z7_5G\/YTK?>3Z_T-
M)+_JS^'\Z5OO)]?Z&@!&_P!:GT/]*!_KC_NC^M#?ZU/H?Z4#_7'_ '1_6@!5
M^\_U_H*2/[I_WC_.E7[S_7^@I(_NG_>/\Z $_P"7;_@']*&^XOU%'_+M_P
M_I0WW%^HH 5O]:GT- _UQ_W1_6AO]:GT- _UQ_W1_6@ 7_6O^%$?\?\ O&A?
M]:_X41_Q_P"\: &_\NO_  #^E.D^Z/\ >'\Z;_RZ_P# /Z4Z3[H_WA_.@ ;[
MZ?4_RH_Y;#_=-#??3ZG^5'_+8?[IH %_UK_A2I]Y_P#>_H*1?]:_X4J?>?\
MWOZ"@!@_X]C_ +IITO\ J_Q'\Z:/^/8_[IITO^K_ !'\Z !^J?[W]#0?]:OT
M/]*'ZI_O?T-!_P!:OT/]*  ?ZYO]T?UI5^\_^]_04@_US?[H_K2K]Y_][^@H
M 1/]6?J?YTWI;K]!3D_U9^I_G33_ ,>Z_04 .?JG^]_2J=UI.G76I6U]<64$
MMW#Q%,Z LF,G@]NIJX_5/][^E#?ZQ/Q_E0-2<=4[%4:=:C5C?",_:"F"VX_3
MITK/TKP\--UC4K\7)D-VQ/EE,;<G=USSUK:_Y;?\!_K2K]Y_K_05FJ4%JEY_
M,F:]HXRGJX['!:E87.G_  W\4+=1^66M)B/F!X\L^E>>Q$']F:3!S_I?_MP*
M][,4<T,L4J+)&Y(9'&0P]"*S=0\/:1JGA]]*NK"(V#X=H(QY:Y!W _+COS6F
M$C'#4HTH[)CQ$I5ZCJ/=G&VG_)+/"_\ U[Q?^@5#\0/^1X\'_P#75?\ T8E=
ME?>&[=M%L],LB+6VM-JQ+@OA0, <G/>N.^(0V^.O""^DRC_R(E<,J<EB:M1K
M1\MOE<]C+YQ?LX)ZI3_]).FG_P"1_M_^N7_LK4FE_P#(XZK_ +C?S6EG_P"1
M_M_^N7_LK4FE_P#(XZK_ +C?S6O/C_&7_7U_^DBE_"?_ %[7YF7X$_Y &L_[
M[?\ H%6;#_D0KW_?/\UJMX$_Y &L_P"^W_H%6;#_ )$*]_WS_-:=?>/^"9Y^
M3?[E'_%'\V27?_)/H/\ @/\ Z$:Y3XF_\AKX=?\ 7\O_ *%#75W?_)/H/^ _
M^A&N4^)O_(:^'7_7\O\ Z%#7;E?^\+_KW'\F:X_^"_\ '+]#L[C_ )'ZV_ZY
M?^RM2Z5_R.NI_P"Z?YK27'_(_6W_ %R_]E:ETK_D==3_ -T_S6N&/\9?]?7_
M .DG6_X3_P"O:_,YSP)_R%/'/_7TW\Y*UM/_ .1#OO\ ?/\ [+63X$_Y"GCG
M_KZ;^<E:VG_\B'??[Y_]EK3%_P 1?X)G15^.7^*G^2*7B'_DG%C_ -=E_P#9
MJ/%W_'AX8_X#_)*/$/\ R3BQ_P"NR_\ LU'B[_CP\,?\!_DE:T_X*_PQ_0^0
MS/\ WBO\O_2BUXL_Y'3P]_OK_P"ABNXKA_%G_(Z>'O\ ?7_T,5W%=]+XY^OZ
M&N'_ (M7U7Y!1116QUA1110!#=74-G;M-,X55!ZGECC.!ZGVJCIFNVVJNJP1
MS*&4D,Z@#(QD<'J-R_G6E)&DL;1R*KHPPRL,@BJ]M865JY>VMX8W*@%D49(H
M CTQUD-XZ'*FY;G&.PJW_P MO^ U6L/]9>_]?!_]!6K/_+;_ (#0 #_6O]!_
M6B/HW^\?YT#_ %K_ $']:(^C?[Q_G0 B?Z@_C0W_ ![CZ"A/]0?QH;_CW'T%
M "R=4_WJ4_ZU?]T_TI).J?[U*?\ 6K_NG^E "?\ +8_[HH7[[_7^E'_+8_[H
MH7[[_7^E "+_ *D_C2-_Q[CZ"E7_ %)_&D;_ (]Q]!0 Z3^#_>%#?ZU/H:)/
MX/\ >%#?ZU/H: #_ );'_=%"_??ZC^5'_+8_[HH7[[_4?RH (_X_]XTW_EU_
MX!_2G1_Q_P"\:;_RZ_\  /Z4 /D^Z/\ >'\Z1O\ 6I^-+)]T?[P_G2-_K4_&
M@ _Y;#_=-"_ZU_H*/^6P_P!TT+_K7^@H (^K_P"]2+_Q[GZ&ECZO_O4B_P#'
MN?H:  _ZI/JO\Z5_OI]?Z&D/^J3ZK_.E?[Z?7^AH #_KA_NG^E"_ZU_H*#_K
MA_NG^E"_ZU_H* "/J_\ O4W_ )=F^AIT?5_]ZF_\NS?0T .E_P!6?P_G2M]Y
M/K_0TDO^K/X?SI6^\GU_H: $;_6I]#_2@?ZX_P"Z/ZT-_K4^A_I0/]<?]T?U
MH 5?O/\ 7^@I(_NG_>/\Z5?O/]?Z"DC^Z?\ >/\ .@!/^7;_ (!_2AON+]11
M_P NW_ /Z4-]Q?J* %;_ %J?0T#_ %Q_W1_6AO\ 6I]#0/\ 7'_=']: !?\
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MJ?\ NG^:TEQ_R/UM_P!<O_96I=*_Y'74_P#=/\UKSH_QE_U]?_I)VO\ A/\
MZ]K\SG/ G_(4\<_]?3?SDK6T_P#Y$.^_WS_[+63X$_Y"GCG_ *^F_G)6MI__
M "(=]_OG_P!EK3%_Q%_@F=%7XY?XJ?Y(I>(?^2<6/_79?_9J/%W_ !X>&/\
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M]T?[P_G3?^77_@']*=)]T?[P_G0 -]]/J?Y4?\MA_NFAOOI]3_*C_EL/]TT
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MQ-&I*HFE]F:^;V^\VJUZ;FVI+>'X)7^XP_$/_).+'_KLO_LU'B[_ (\/#'_
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,Z9IU%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_005.jpg
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #] <$# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <[KNEZY>ZA'+IVH&"V$6UXQ(5+'/; ./K[8[UH2QRK?Z:9)MQ
M 96 48+;#EO6L[7=3UZTU..'3+!9K9HLM*86?:^?9AV'3WSVK1EDE>_TWS(2
MA(9F.X8#;#E?6A;!U-*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '!_$O3=-;34U6_CNYO*Q#Y<,PC3!).6.T^GYD5N>"ULT\+VR:?
M'*EHI<1>:<EAN/S9P,@_2JOQ :<>'%%JMTTS3 *MN0,C#9#9!&,9_'%3> W5
M_"%H45TCRX1'<OM7<< ,>HHCLPET)->U36K*[@BTS3//A=27G*%PA[#:"#_^
ML>AJ]*\SW^FF2-4!W%OFR0VPY&,=/>F:IXALM(N8K>Z6X,DJEH_+B+!L=0".
M^.<>@-237$4NHZ<$?);=(.#RI0\T+8.IG^-?^1>;_KJG\Z\YKT;QK_R+S?\
M75/YUYS7FXO^)\CR<;_%^1ZAX8_Y%NQ_W#_,UI7%Q':VTEQ,<1QJ68@9P!6;
MX8_Y%NQ_W#_,U/KW_( O_P#K@W\J[HNU-/R_0]&#M23\OT*7_"8:+_S\O_WZ
M;_"M+3]2M=4@:>T<O&K;22I'/X_6O(Z] \#?\@2;_KX;^2UST,1*<^5G+A\3
M.I/ED=/11178=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.,V<'&_'[L?Q_?\ S[^M %O(]:,U3&E:>$V"RMPFQ(]OEC&U#E5^@/0=J?\
MV?9B02?98=XD,H;8,AR,%OJ1QF@"SD>M&:I+H^F)"(4L+98Q%Y(01#'EYSMQ
MZ9YQ4AT^S9]YM82_F++NV#.]1@-]0.,T 6<CUHR/6J::3IT:*B6-NJ*'4*(P
M  YRX_X$>OK3CIEB00;. @[,_NQ_!]S\NWI0!:R*,CUJL-.L@ZN+2$,KO(#L
M&0S?>/U/?UIATG3C%Y9L;<QF,1;?+&-@.0OT![4 7,T9'K5;^S[/?O\ LL.[
MS?/SL&?,QC=]<<9IO]E:?Y?E_8K?9Y;1[?+&-C'++]">HH MY'K1D55.FV)+
M$V<!+,CG]V.63A3]1@8]*/[-LL@_9(,@N1\@ZO\ >_/OZT 6LCUHS5,Z5IY0
MH;&W*%$0KY8P53[H^@[>E2"PLQ)Y@M8=_F&7=L&=Y&"WUQQF@"QD>M&:I?V1
MIOE&+[!;>68O)*^4,;,YV_3/.*D.GV9?>;6'=O63.P9W*,*?J!TH LY'K1D5
M4&EV 4*+*W "NF/+'W7.7'T)Z^M*=-L6SNM(#D(#E!R$Y7\NWI0!:R/6C(]:
MJC3;$2;Q:0!][/N\L9W,,,?J1U]:0Z7IYC\LV5N4\H0[?+&-@.0OTSVH MY%
M&1ZU6_L^S\WS?LL/F>;YV[8,[\;=WUQQGTIHTNP$8C%E!L6-HPOEC 1N67Z'
MN* +>1ZT9%53IEB6W&S@+;D;/ECJGW3^';TI1IUD"I%I"-I=E^0<%_O'\>_K
M0!9R/6C-4SI6GE-ILK?;L2/'EC&U3E1] >1Z4_\ L^S\P2?98=XD,H;8,AR,
M%OKCO0!9R/6C-4SI.G&/RS8V^SRS%M\L8V$Y*_3/.*>=.LF<NUK"6,BR9*#.
M]1@-]0.,T 6<CUHR/6JATNP( -E;X <?ZL='^^/Q[^M+_9MB<_Z'!SLS^['\
M'W/R[>E %K(HR/6JW]G66\/]EAWAVD#;!G<PPS?4C@FF?V5I_E>5]AM_+\L1
M;?+&-@.0OT!YQ0!<S1D>M5FT^S:3S&M82YD$VXH,[P,!OKCC-,&E:>(Q&+*W
M"!&CV^6,;&.67Z$]10!<R*,BJS:=9.26M(224))0<E/N_EV]*0:;8@@BT@!!
M<_ZL=7^^?Q[^M %K(]:,BJ9TK3V5E-C;E6C6(@QC!1>57Z#L*>-/LQ)Y@M80
M_F&7=L&=Y&"WUQQF@"SD>M%4FT?37A,36%L8S$82AB&/+)R5QZ9YQ5Q5"J%4
M  #  [4 +1110!RWCUK<^'A'.Y_U\3!1%YW\0Y:/JZ^HJSX,MH+7P[&EO.\J
M-([Y-NT 4DY(6,\JH["JOCBP\/OI\6HZY:2S_9G41&!RKDD_=R"./J:TO#,N
MF2:0!I"NMJDC)AW+'=WY).?SHCLP?0BUW1[_ %.XC-K>""(1E'7>ZECN!!^4
MCIBK<L+1W^FEYG=@&0YZ$A#\V/6G:T=0&G-_9G_'SN&" I(&><!B!4%\]^+C
M3C'!"\W)(:4J-VPY'0\4= *OC7_D7F_ZZI_.O.:]!UVRUW5M,-JEK8(Q=6R;
MAL<?\ KEQX-\1%V7;IV5QG_2'_\ B*X<12G.=XH\[%4*DZEXH[?PQ_R+=C_N
M'^9J?7O^0!?_ /7!OY5GZ3!KFG:7;VC6EBS1+@L+AL'G_<J34$UR]TZXMA:6
M*F6,H";EN,C_ '*ZE%^SMY?H=BB_9<O6WZ'FE>@>!O\ D"3?]?#?R6N8_P"$
M-\1!PFW3LD$_\?#]O^ >]=+X?T_7M&L'MWMK"0M(7RMPW< ?W/:N3#TIQG>2
M.+"T*D*EY(ZFBLSSM;_Y\K+_ ,"6_P#B*8;G6A(J?8;++9_Y>6[?\ KO/2-:
MBLSSM;_Y\K+_ ,"6_P#B*/.UO_GRLO\ P);_ .(H TZ*X.3Q]?QRO&='@)1B
MI/VH]CC^[6AH_BG4]9N)(8M+MHS&FXEKH\\X_N5FJT&[)F4:].3Y4]3K**S/
M.UO_ )\K+_P);_XBL+5O%VI:3??99=*MW;8&RMT<<_\  ?:JE.,5>1<YQ@KR
M=CL**X-/']^[JHT>'+$#_CZ/?_@-=3YVM_\ /E9?^!+?_$4H5(S^%BA4A/X7
M<TZ*Y;6?$FJ:*81-IEK)YN<;+H\8Q_L>]97_  L&^_Z \/\ X%'_ .)I2K0B
M[-DRKTXNTGJ=]16/;7NLW5K#<+8V865 X!N6XR,_W*CU#4]8T^QDNI+"S98\
M9"W+9.3C^Y[U4IQC%R;T1M%.;2CU-RBN&_X3K4/^@1!_X%'_ .)K;TW5=8U*
MR6ZCT^T16)&&N6SP<?W*PHXRA6ERTY79M4PU6DN:<;(WJ*S/.UO_ )\K+_P)
M;_XBN:;QSJ"L5_LB#@X_X^C_ /$U5;$TJ%O:RM<FE0J5;^S5['<45R^D^(]4
MU>66.+3+5#&H8[KD\Y_X!6KYVM_\^5E_X$M_\15TJL*L>>F[HFI3E3ERS5F:
M=%<;>>,=1L[R6V?2K=FC;:2+HX/_ ([1:>,=1O+R&V32K=6E;:";HX'_ ([7
M/]?PW-R<ZO>WS^XV^IU^7FY=-SLJ*S/.UO\ Y\K+_P "6_\ B*QM4\4:GI5V
M+>33+9V*!LK=''.?]CVK>K6IT8\]1V1E3I3JRY8*[.LHKAQXYU D#^R(.3C_
M (^C_P#$UTOG:W_SY67_ ($M_P#$5-'$TJ]_92O8=6A4I6]HK7-.BN9U;Q!J
MND"$RZ;:OYN<;;D\8Q_L>]9A\=7X'_((@_\  H__ !-15QV'I2<)S2:+IX2M
M4CS0C='<T5E+<:VR*PLK+D9_X^6_^(JIJFL:OI=G]IET^T==P7"W+9Y_X!6\
MYQA%SD[)&,82E)1BM6=!17#?\)UJ'_0(@_\  H__ !-;6F:MJ^IV0N8]/M$4
ML5PURV>/^ 5C1QE"M+EIRNS6IAJU*/-.-D;]%9,MUK443R&QLB%4L0+ENW_
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MK4U0S]8O^N@_K0!-1110 R7_ %+_ .Z:(?\ 41_[H_E1+_J7_P!TT0_ZB/\
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M>':<S2HQ&[/7Y,_*0/KDCBM>6262_P!-+P[%8,QRW(;8?EQ_6A; ]S2J)/\
MCYF^B_UJ6HD_X^9OHO\ 6@"6BBB@"(_\?2?[C?S%2U$?^/I/]QOYBI: "HG_
M ./F'Z-_2I:B?_CYA^C?TH EHHHH ANO^/=_P_G4U0W7_'N_X?SJ:@ HHHH
MAMO]0/J?YFIJAMO]0/J?YFIJ "HHOOS?[_\ 05+447WYO]_^@H EHHHH B'_
M !]M_P!<Q_,U+40_X^V_ZYC^9J6@ J&?K%_UT']:FJ&?K%_UT']: )J*** &
M2_ZE_P#=-$/^HC_W1_*B7_4O_NFB'_41_P"Z/Y4 /HHHH BMO]3_ ,";^9J6
MHK;_ %/_  )OYFI: "HHO];-_O#_ -!%2U%%_K9O]X?^@B@"6BBB@"'_ )?#
M_P!<Q_.IJA_Y?#_US'\ZFH *X7QG\2M%\-BWCCNH+NZ%VD<T$;Y:-,_.3CH0
M.U=U7E?Q#^&$WB_Q-;WEH]K81"#;-<;<O-(2< @>@[^] 'H6C:_I7B"V:XTF
M^BNXE(#-'G@^A]ZTJYWP-H4OAOPC9:7<0P1W$(82F#[LAR?GSZD8/-=%0!Y9
MJ!_XF5W_ -=G_P#0C6UX,_Y"\O\ UP/_ *$*ZNYTZR(WFSMRS.N28QDY(S4\
M-G:V[EX;:&-B,$H@!Q^%>%0RB=+$*LY*R=]GY_YGKU<RA4HNFHO56_(GKSSQ
M1_R,-S]$_P#017H=8&I>%XM2OY+MKJ2,OCY0H(&!BNO-,-4Q%%0IJ[O_ )G-
ME]>%&JY3>ECC-._Y"EI_UV3_ -"%>I5R]EX1ACDM[D7DI*LLFW:.QSBNHK/*
M<+5P\)*JK7:_(O,<13KRBZ;O8Y3QO_JK+_>?^0KCF^Z?I78^-_\ 567^\_\
M(5QS?=/TKP\W_P![G\OR/6RW_=H_/\SU>V_X]8?]Q?Y5+45M_P >L/\ N+_*
MI:^PA\*/F9?$PHHHJA!1110!@:AXPTS3K[[&WG3S<\0A2-P/*Y)'(Z__ %^*
MO37"37^F[-Q#[I =IQ@H>_K[57O=5\.AP;VYL"S*0#+M)(#8QSZ&KEQ@WNGE
M<;=S8QT^X:.@=2[42?\ 'S-]%_K4M1)_Q\S?1?ZT 2T444 1'_CZ3_<;^8J6
MHC_Q])_N-_,5+0 5$_\ Q\P_1OZ5+43_ /'S#]&_I0!+1110!#=?\>[_ (?S
MJ:H;K_CW?\/YU-0 4444 0VW^H'U/\S4U0VW^H'U/\S4U !447WYO]_^@J6H
MHOOS?[_]!0!+1110!$/^/MO^N8_F:EJ(?\?;?]<Q_,U+0 5#/UB_ZZ#^M35#
M/UB_ZZ#^M $U%%% #)?]2_\ NFB'_41_[H_E1+_J7_W31#_J(_\ ='\J 'T4
M44 16W^I_P"!-_,U+45M_J?^!-_,U+0 5%%_K9O]X?\ H(J6HHO];-_O#_T$
M4 2T444 0_\ +X?^N8_G4U0_\OA_ZYC^=34 %0W'_++_ *Z"IJAN/^67_704
M 34444 17'^K7_?7^8J6HKC_ %:_[Z_S%2T %%%% $5M_P >L7^Z*EJ*V_X]
M8O\ =%2T <IXW_U5E_O/_(5QS?=/TKL?&_\ JK+_ 'G_ )"N.;[I^E?&YO\
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MR2R$AW=VD.[ER7^;GWI1U38/2QU-%%<WX\NM.L_!]]/JUN]Q9J%#QI,8F.2
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MJ:L2F5[JQM;T*+J!)0G*[QG%4HM#TM@^ZQ@/S''R]JK^-)+:+P=JDEV91;K
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M&1[Y_"O5**2T=P>JL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_006.jpg
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N :P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_02;_P "$_PH_P"$7\/?]!)O_ A/\*+8C^9?>@MB?YE]Z*O_  GMQ_T#XO\
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M*M'POX>"DC46S_U\)_A2)X8\/LBDZBP) )_TA/\ "BV(_F7WH+8G^9?>BO\
M\)[<?\^$7_?P_P"%'_">W'_/A%_W\/\ A5K_ (1?P]_T$F_\"$_PH_X1?P]_
MT$F_\"$_PHMB/YE]Z"V)_F7WHHS^.IY+>1#I\1#*1_K#Z>PIZ>/;G8N;"+.!
MG]X1_2K$WA?P_P"1)C46)VG \]#V],41>%_#_E)G46!VC_EN@_I1;$?S+[T%
ML3_,OO1!_P )[<?\^$7_ '\/^%'_  GMQ_SX1?\ ?P_X5:_X1?P]_P!!)O\
MP(3_  H_X1?P]_T$F_\  A/\*+8C^9?>@MB?YE]Z*@\=W +'[!&<G/\ K3QQ
M]*7_ (3VX_Y\(O\ OX?\*L+X8\/EG!U%L X'^D)Z#VIW_"+^'O\ H)-_X$)_
MA1;$?S+[T%L3_,OO15_X3VX_Y\(O^_A_PH_X3VX_Y\(O^_A_PJU_PB_A[_H)
M-_X$)_A4-KX?\.7EQ)!#?3F5&*E3(H)^G'(^E'[_ /F7WH/]IVYE]Z(_^$]N
M/^?"+_OX?\*/^$]N/^?"+_OX?\*T_P#A!M+_ .>MU_WV/\*/^$&TO_GK=?\
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M?"^CZA::_#-<64L481P79>!D546G))T_S*@U*23I?F:DW@?3!!(1+=9VG'S
M]O0"EB\#Z884S+=9VC^(#^E=+<<VTO\ N'L3V]!S2P_ZB/\ W1V([>]=?L*?
M\IW?5Z7\IS\'@O38+B.9);DM&X<9<8R#GTKHZ**N,(Q^%6+A3C#X58CC_P!9
M+_O?T%25''_K)?\ >_H*DJBPHHHH **** "HG_X^(OHW]*EJ)_\ CXB^C?TH
M EHHHH **** "BBB@"*X_P"/=_I4M17'_'N_TJ6@ HHHH **** "BBB@#)\3
M:U_PCOAZZU4P^<+<*2@."06 /\ZXAOBI<KJ5UIW]F0&YM]P8B<[>"N.=O((9
MORKT2_@L[BT:*^6)K<D;A*<*3D8_7%8,?A[P8^_R[736+C#%9 20".^?4C\Q
M0MP+?AK79]<@NFN+1+9X90FQ9-_!4,,GUP><<5D7GBN72=2O+1+1) LQ.XN1
MG.#Z5T>DV6EV<$O]E1VZ1/(2_D$$%AP>GIC&.U8=QH6D7]_=W%W>-%,TS J)
M57&.G!%95^>R]GH85_:<O[MV93_X3V?_ *!\?_?T_P"%'_">S_\ 0/C_ ._I
M_P *L_\ "+>'_P#H(O\ ]_T_PH_X1;P__P!!%_\ O^G^%<UL1_,OO1RVQ/\
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M V?_ +YH_P"$?U;_ *!L_P#WS5S_ (2_6O\ GYC_ ._2T?\ "7ZU_P _,?\
MWZ6BU'N_P"U#N_P*?_"/ZM_T#9_^^:/^$?U;_H&S_P#?-7/^$OUK_GYC_P"_
M2T?\)?K7_/S'_P!^EHM1[O\  +4.[_ I?V!JI)']FS\=?EI?^$?U;_H&S_\
M?-6QXMUD$D7$>3U_=+2_\)?K7_/S'_WZ6BU'N_P"U#N_P*?_  C^K?\ 0-G_
M .^:/^$?U;_H&S_]\U<_X2_6O^?F/_OTM'_"7ZU_S\Q_]^EHM1[O\ M0[O\
M I_\(_JW_0-G_P"^:8=!U1;J'.F3]_X#Z?E^=7_^$OUK_GYC_P"_2U$_BW6C
M<0G[2G&[_EF/3\OSH<:+5KO\"H.C"2DF[KR0IT?4B646$Y('(V56.@:J!SIL
M_P#WS5W_ (2_6O\ GYC_ ._2TC>+M988-Q'C(/\ JEK##X;#T4TFW?T.[,,P
MIXZ49335NQ4_X1_5O^@;/_WS1_PC^K?] V?_ +YJY_PE^M?\_,?_ 'Z6C_A+
M]:_Y^8_^_2UO:CW?X'GVH=W^!3_X1_5O^@;/_P!\T?\ "/ZM_P! V?\ [YJY
M_P )?K7_ #\Q_P#?I:/^$OUK_GYC_P"_2T6H]W^ 6H=W^!3_ .$?U;_H&S_]
M\T?\(_JW_0-G_P"^:N?\)?K7_/S'_P!^EILOBO6)HGB>X3:ZE3B, X/O1:CW
M?X"M0[O\"A/I&H6B!Y[&:-2=H)7J?2MW0O#.K&1+GSVL$/.0?G8?3_&JVG>+
M;^S"QW&+J(<#?]\?0_XUWNF7BWUA%,L4L0( VRKM/_ZJVH4J4G=-G1AZ-&;N
MF_0LHI6-59RY P6/4TZBBO0/3([C_CWE_P!P^OI[<_E2P_ZB/_='KZ>_-)<?
M\>TO;Y#Z^GMS^5+#_J(_]T>OI[\T /HHHH CC_UDO^]_05)4<?\ K)?][^@J
M2@ HHHH **** "HG_P"/B+Z-_2I:B?\ X^(OHW]* ):*** "BBB@ HHHH BN
M/^/=_I4M17'_ ![O]*EH **** "BBB@ KBT:"'XI21+)(LDMN'\M8BJGY3DD
M@X/0<D>@S7:5P=G972_%&YGMS%-8@?O2A3="Y3[IP,X)[9ZT+XD#V9V=_+9P
MVC27[1+;@C<9L;<Y&,Y]\5A1WW@R7<B-HYW<,OEH,X91CIZLOXD5?\3Z*?$7
MAZZTKSO)%P%!?T 8$_RKCK/X:WT.LW^HSZG [W:CY%B(5&WHQ(Y[^6*<=]0>
MVAZ!9R6<T3R630M&9&#-%C!<'#=.IR,?A7-7$_AM+^[74HXVNO.;<3&Q..W(
M]JWM)T]M-M986=7WW$LH*C  =RP'ZUR>H^&+_4]6O+JW: 1M*0-[$'@ >E85
MW+E7*KG/B'/E7+&Y;^U>#/\ GC%_WY?_  H^U>#/^>,7_?E_\*S/^$(U7^_:
M_P#?9_PH_P"$(U7^_:_]]G_"N:]7^1?<<EZW_/M?<:?VKP9_SQB_[\O_ (4"
MX\&G.V",GT$+5F?\(1JO]^U_[[/^%.7P9JL09LV[<=%D.3^8K.K.O&#<::;]
M#HPL7.M&-6"46]78T%N?!Y3<]HD?/1HFS^F:7[5X,_YXQ?\ ?E_\*S5\):M/
M$<I%%STD?G],TG_"$:K_ '[7_OL_X5&'J8B=-.I32?H;9A3C2KN.'BI1TZ?J
M:*W/@[>^88L9X_=/Z?2G?:O!G_/&+_OR_P#A64/!6J%F4/;97K\Y_P *=_PA
M&J_W[7_OL_X5O>K_ "+[CAO6_P"?:^XT_M7@S_GC%_WY?_"C[5X,_P">,7_?
ME_\ "LS_ (0C5?[]K_WV?\*/^$(U7^_:_P#?9_PHO5_D7W!>M_S[7W&G]J\&
M?\\8O^_+_P"%127/@W[1#B&''S9_=2>GTQ^=4?\ A"-5_OVO_?9_PJ)_!6J"
MXA4R6V3NP/,;T^F/SHO5_D7W!>M_S[7W&Q]J\&?\\8O^_+_X4U[GP=M^6&+.
M1_RR?IGGM6=_PA&J_P!^U_[[/^%-;P5JJC)>VZ@??/?\*+U?Y%]P7K?\^U]Q
MJ_:O!G_/&+_OR_\ A1]J\&?\\8O^_+_X5F?\(1JO]^U_[[/^%'_"$:K_ '[7
M_OL_X47J_P B^X+UO^?:^XT_M7@S_GC%_P!^7_PH^U>#/^>,7_?E_P#"LS_A
M"-5_OVO_ 'V?\*/^$(U7^_:_]]G_  HO5_D7W!>M_P ^U]Q<FU#PE'/&J6"2
MQMG<ZH1L_ ]:UXM&\/ZG9R&QAMSN4@.@R4)'7%<E<>%=5MYXH1"LS29(,1R%
M^I(&*Z+1?"#64JW-U=N)1R$@8J/Q/>G3YY2M*"_(JE[24K2IJWI8TM/\-Z=I
MB;DB\V8#_6R\G\/2M:'_ %,?^Z/Y4K_<;Z4D/^HC_P!T?RKMC%15DCOC",5:
M*L/HHHIE$<__ ![R_P"X>Y';VY_*EA_U,?\ NCU]/?FDN.+>7_</<CM[<TL/
M^HC_ -T=R>WO0 ^BBB@"./\ UDO^]_05)4<?^LE_WOZ"I* "BBB@ HHHH *B
M?_CXB^C?TJ6HG_X^(OHW]* ):*** "BBB@ HHHH BN/^/=_I4M17'_'N_P!*
MEH **** "BBB@ KA[,P67Q'>V&C&*:<.YO([B0HV1NP5/&?PXS7<5PJ7+S_%
M%%DAV%(W53'/N#+M/+#'3MCJ#BA;H'LS>\8:G>Z/X7O+[3U#W<6WRT(SN)8#
M'XYKS0_$/Q"=3O;1+R,V\ )6Z-NH# E-I]/[P_&O8;JYM[.W:>ZE2*%2 7<X
M R<#]:S(_$GAZ4[4U*R)YXWCL5'\V4?B*%N!E^ =?U#7]+N)]2QYZ2 %0H 3
M(SMX]/0\BLS5/$6IZ=K%[;6TR+$LI(!C!Z@&NYM;FVNA*;:6.01RM'(4.<..
MH/N*YFXF\-)?W:ZE'&;KSFW$QL3CMT]JQQ%VE9V.?$*7*K2L87_"8:U_S\1_
M]^EH_P"$PUK_ )^(_P#OTM;7VGP7_P \HO\ OT_^%'VGP7_SRB_[]/\ X5RV
MG_S\7WG'RU/^?J^\Q?\ A,-:_P"?B/\ []+1_P )AK7_ #\1_P#?I:VOM/@O
M_GE%_P!^G_PH^T^"_P#GE%_WZ?\ PHM/_GXOO#EJ?\_5]YB_\)AK7_/Q'_WZ
M6C_A,-:_Y^(_^_2UM"X\&G@0Q$^GE/38[KPBP8O9"(#^_&3G\LUG*?+)1=57
M?F;0PN)G!U(SO%;O6QD1>*]89V_TA!GKB(4H\3:O!&VV[W<Y^= U:RW/@X._
M[N,#^$B)_2B.?P:BE3B3)S\Z.?Z5A4H8B5:,XU59>;_K4[\/B:$,'.C4:<W>
MSO\ =KNK&/\ \)AK7_/Q'_WZ6C_A,-:_Y^(_^_2UM?:?!?\ SRB_[]/_ (4?
M:?!?_/*+_OT_^%==I_\ /Q?>>5RU/^?J^\Q?^$PUK_GXC_[]+43^+M:-Q"?M
M2#&[@1CGCTZ'\:W_ +3X+_YY1?\ ?I_\*ADN?!OVF'$46/FS\D@[>F,'\:.6
M?_/Q?>'+/_GZOO,O_A,-:_Y^(_\ OTM(WB[66&#<1XSG_5"MO[3X+_YY1?\
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MN-]*;#_J(_\ ='\J[#O'T444 1W'%M+SCY#SDCM[<TL/^HCYS\H[GT]Z2?\
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MIWFC^%[R_P!/4/=1;?+0C.XE@,?K7GUEX\\07&L:A:+=Q/!:KO2=K<8D!DB
MZ=."]..^@/;4]!\+:#-X>TZXM)KI;EI+J2?S%0IG><G(R><Y/XU@:CX8O]3U
M:\NK=H!&TI WN0> !Z5O>%+^YU+2Y;FXO(KM3.XBEC 7*#ID#ISG /.,9YKE
M=9UG4;/7+V"WO9(HQ*2%7&!D"N;$N"BN?^M#EQ;ARKG3W)/^$)U7^];?]_#_
M (4?\(3JO]ZV_P"_A_PK-_X2/5_^@C+^G^%'_"1ZO_T$9?T_PKCO0[,X.;#]
MG]YI?\(3JO\ >MO^_A_PH_X0G5?[UM_W\/\ A6;_ ,)'J_\ T$9?T_PH_P"$
MCU?_ *",OZ?X47H=F'-A^S^\U(_!>JHV=UM_W\/^% \(ZM(C I#&>GSR=?RS
M6='XAU9VVMJ,V"/4?X4+J^H6R.8KZ9,\GYLY_.O.Q$L)]8CS1E?U^X^BP'.\
MNJ.D[0UT>^VNO3YET>"]5+, UME>O[P_X4[_ (0G5?[UM_W\/^%9H\1:N"3_
M &C+SUZ?X4?\)'J__01E_3_"O1O0[,^=YL/V?WFE_P (3JO]ZV_[^'_"C_A"
M=5_O6W_?P_X5F_\ "1ZO_P!!&7]/\*/^$CU?_H(R_I_A1>AV8<V'[/[S2_X0
MG5?[UM_W\/\ A43^"]4%Q"IDM06W8'FMSQZ8YJE_PD>K_P#01E_3_"HW\2:O
MY\0_M.;^+C<.>/3'-%Z'9C4L/V?WFM_PA.J_WK;_ +^'_"FMX+U51DM;=0/]
M8?\ "L__ (2/5_\ H(R_I_A0?$6KD8.HR_I_A1>AV8N;#]G]YI?\(3JO]ZV_
M[^'_  H_X0G5?[UM_P!_#_A6;_PD>K_]!&7]/\*/^$CU?_H(R_I_A1>AV8<V
M'[/[S2_X0G5?[UM_W\/^%5Y_">IPPM(ODS;6VE87+-G/TJK_ ,)'J_\ T$9?
MT_PJ&WU6_M[MKF&YD6:1MS$'[Y]QT-)NCT3$W0Z)_>='IG@B9RLNH3>4.OEQ
M'YOQ/;\*[2&%8(4B3=M08&YB3^9K+T&_U*^@W7]CY(Q\LF<;_P#@/45L5WT8
M0C&\4>G0IPC&\%N(_P!QOI38?]1'_NC^5.?[C?2FP_ZB/_='\JV-Q]%%% $<
MYQ;RG./D/.2.WJ.E+#S!&<Y^4=\]O6DN#BWE.<80\YQCCUI83F",YS\HYSGM
M0 ^BBB@"./\ UDO^]_05)4<?^LE_WOZ"I* "BBB@ HHHH *B?_CXB^C?TJ6H
MG_X^(OHW]* ):*** "BBB@ HHHH BN/^/=_I4M17'_'N_P!*EH **** "BBB
M@ HHHH JZC?VFF64EW>R"*WCQO=AD#)P/U-8L?C3PT\CQB\577.Y6@<$891S
MQZNOYUH^(=%B\0Z'<Z5/(R17  =E&3@$'^E<I;?#&*'4K^_DU>:2>]0)(?*
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M $$9?T_PKK_[9\*_W+;_ ,!?_L:/[9\*_P!RV_\  7_[&CV;_P"?GXA[)_\
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MOI]:D_M?3?\ H(6O_?Y?\:Z^5=CLY8]B[15+^U]-_P"@A:_]_E_QH_M?3?\
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M^:*%$=O5@H!-6J**;=W<%H%%%%( HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
